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There are two rules for a good scientific presentation:  
1.) Never tell everything you know... 
 
 
Accordingly, the projects summarized in this thesis sought to explore and possibly overcome 
human glioma cells´ resistance to apoptosis as well as their escape from host immune 
surveillance. Work from other areas to which I also contributed has been omitted (see 
attached reference list). 
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Introductory Remark 
 
In order to give this PhD thesis more structured contours, I decided to split it into various 
chapters by projects, each consisting of an introduction, a material and methods section, the 
results paragraph and a discussion. All references as well as a summary are provided at the 
end. The introductory paragraphs on apoptosis and on tumour immunology are intended to 
provide the background for the understanding of the work that follows. This format should 
enable readers who are interested in a specific part of the work outlined here to find all 
relevant information within a concise standard format. All sections represent the state-of-the-
art when the respective project was prepared for publication and have been supplemented with 
the most relevant recent findings. 
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I. Introduction 
 
Glioma biology and therapy 
 
Prognosis and current treatment 
Glioblastoma is a primary brain tumour of unknown origin carrying an extremely poor 
prognosis. The pathological diagnosis is based on nuclear atypia, mitoses, microvascular 
proliferation and necrosis observed in the most malignant region of the tumour (1). In order of 
increasing anaplasia, the WHO distinguishes (2) pilocytic astrocytoma (grade I), diffuse 
astrocytoma (grade II), anaplastic astrocytoma (grade III), and eventually glioblastoma (grade 
IV), the most common subtype in adults, which is among the most lethal of all cancers. 
Traditionally, cancer is resected and treated with radiotherapy and cytotoxic agents supposed 
to have a greater effect on proliferating cancer cells than on non-cancerous cells. For some 
types of cancer, this approach has translated into increased survival. However, despite 
advanced neurosurgery, optimized radiation therapy regimens and a wide variety of cytotoxic 
chemotherapies (3), the median survival of glioblastoma patients is approximately one year 
from the time of diagnosis—the same as it was 10 years ago (1, 4-6). 
 
Glioblastomas are characterized by localized, non-metastatic growth. Inside the brain, 
however, glioma cells tend to migrate and diffusely infiltrate irreplaceable neuronal tissue. 
Surgical approaches are limited by the delicacy of intervening in the human brain: Even if the 
bulk of the tumour mass can be surgically removed, the surrounding tissue which is likely to 
be invaded by glioma cells must be spared. Thus resection does not prevent recurrence and 
has little impact on the life-span of glioma patients. The more optimistic estimates suggest 
that neurosurgery can prolong a patient’s life by two to three months and there is little hope 
that this clinical outcome will be greatly improved (7). 
 
The most effective current treatment modality is radiotherapy (8): median survival after 
resection is increased from 4 months without irradiation to 10 months. Since glioma cell lines 
do not undergo apoptosis upon treatment with γ-irradiation up to 8 Gy, the sensitivity of the 
endothelial cells of the tumour vasculature may be the major determinant of tumour responses 
(9). Therefore, the effect of radiotherapy may at least partially be mediated by an anti-
angiogenic mechanism involving endothelial cell apoptosis. Traditional chemotherapy aims at 
inducing apoptosis selectively in cancer cells. Delivery of  anti-cancer drugs into the brain 
does not present a major problem since the blood-brain barrier is largely destroyed in the 
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areas of glioblastoma growth. However, the efficiency of chemotherapeutics is limited 
because of the intrinsic apoptosis resistance observed in glioma cells. Thus chemotherapy 
helps to increase the rate of survivors at 18 months from less than 5% to 15-20%, but the 
majority of patients seems to draw very little benefit from this treatment (10, 11). This still 
leaves us with the need for an effective therapy that directly targets the glioma cells. Thus, 
new approaches for the treatment of glioma are badly needed. 
 
Perspectives 
The design of novel anti-tumour therapeutics should be guided by our substantially improved 
understanding of cancer biology that has become possible through major advances in 
molecular biology, cellular biology and genomics (12, 13). The hallmark of primary 
glioblastoma is amplification of the oncogenic epidermal growth factor receptor (EGFR) (14). 
Constitutive signalling through EGFR enhances survival of glioma cells in vivo. Another 
common event in malignant gliomas that contributes to resistance to apoptosis is loss of the 
tumour suppressor phosphatase and tensin homolog deleted on chromosome ten (PTEN) (15, 
16). Mutational inactivation of the tumour suppressor protein p53 is found in >50% of all 
human cancers and in 65% of secondary gliomas (15, 17). These alterations are thought to be 
critical for tumour growth and survival and may paradoxically represent the tumour’s 
“Achilles heel”: while promoting malignant behaviour, they also provide molecularly defined 
targets for new therapeutic approaches. Approaches aiming at the inhibition of the oncogenic 
EGFR (18) are already undergoing clinical trials for a variety of cancers, strategies for the 
rescue of mutant p53 function (19, 20) have successfully been tested in murine tumour 
models. These approaches can build upon substantial advances in the understanding of 
apoptosis, a biological principle that is thought to physiologically protect multicellular 
organisms against the occurrence of cancer. 
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Apoptosis: 
 
Physiological significance 
The term “apoptosis” is of Greek origin and describes the defoliation of a tree in autumn or 
the falling of petals from a flower. In 1972, Kerr, Wyllie and Currie introduced this term to 
describe a cellular suicide program morphologically defined by nuclear condensation and 
fragmentation, membrane blebbing and the formation of apoptotic bodies (21). Apoptotic cell 
death allows for the elimination of large numbers of cells no longer needed without 
inflammation of the surrounding tissue. All of these features distinguish apoptosis from 
necrosis which is commonly induced by external trauma in its broadest sense (mechanical 
trauma, heat, bacterial inflammation, and others) and affects continuous tissues rather than 
single cells within tissues. The cellular suicide program called apoptosis is an essential part of 
life for any multicellular organism and is largely conserved from worms to mammals (22, 23). 
In humans, optimum body maintenance requires about 10 billion of our cells to die on a 
normal day just to balance the new cells arising through mitosis. This process has to be tightly 
regulated (24) since too little or too much cell death may lead to developmental defects, 
neurodegeneration, autoimmune diseases or cancer. 
 
During development apoptosis helps to sculpture the body, shape the organs, and carve out 
fingers and toes (25). It is only by apoptotic elimination of the cells in between that the 
fingers can separate (26). The nervous system arises through overproduction of cells followed 
by the death of those that fail to establish functional synaptic connections (27). However, 
once a functional nervous system has been established, apoptotic deletion of neuronal cell 
types must be kept to a minimum. Pathological apoptosis in the adult brain may play a role in 
neurodegenerative diseases such as Alzheimer’s, Parkinson’s, Huntington’s disease or 
amyotrophic lateral sclerosis (28).  
In the immune system that must cope, on the one hand, with a broad variety of antigens and, 
on the other hand, with the danger of autoimmunity, more cells than finally needed are 
produced, followed by apoptotic elimination of autoreactive and dysfunctional T cells (29). 
Another distinctive feature in the immune system is its homeostatic control: after a clonal 
expansion phase, the number of antigen-reactive lymphocytes must be titrated back until the 
pool of lymphoid cells reaches the baseline level again (30). This is achieved by balanced 
fine-tuning between growth/expansion and death by apoptosis. Thus it is not surprising that 
too little or too much apoptosis results in immunodeficiency or autoimmunity.  
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In dividing cells, apoptosis is a common response to DNA injury. Accumulation of genetic 
alterations and subsequent malignant transformation can only occur when a cell fails to 
initiate apoptosis upon DNA damage. This implies that a defective apoptotic pathway is a 
prerequisite for tumour development – and the alterations responsible for this defect will also 
reduce sensitivity towards treatment with apoptosis-inducing anticancer agents (31). 
Therefore understanding apoptosis is often considered a key to understand the genesis of 
tumours and to devise innovative strategies for their treatment.  
Mechanisms (I): the intrinsic pathway 
Apoptosis can be initiated via two different pathways, the so-called intrinsic and the extrinsic 
(death receptor) pathway. The intrinsic pathway is activated by signals from within the cell 
such as genotoxic stress leading to DNA damage or nutrient deprivation (32, 33). Upstream 
sensors, including p53 and pro-apoptotic “BH3-only” proteins of the BCL-2 family (Bad, 
Bim, Noxa, and Puma, among others) (34-37), respond to select death signals and 
subsequently trigger the activation of the multidomain death effectors BAX and BAK (38, 
39). Activation of BAX and BAK can be prevented through sequestration of translocated BH-
3 only molecules by antiapoptotic BCL-2 or BCL-XL   (40). In most cell types, BAX and 
BAK constitute an essential gateway to the intrinsic death pathway operating at the level of 
both mitochondria and endoplasmic reticulum Ca2+ dynamics (41). Activated homo-
oligomerized BAX or BAK result in the permeabilization of the mitochondrial outer 
membrane and the release of proteins including cytochrome c (42). Released cytochrome c 
binds to monomers of Apaf-1 in the cytosol, inducing a conformational change that enables 
stable association with (deoxy)adenosine triphosphate. Apaf-1 monomers then assemble into 
the heptameric apoptosome, a caspase-activating scaffold which in turn binds to procaspase-9. 
Once procaspase-9 has been recruited to the apoptosome, it acquires catalytic competency, is 
proteolytically cleaved, and activates in turn the downstream effectors caspase-3, -6, and -7. 
These cysteine aspartyl proteases are the central executioners of most apoptotic processes 
(43).  They are synthesized as inactive pro-enzymes and become activated upon proteolytical 
cleavage by upstream caspases. This cascade of mutual caspase activation culminates in 
apoptotic cell death. 
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Fig. 1.1: The intrinsic (upper panel) and the extrinsic/death receptor (lower panel) pathway for apoptosis. Figures 
are modified from (24), Danial and Korsmeyer, 2004. See text for details. 
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In many experimental paradigms, apoptotic cell death can be prevented by pharmacological 
inhibition of caspases by suicide substrates such as zVAD-fmk. Inhibition of caspase–9, -3 
and –7 by elevated expression of XIAP (X-linked inhibitor of apoptosis) (44) contributes to 
the apoptosis resistance of many cancer cell lines (including glioma cells). However, it would 
be dangerous for an organism to depend on a single protease family for the clearance of 
unwanted and potentially harmful cells. Consequently, other proteases, including granzymes, 
lysosomal cathepsins, matrix metalloproteinases, and proteasomal proteases have also been 
implicated in apoptotic cell death. While these mechanisms are not fully consistent with 
classical apoptosis, they contribute to an active process that depends on signalling events in 
the dying cell and is thus distinct from necrosis. Often, this caspase-independent cell death 
also shows some characteristics of apoptosis. 
Mechanisms (II): the extrinsic pathway 
The detection of endogenous death ligands mediating the death of distinct target cell 
populations via activation of specific death receptors at the cell surface has led to the concept 
of what is now commonly called the extrinsic apoptotic pathway. The most important death 
ligands are tumour necrosis factor alpha (TNF-α) (45), CD95 ligand (CD95L), also known as 
Fas ligand or Apo-1 ligand (46), and Apo-2 ligand/TNF-related apoptosis-inducing ligand 
(Apo2L/TRAIL) (47). The receptors for these death ligands belong to the superfamily of TNF 
receptors (TNFR) (48). These membrane-bound receptors can be divided into two main 
subgroups on the basis of the cytoplasmic region of the receptor: the death receptor subfamily 
of TNFR contains a cytoplasmic death domain whereas the other subfamily does not. The 
death domain is crucial for the signalling of apoptotic cell death. It mediates the homotypic 
interaction of the death receptor with an adaptor protein containing both a death and a death 
effector domain. The members of this subfamily are TNF-R1, Fas/CD95, DR-3/Apo-
3/TRAMP, TRAIL-R1/DR4, TRAIL-R2/DR5/Killer and DR6. The TNFR family members 
TNFR2, CD27, CD30 and CD40 do not contain a death domain and need to recruit adaptor 
proteins such as SIVA-1 (49) in order to transduce apoptotic signals. However, in most cases 
these receptors transmit survival rather than death signals. Further, there are decoy receptors 
for TRAIL (TRAIL-R3, TRAIL-R4, osteoprotegerin) (50) and CD95/FasL (DcR3) (51, 52) 
that seem to have, if any, antiapoptotic properties. The differential distribution of agonistic 
and decoy receptors in normal tissue and in tumour cells may underlie the selective activity of 
Apo2L/TRAIL against tumour cells. Activation of death receptors requires engagement by 
trimeric ligand, leading to the formation of multimeric protein complexes. The CD95/Fas-
associated DISC (death-inducing signalling complex) (53) consists of the death receptor 
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Fas/CD95 itself, its adaptor protein FADD (Fas-associating protein with death domain) and 
procaspase 8. Instead of procaspase 8, its anti-apoptotic homologue c-FLIP (54, 55) may be 
incorporated into the complex where it prevents activation of the caspase cascade. However, 
if procaspase-8 assembles in the DISC to a high local concentration, this will lead to  
autoproteolytic cleavage and release of active caspase 8 into the cytosol. In SKW6.4 cells (56, 
57), where the Fas/CD95 pathway for apoptosis was discovered, caspase 8 may directly 
activate the downstream effector caspase 3 by proteolytic cleavage (see lower panel, Figure 
1.1). In most other cell types (including glioma cell lines), the DISC is formed quite poorly 
and only a small amount of active caspase 8 is produced.  This small amount of activated 
caspase 8 may, however, initiate a cascade leading to the release of cytochrome c from the 
mitochondrial intermembrane space, the assembly of the apoptosome, the activation of 
caspase 9 and the subsequent activation of caspases 3, 6 and 7. The molecular mechanisms 
underlying the amplification of the initial pro-apoptotic signal have not yet been fully 
resolved. In HeLa, Jurkat or MCF7 cells, caspase 8-mediated cleavage of the BH3 domain 
containing Bcl-2 family member BID (58, 59) may induce the proapoptotic functions of the 
mitochondria by causing aggregation of Bax or Bak (60), whereas similar experiments in 
glioma cells failed to reveal a critical role for tBID (61). Nevertheless, these experiments 
confirmed the requirement for mitochondrial amplification of the receptor-mediated pro-
apoptotic signal since overexpression of the antiapoptotic members of the Bcl-2 family was 
found to protect glioma cells against CD95L or Apo-2L/TRAIL-induced apoptosis (61, 62). 
Consequently, the intrinsic and the extrinsic apoptotic pathway converge at the mitochondria, 
which appear to be the central integrators of pro- and anti-apoptotic signalling. 
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Fig. 1.2. A schematic representation of the apoptotic pathways in glioma cells, showing the convergence of the
intrinsic and the extrinsic apoptotic pathway at the level of effector caspases and the mitochondrion. In the
extrinsic pathway the engagement of death receptors by death ligand results in the formation of the death-
inducing signaling complex (DISC) together with adaptor molecules, leading to the proteolytic activation of
regulatory caspases, typically caspase 8, and thereby caspases 3 and 7. In one instance of the intrinsic pathway,
DNA damage, expression of multi-domain pro-apoptotic members of the bcl-2 family, for example BAX or
BAK, or other unknown events causes mitochondrial pore formation and the release of cytochrome c. This in
turn allows the formation of the apoptosome together with APAF-1 and the activation of a regulatory caspase,
usually caspase 9, and thereby caspases 3 and 7. In addition survival signals emanating from survival ligands and
receptors can inhibit the pro-apoptotic members of the bcl-2 family, or caspases via caspase inhibitors such as
IAP or XIAP. Under conditions, where caspase activation is blocked (or triggered inefficiently), Ca2+
mobilization or cytochrome C release may also result in caspase-independent cell death. Cross talk between the
pathways is indicated by the proteolytic activation of a pro-apoptotic member of the bcl-2 family by caspase 8
(modified from (431),  Bögler and Weller, 2002). 
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Apoptosis in cancer therapy 
Selective induction of apoptosis in cancer cells is a key concept for the therapy of malignant 
gliomas (62, 63). Current therapeutic strategies, including radiotherapy and chemotherapy, do 
probably not induce a substantial degree of apoptosis in human malignant gliomas, since 
current glioma treatments, if successful at all, seem to stop growth rather than actually kill (as 
judged from the failure to induce a regression of the tumour size). This is likely to be due to 
an overexpression of antiapoptotic (BCL-2, BCL-XL, XIAP) relative to proapoptotic (BAX, 
BAD, BAK) regulators of apoptosis (64, 65). However, death receptors of the tumour necrosis 
factor (TNF)-receptor family are (over)expressed on tumour cells (66) and therefore represent 
potential therapeutic targets. Sensitization of glioma cells to TRAIL/Apo-2L-induced 
apoptosis can be achieved in vitro and in vivo by antagonizing BCL-2 and BCL-XL using 
Smac peptides (67). Given the increased selectivity achieved through combined treatment 
with an appropriate sensitizer and an apoptotic stimulus (that may be regionally delivered), 
therapeutic regimens inducing a substantial degree of apoptosis in glioma cells without 
detectable toxicity to normal brain tissue may become possible in the future. 
 
The ultimate goal of an anti-glioma therapy based on the selective induction of apoptosis in 
tumour cells would, of course, be the complete eradication of the tumour. Further, it has been 
shown that apoptotic tumour cells can be taken up by antigen-presenting cells and induce a 
potent anti-tumour immune response in vivo (68-71). Therefore, successful induction of 
apoptosis in a reasonably large proportion of glioma cells might trigger a subsequent 
immunological response, leading to a more favourable clinical outcome than would be 
expected based on the efficiency of the pro-apoptotic strategy alone. 
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Tumour immunology and immunotherapy: 
 
The concept of immune surveillance – a historical overview 
Tumour immunotherapy was initiated in 1893 when William Coley used extracts of pyogenic 
bacteria to cause sporadic anti-tumour responses (72). The concept that the immune system 
can recognize and eliminate developing tumours in the absence of external therapeutic 
intervention has first been proposed in 1909 by Paul Ehrlich (73). In 1959, Lewis Thomas 
described homograft rejection as a primary defence against neoplasia (74). The term “tumour 
immune surveillance”  was coined by Frank Macfarlane Burnet in 1967 (75-77). Clinically, a 
highly elevated incidence of virally induced malignancies such as HHV-8 (human herpes 
virus type 8)-dependent Kaposi's sarcoma and EBV (Epstein-Barr-virus)-associated primary 
cerebral lymphoma has been documented in immunodeficient or immunosuppressed 
individuals. However, the hypothesis of immune surveillance against non-viral cancers was 
challenged in 1974 when nude mice, lacking T cells, did not show a higher incidence of 
cancer than syngeneic immunocompetent mice (78, 79). These experiments were considered 
to be so convincing that it led most researchers to give up the cancer immunosurveillance 
hypothesis. What was not recognized at that time is that nude mice are an imperfect model for 
immunodeficiency: They possess a fully functional innate and a residual adaptive immune 
system. Improved models of immunodeficiency have now led to a renaissance of the concept  
of immunosurveillance. Compared to their wild-type counterparts, IFN-γ /  C57BL/6 mice 
show an increased incidence of disseminated lymphomas, and IFN-γ /  BALB/c mice display 
an increased incidence of spontaneous lung adenocarcinomas (80). Mice lacking perforin 
(pfp /  ) are more susceptible to chemically induced and spontaneous tumour formation than 
the respective control mice (81). Finally, the existence of a lymphocyte-dependent cancer 
immunosurveillance process has been demonstrated in experiments employing gene-targeted 
mice that lack the recombinase activating gene (RAG)-2 (82). These mice cannot rearrange 
lymphocyte antigen receptors and thus lack T, B, and NKT cells (83). Since RAG-2 
expression is limited to cells of the immune system, the knockout of RAG has no direct 
effects on  nonlymphoid cells undergoing transformation. Thus RAG-2 /  mice provide a 
suitable system for studying the effects of host immunodeficiency on tumour development. 
Within 2 years, all of 26 RAG-2 /   mice succumbed to spontaneous epithelial tumours 
whereas only 5 of 20 wild-type control mice developed (predominantly benign) spontaneous 
neoplasias. Based on these observations, the concept of immunological anti-tumour 
surveillance has now been widely accepted. 
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Basic functions of the immune system 
In order to understand how the immune system can protect an organism against cancer, it is 
necessary to understand the basic principles of immunological recognition of cellular targets. 
The principal function of the immune system is to protect the organism against the attack of 
foreign pathogenic organisms, such as parasites, fungi, bacteria and viruses. An efficient 
destruction of pathogens is essential for survival in any non-sterile environment while 
harmless environmental influences (such as pollen) should not induce an immune reaction. 
Tolerance towards the components of the own body is crucial for the prevention of 
autoimmunity while reactivity against aberrant cells is required for tumour 
immunosurveillance. Thus the immune system has to discriminate between “self”, “altered 
self” (84) and “non-self” – and, in the case of “non-self”, to decide whether it is necessary to 
launch an attack against the detected antigen. 
 
These complex requirements can only be met by a well-organized ensemble of cells with 
different specificities. All cells of the immune system derive from the pluripotent 
haematopoietic stem cells in the bone marrow. In newborns, only the innate immune system is 
fully evolved whereas the adaptive immune system arises through constant learning from 
environmental influences. 
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Innate immunity 
The innate immune system consists of anatomical barriers such as skin and mucosae, of 
soluble factors including lysozyme, interferons and complement and of cellular components, 
namely granulocytes, macrophages, monocytes, mast cells, natural killer (NK) and γ:δ T cells. 
These components of the innate immune system can destroy invading pathogens without 
deliberate immunization or activation. Innate immune cells recognize pathogen-associated 
molecular patterns (PAMPs), i.e. structural motifs that are conserved on pathogenic 
microorganisms and absent from eukaryotic cells via pattern recognition receptors (PRR). 
Endocytic pattern-recognition receptors (mannose or scavenger receptors) are found on the 
surface of phagocytes like macrophages or neutrophilic granulocytes. Their activation 
promotes the engulfment and destruction of microorganisms (85). Signalling PRR include 
CD14 and the group of toll-like receptors (TLR). Importantly, expression of TLR is not 
restricted to innate immune cells (86). 
 
NK cells (87) are cytotoxic effectors (88) of innate immunity that can lyse tumour cells or 
virus-infected cells without prior activation (89). However, they also respond to stimuli from 
antigen-presenting cells sensing pathogens or cellular stress signals (90). NK cells 
preferentially attack targets lacking the “self” recognition signal provided by expression of the 
major histocompatibility complex (MHC) class I antigen found on the surface of most 
nucleated cells (91). Further, they transmit danger signals (92) by the release of inflammatory 
cytokines, triggering a subsequent, antigen-specific adaptive immune response.  
 
Recent studies have shown that the innate arm of the human immune system may also 
participate in cancer immunosurveillance. Discrimination between tumour cells and normal 
cells can be achieved through “induced self-recognition”: The activation state of NK cells is 
regulated by the equilibrium between the input received from stimulatory (NKp, NKG2D) and 
inhibitory (NKG2A, KIR) NK cell receptors (93). Cellular stress like viral infection or 
malignant transformation induces MHC class I chain-related proteins A and B (MICA/B) and 
UL-16 binding proteins (ULBP1-4), all of which are absent from normal somatic cells. Some 
expression is found on intestinal epithelia, most likely due to the continuous presence of 
symbiotic bacteria on these tissues. Activation of the NKG2D receptor by these ligands (94, 
95) may overcome the inhibitory effect of “self recognition”. Activated NK cells would then 
induce apoptosis in the recognized target cell by releasing cytotoxic granules containing 
perforin and granzyme B and by upregulating death ligands (88, 96, 97). This NK cell 
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response may therefore clear malignant cells before they can form a tumour (98). Further, 
IFN-γ and other inflammatory cytokines are released by activated NK cells. Innate immunity 
thus provides a strong activation stimulus for the adaptive immune system while specific T 
cells can build up in the lymph nodes. 
 
 
Adaptive immunity (I): Lymphocytes 
The main features of the adaptive immune system are specificity, diversity, long-term 
memory and the ability to distinguish between self, altered self and non-self. These attributes 
are guaranteed by subsets of professional antigen presenting cells (APC) and lymphocytes. In 
birds, B lymphocytes mature in the bursa fabriciis, in humans, they originate (like all other 
lymphocytes) from lymphoid progenitors in the bone marrow. B cells are responsible for 
antibody production and thus for humoral immunity. The cellular effectors of the adaptive 
immune system are T cells. 
 
 
Antigen recognition by T cells 
T cells recognize fragments from proteins degraded in the cytosol or nucleus or generated in 
the endocytic pathway when these peptides are presented on MHC (major histocompatibility 
complex) molecules. MHC class I enables the immune system to spot hidden pathogens. Once 
the proteasome has cleaved proteins into peptide fragments, these are translocated into the 
lumen of the endoplasmatic reticulum by a specific transporter associated with antigen 
processing (TAP). 
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 cartoon by Eric Reits 
Fig. 1.3: The generation of antigenic peptides for MHC class I. (With kind permission from Eric Reits) 
 
In the endoplasmatic reticulum, peptide binding to the MHC class I complex occurs. This 
MHC class I complex consists of an α or heavy chain encoded in the MHC and a smaller, 
non-covalently associated chain, β2-microglobulin, which is not encoded in the MHC. Upon 
loading with peptide, the MHC class I complex is transported to the plasma membrane where 
the antigenic peptide is presented to CD8+ T cells (CTL). 
  
s cartoon by Eric Reit
 
)Fig. 1.4: MHC class I loading with antigen. (With kind permission from Eric Reits
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CD4+ T “helper” cells recognize antigens presented on MHC class II. MHC class II epitopes 
are generated by cathepsin-dependent cleavage of antigens taken up in the endocytotic 
pathway. Peptide-loading of MHC class II molecules is supported by the chaperone HLA-
DM. HLA-DO can interact with HLA-DM  and restrict peptide loading of HLA-class II 
molecules to late endocytic structures (99). 
 
 cartoon by Eric Reits 
.
 
 
T cell development 
During their development, T cells have to pass through the thymus where a diverse and 
polymorphic T cell repertoire is generated by random recombination of discrete T cell 
receptor gene segments. Recombinatorial diversity would allow for a calculated 1016 different 
T cell receptor specificities, even though there are only up to 1012 T cells in the human body. 
This repertoire is then shaped by intrathymic selection for two criteria: Dysfunctional T cells 
that fail to express a T cell receptor that recognizes self-MHC are deleted during positive 
selection (100). Cells that react with self-antigens presented in the thymic medulla are 
eliminated during negative selection (101). The former requirement guarantees that T cells 
recognize presented peptides only in the context of self-MHC, named “self restriction” (102). Fig. 1.5. MHC class II loading (with kind permission from Eric Reits) 
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The second selection step secures that autoreactive T cells, i.e. T cells specific for “self”-
peptides presented on ”self”-MHC, are eliminated, leading to self-tolerance. During this 
thymic selection process, 96-98% of all T cell precursors are deleted through apoptosis. The 
selected T cell repertoire still comprises an estimated 2.5x107 T cell clones with different 
specificities (103). Thus, the naїve T cell repertoire is shaped to show a rather high diversity - 
at the expense of a limited number of copies of each clone in the body. This highly diverse 
pool of cells expressing the αβ T cell receptor can be divided in two major subsets defined by 
expression of the respective co-receptor: CD8+ T cells or cytotoxic T lymphocytes (CTL) can 
secrete cytotoxic granules and upregulate death ligands when they “see” their cognate peptide 
(8-10 amino acids) presented in the context of MHC class I (104-106). CD4+ T cells 
recognize their antigen (15-20 amino acid epitopes) through presentation on MHC class II 
(107).  The cytotoxic potential of CD4+ T cells is restricted to the expression of death ligands 
(CD95/FasL, Apo2L/TRAIL). The main function of CD4+ “helper” T cells is to secrete 
cytokines (chemical messengers) that activate and regulate B cells, CTL and APC. 
 
Adaptive immunity (II): antigen-presenting cells 
“Nature’s best antigen-presenting cells” are the so-called dendritic cells (DC) (108, 109). The 
two major subsets of DC are myeloid-derived DC (110, 111) and plasmacytoid DC (112). 
However, it is not yet clear whether they fulfil different functions. Immature DC (and 
macrophages) can take up antigen via pinocytosis and, more importantly, via receptor-
mediated endocytosis of apoptotic and necrotic cellular material. This has been explained by 
expression of CD36, αvβ3- and αvβ5-integrins on immature, but not on mature dendritic cells 
(113). CD36 is a receptor for phosphatidylserine that is normally restricted to the inner leaflet 
of the cell membrane, but becomes exposed on the outside during apoptosis and late necrosis. 
In the presence of danger signals (92, 114), DC then maturate. Danger signals can be 
stimulatory cytokines like TNF-α, TNF-related cellular (or soluble) ligands like CD40L, but 
also microbial products recognized by TLR that are abundantly expressed on DC (115, 116). 
Mature DC upregulate their antigen processing machinery (the so-called immunoproteasome) 
to generate and present antigenic peptides derived from the engulfed material. Interestingly, 
certain components of the immunoproteasome assemble in an IFN-γ-dependent manner. Thus, 
the quality and quantity of antigenic peptides generated from a certain target antigen is likely 
to change in the course of an ongoing immune reaction (117). Presentation of antigens by 
professional APC has, at least, two distinct advantages. While virtually all somatic cells 
except testis and some transformed cells express MHC class I and can therefore present 
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peptide epitopes to CTL, MHC class II is mainly expressed on APC. Therefore the helper T 
cells required to orchestrate the adaptive immune response are only insufficiently activated by 
presentation of pathogenic material on non-professional APC. Further, activated DC provide 
co-stimulation to T cells, mainly via expression of B7.1 (CD80) and B7.2 (CD86) (118).  
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Tumour cell recognition by the adaptive immune system 
In order to understand the basis for the recognition of cancer cells by the components of the 
adaptive immune system it has to be envisaged that cancer is a genetic disease. Cancer cells 
are “altered self” by virtue of aberrant gene expression. The genetic alterations occurring 
during tumorigenesis lead to expression of proteins that are not found in normal cells, or not 
expressed at high levels in normal cells, or only expressed in normal cells at certain stages of 
development. While overexpression of self may not necessarily be immunogeneic, de novo 
induced tumour-associated antigens (121) should be recognized by the immune system as 
altered self. 
 
Despite strong evidence supporting the existence of a functional cancer immunosurveillance 
process (122, 123), immunocompetent individuals still develop cancer. This may be due to 
cancer cells simply overgrowing the response – or to the outgrowth of tumours that interfere 
with the cascade from tumour cell recognition to tumour cell elimination. Immunotherapy 
now aims at overcoming this inhibition (124). In order to devise a rationally designed 
immunotherapy, the possible shortcomings of the spontaneous anti-tumour response have to 
be analysed. 
 
Evidently, the concept of anti-cancer immunotherapy requires the respective tumour to be 
immunogenic. Consequently, identification of tumour antigens that might enable T cell 
recognition of transformed cells is of major interest. Serological analysis of tumour antigens 
by recombinant cDNA expression cloning (SEREX) (125) relies on antibody responses in 
cancer patients and cancer-free individuals. One major shortcoming of SEREX is that 
responses against post-translationally modified proteins cannot be detected since the method 
screens for serum reactivity against a bacterially expressed cancer cell cDNA library. 
Expressing the tumour cell cDNA library in yeast rather than in bacteria may overcome this 
limitation. A further problem is posed by the assumption that antigens which induce a B cell 
and CD4+ T cell-dependent antibody response may also be suitable targets for CTL activation. 
While this seems to be true in some cases, the number of tumour antigens defined by SEREX 
screening currently greatly exceeds the number of tumour-specific CTL epitopes known. 
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s being pursued in Tübingen (126): Protein and mRNA from tumour and surrounding tissue 
re extracted in parallel and MHC complexes from tumour and normal tissue are eluted to 
etermine tumour-specific peptides. Then the immunogenicity of these peptides is determined 
sing autologous PBMC. Further, a gene chip array screens for tumour-specific antigen 
xpression. The results of this array are then correlated with the antigenic peptides found in 
he respective tumour - and with the individual HLA isotype of the patient. Since each HLA 
olecule owns its own peptide specificity, the target epitopes that are presented (and 
ecognized) do not only depend on the expression of the respective tumour antigen, but also 
n the HLA context in which they are presented. Eventually this approach may enable the 
rediction of an individually-customized selection of antigenic peptides for each tumour 
atient according to the results of a gene chip array and his or her HLA isotypes. 
mmunogenic tumour antigens have now been identified for most human tumour types, 
ncluding glioma (127). Of the greatest interest are those tumour-associated antigens that are 
ot found in adult normal tissues. Typically these are differentiation antigens (e.g., 
elanocyte differentiation antigen, Melan-A/MART-1, tyrosinase, gp-100), expressed 
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exclusively in germ cells in the testis and therefore named “cancer testis” or “cancer germline 
antigens” (128). However, since germ cells do not express MHC molecules, immunological 
presentation of these antigens is strictly confined to tumour cells. Further, mutational antigens 
(e.g., abnormal forms of p53) may be highly tumour-specific. Also overexpressed/amplified 
antigens (e.g., HER-2/neu, telomerase) and viral antigens (e.g., Epstein Barr virus and human 
papilloma virus) may be good targets for an anti-tumour immune response, especially when 
they are both immunogenic and responsible for the malignant phenotype – otherwise the 
genomic instability of tumour cells (129) may lead to antigen loss, giving rise to new tumour 
cell variants displaying increased resistance to immune attack. Thus the selection of a good 
target antigen, or, much better, simultaneous targeting of different tumour antigens, is critical 
for immunotherapy. 
 
Cancer immunotherapy: current strategies 
The problem of defining an optimal antigen is circumvented by approaches that attempt to 
stimulate anti-tumour immunity in general and do not target specific antigens. This may be 
achieved by the administration of cytokines (130). Clinical trials have shown some tumour 
regressions in response to IL-2, GM-CSF, IL-15 and IL-18. However, while cytokines may 
well be used as adjuvants in combination with other treatments, on their own they only have a 
modest therapeutic effect. 
 
An innate immune response can be elicited by administration of autologous, irradiated tumour 
cells that have been engineered to overexpress stimulatory NK cell ligands. These 
“therapeutic tumour cells” are thought to be lysed by NK cells. Further, this vaccine 
stimulates NK cells to produce IFN-γ, thus setting up an inflammatory cascade. As a result of 
these processes, a source of tumour antigens from apoptotic tumour cells becomes available 
and the adaptive immune system is recruited into the process. For gliomas, this approach has 
been successfully employed in a mouse model (131).  Basically any process that causes 
limited destruction of tumour material which can then be taken up and transported into the 
lymph nodes by DC could provide such a trigger to the adaptive immune system. Thus, 
spontaneous or therapeutically induced apoptosis of tumour cells in conjunction with 
inflammatory cytokines might also assist in the initiation of an anti-tumour immune response. 
 
However, while most tumours display antigens that could - upon appropriate presentation by 
DC - initiate an anti-tumour T cell response, antigen presentation is compromised in tumour 
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patients. Treatment of DC with tumour cell supernatant leads to a decreased expression of the 
components of the antigen-processing machinery and inhibits maturation and expression of 
costimulatory molecules. T cells “seeing” their cognate antigen on such immature DC become 
anergic. Still, infiltration of tumour with DC can be predictive for long-term survival (132), 
providing a good rationale for a DC-based cancer immunotherapy. Further, a clinical trial 
using DC with mRNA encoding a tumour antigen (in this case, prostate specific antigen) 
yielded some clinical responses (133). 
 
Considering the importance of DC maturation states, ex vivo antigen loading with apoptotic 
tumour cells or tumour cell mRNA, followed by cytokine-induced maturation and subsequent 
adoptive transfer has been chosen for most clinical trials (134-136). However, in the in vivo 
situation, external loading may not be necessary, since a wide variety of antigens is constantly 
taken up by immature DC. When maturation and activation of immature DC is induced in 
vivo (e.g. by injection of suitable adjuvants), these matured DC migrate towards the lymph 
nodes where the naturally ingested antigens are presented to T cells. Upon antigen encounter 
on mature DC, these T cells expand, downregulate their homing receptors CD62L and CCR7 
and locate to the tumour. This may have happened in those cancer patients that were treated 
with bacterial extracts by William Coley in 1893 (72). A molecularly more defined approach 
is the administration of unmethylated cytidine-phosphate-guanosine dinucleotides in specific 
sequence contexts. These CpG-oligodeoxynucleotides (CpG-ODN) mimic the 
immunostimulatory characteristic of bacterial cDNA and provide a strong maturation stimulus 
for TLR9 (137, 138). While CpG-ODN on their own (139) or as adjuvants (140) can elicit 
potent anti-tumour responses in mice, they have strong side-effects (141). A safer alternative 
may be the use of stabilized single-stranded RNA molecules that activate TLR7 (142, 143). 
 
A DC-related approach is based on the use of DC-derived exosomes (DEX) (144). These are 
small vesicles (60-80 nm) containing MHC class I, MHC class II, hsc73, hsp54 and CD86, 
among others. DEX can be obtained from leukapheresis and loaded with antigens indirectly 
via DC or directly with peptides. They can stimulate T cell responses when co-stimulation is 
provided by some other means. A clinical phase I trial has shown that DEX can be obtained 
from cancer patients, are generally well tolerated and elicit NK cell-dependent anti-tumour 
responses. DEX-induced, specific CTL can be found, but show poor killing capacity.  
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Tumour cell derived exosomes (TEX) exist in vivo, too (145). TEX content differs from 
whole cell protein content in that it is enriched in MHC class I and contain neither MHC class 
II nor heat shock proteins. Ascites-derived TEX elicit an immune response in otherwise 
poorly immunogenic mouse models. Also peptide-hsp70-gp96 complexes may be eluted from 
tumours. Administration of autologous, tumour-derived peptide-heat shock protein complexes 
(Oncophage) appears to be a safe, but laborious method that induced anti-tumour CD8+ T cell 
responses in about 50% of the treated patients (146). A major advantage is the large peptide 
repertoire contained in these complexes as well as in TEX. 
 
Vaccination strategies using distinct antigenic peptides are also being employed. Since natural 
antigenic peptides are suboptimal immunogens, most studies use adjuvants or modified 
peptides to enhance the vaccination effect. Further, simultaneous targeting of several antigens 
could reduce the danger of immune escape by antigen loss (147). Long peptides that require 
processing by professional APC may have more favourable pharmacokinetics since they 
cannot be loaded on MHC molecules on non-professional antigen-presenting cells where they 
would be presented in the absence of co-stimulation and could induce tolerance. Finally, 
peptides encompassing both MHC class I and MHC class II epitopes have turned out to be 
most effective in a mouse model, supporting a role for CD4+ helper T cells as well as for CTL 
(148). 
 
Irrespective of the stimulus provided, any successful immunotherapy must induce a sufficient 
number of fully activated tumour-specific CTL that go into the tumour. Therefore a 
monitoring of T cell responses in cancer patients should include the therapeutically induced 
expansion of antigen-reactive T cells as well as their functional characteristics and 
localisation. The relative frequency of tumour-specific T cells induced upon vaccination can 
be analysed by tetramer staining for antigen reactivity (detection limit 1: 5000). In order to 
distinguish between clonal expansion and high thymic output, the proliferative history of T 
cells can further be traced by T cell receptor excision circles (TREC) (149) and telomere 
lengths (150). Functional criteria for tumour-specific CTL are IFN-γ production and lytic 
activity in response to challenge with antigenic peptide or syngeneic tumour cells. 
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Cancer immunotherapy: clinical responses 
Cancer immunotherapy has already shown that it can be clinically effective, even though this 
is rather the exception than the rule. This may partly be due to immunotherapy being largely 
restricted to late-stage cancer patients that have already gone through several (unsuccessful) 
conventional therapies. Throughout most clinical trials, however, tumour regression is 
observed in a small but significant proportion of patients that respond to vaccination with 
selective expansion of antigen-specific CTL whereas regression hardly occurs in the absence 
of T cell expansion. Surprisingly, data from melanoma patients vaccinated with MAGE3.A1 
peptide together with different adjuvants suggest that clinical efficacy does not critically 
depend on the immunogenicity of the vaccine. Neither does the rate of expansion of peptide-
specific CTL clones correlate with clinical outcome. Low-frequency CTL may be sufficient to 
induce a relevant response. Instead, tumour regression was found to be associated with the 
presence of a broad repertoire of CTL that did not necessarily recognize the initial vaccine, 
but displayed lytic activity against autologous tumour cells. Frequency calculations suggested 
that these T cell clones had been activated in vivo after the vaccination (151). Apparently a 
successful vaccination can induce one or more tumour-specific T cell clones that may destroy 
some tumour tissue which can then be taken up by professional APCs, most likely by DC. If 
these can present the ingested antigens appropriately, they will induce responses from new 
precursors. This is called “epitope spreading” and appears to be crucial for the clinical 
outcome. However, antigen spreading seems to occur in only ~ 20% of cancer patients. 
Intriguingly, the clinical efficacy through all immunotherapeutical trials is rather constantly ~ 
20% (personal communication from Pierre Coulie, Brussels), suggesting that 80% of non-
responders have their immune-response compromised by tumour-derived immunosuppressive 
factors. 
 
Tolerization of T cells against tumour cells has been observed in melanoma patients that were 
vaccinated with MART-1 specific peptides (152). Antigen-driven expansion of MART-1- 
reactive T cells was found in tumour-infiltrated lymph nodes of all responders (T cell 
frequency: 1,4 ± 3 %). However, these CD8+ T cells contained hardly any perforin or 
granzyme B and showed no detectable IFN-γ release upon challenge with an antigenic 
peptide, while responding normally to PMA/ionomycin. Since MART-1-reactive T cells from 
the peripheral blood of these patients were fully functional, tolerization must have occurred in 
the metastatic lymph nodes. In vitro stimulation with IL-2 could re-functionalize these cells. 
Other studies also described massive lymphocyte apoptosis in the tumour microenvironment. 
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While TREC numbers indicated increased T cell proliferation rates, apoptosis (as assessed by 
AnnnexinV-staining) was dominant, leading to lymphopenia, a symptom that is frequently 
observed in tumour patients. In particular, 97% of MART1-reactive CD8+ T cells were 
apoptotic. 
 
Cancer immunoediting and immune escape 
These strong immunosuppressive properties of tumour cells have led to the concept of “cancer 
immunoediting” (153, 154). Tumours are shaped by a constant interaction with the host’s 
immune system. During tumorigenesis the majority of transformed cells may be eliminated by 
the immune system. However, new variants carrying different mutations are likely to arise. A 
continuous Darwinian selection process will eventually lead to a population of tumour cell 
clones with reduced immunogenicity that have a better chance of survival in an 
immunocompetent host. Finally, genetic and epigenetic alterations will have produced tumour 
cells that are resistant to immune detection and/or elimination, allowing the tumours to 
expand and become clinically detectable. Accordingly, tumorigenicity dominates 
immunogenicity in any clinically manifest tumour. Stimulating the immune system or 
relieving tumour-dependent immunosuppression may both tilt that balance towards improved 
tumour cell recognition and elimination. 
 
Glioma-dependent immunosuppression 
Glioblastoma is paradigmatic for tumour-induced immunosuppression. Further, glioblastomas 
grow in the “immune-privileged” context of the brain (155). This “immune privilege” has 
formerly been explained by the blood-brain barrier that excludes naïve T cells from the brain. 
However, T cells with an activated phenotype may well enter the inflamed brain (156, 157) 
where they, surprisingly, secrete neurotrophic factors (158, 159). Since the blood-brain barrier 
is largely destroyed at least within the bulk tumour mass in glioma patients, it does not 
preclude anti-tumour immune reactions. The infiltration of malignant gliomas by lymphocytes 
and macrophages confirms a potential for lymphocyte homing and presentation of processed 
tumour antigens (155). However, the exact mechanisms for intracerebral antigen presentation 
remain to be clarified. It is thought to be mediated mainly by microglia, astrocytes, 
endothelial cells and capillary pericytes and thus substantially different from antigen 
presentation in the periphery (160). Further, there is no anatomically defined drainage from 
the brain to the lymph nodes which may explain difficulties in amplifying an initial immune 
response. Instead, the role of lymphatic drainage may be subserved by the movement of 
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cerebrospinal and brain fluid (transporting a bulk of potentially antigenic material) to cervical 
lymph nodes (161-163). Further factors contributing to the immune privilege are a high local 
concentration of immunosuppressive mediators such as neurotransmitters, neurotrophins and 
TGF-β (164), the expression of CD95/FasL and Apo2L/TRAIL on residential brain cells that 
may induce immune cell apoptosis (165) and tolerogenic DC in the brain (166).  
 
The importance of these immunologically unfavourable surroundings is stressed by the fact 
that gliomas do not metastasize outside the brain. This suggests that outside of their immune-
privileged compartment, the immunogenicity of glioma cells can dominate their 
tumorigenicity. Nevertheless, it has now become clear that antigens in the brain, including 
those expressed by cerebral malignancies, can induce immune responses in vivo (167, 168). 
Accordingly, glioma infiltration by tumour-reactive T cells has been described (169). Still, the 
intracerebral tumour-host immune response is in favour of the tumour and immune responses 
are severely compromised in glioma patients (155). Tumour infiltrating (and peripheral) 
lymphocytes show high rates of apoptosis. Glioma-infiltrating T cells show delayed 
hypersensitivity responses, depressed mitogen responsiveness and impaired T cell 
cytotoxicity. Further, activatory T and NK cell receptors become downregulated even in the 
peripheral blood of glioma patients (unpublished observation, see section 8). Lymphocytes 
from healthy donors are similarly compromised in the presence of glioma cells or supernatant, 
proving that glioma cells exert acute immunosuppression (and that the tumour did not arise 
opportunistically as a result of impaired immune function). Antigen presentation is also 
inhibited by glioma cells: glioma cell supernatant strongly inhibits the maturation of dendritic 
cells (unpublished observation). Further, microglial cells, that might serve as APC in the 
brain, seem to support rather than suppress glioma growth (170), indicating that they may be 
functionally controlled by the tumour. 
 
Relieving glioma-induced immunosuppression could tilt the balance of tumour-host immune 
interactions in favour of the host, especially when a good source of antigen (a defined vaccine 
or appropriately presented apoptotic tumour cell material) was provided. Therefore a 
combined approach that induces apoptosis in glioma cells and ameliorates glioma-dependent 
immunosuppression at the same time might enable a therapeutic T cell response. Tumour-
reactive T cells are highly specific, display potent cytotoxicity against their targets (while 
sparing the surrounding tissue), generate long-term immunological memory and would 
therefore be eminently suitable for eliminating dispersed glioma cells in the brain. 
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Experimental overview 
 
Induction of glioma cell death by rescue of mutant p53 using the experimental drug CP-31398 
The first parts of the results section of this PhD thesis describe novel strategies for the 
selective induction of cell death in glioma cells. In this context, the effects of the experimental 
p53 rescue drug CP-31398 (19) on malignant glioma cells were investigated. Mutational 
inactivation of the tumour suppressor protein p53 is the most frequent molecular alteration in 
all human cancers (>50%). Sequencing confirmed that this “guardian of the genome” (171) is 
mutated in 8/12 human glioma cell lines. Functional p53 senses genotoxic stress that may lead 
to DNA damage. Through activation of various p53 response genes, including p21 and bax, 
damaged cells are arrested in G0/1 or G2/M phase. In case of an irreparable cellular damage, 
p53 initiates apoptosis by transcription-dependent and transcription-independent mechanisms 
(39, 172-174). Approaches aiming at pharmacological reactivation of mutant p53 should 
therefore specifically inhibit the growth and survival of cancer cells bearing mutant p53 (175). 
As will be outlined in chapter 2, treatment of malignant glioma cell lines with the 
experimental p53-rescue drug CP-31398 (19) resulted in the induction of p53-dependent 
target genes and in caspase-independent cell death displaying some features of apoptosis. 
However, cell lines harbouring wild-type p53 and p53-/- cell lines were also affected by this 
reagent, showing that the specificity of the experimental drug needs to be greatly improved. 
The present work also sought to characterize the undesirable effects of CP-31398. A better 
understanding of the p53-independent effects of this lead substance may guide the 
development of compounds hitting solely at p53 – or at p53 and its homologues p63 and p73 
(176). In fact, some effects that have been attributed to p53 may rather be mediated by p63 or 
p73 – and they may be repressed by the presence of an excess of mutant p53. This would 
explain the surprising induction of p53-like reporter gene activity in a p53 mutant cell line 
following siRNA-mediated knock-down of mutant p53 (177, 178). Based on this observation, 
the specificity of a commonly used reporter gene for p53 was investigated (chapter 3). It 
turned out that p63 or p73 may be even stronger activators of p53-dependent consensus 
sequences than p53 itself. These data therefore show that much of the literature on p53 may 
represent an oversimplified picture and should be treated with caution. Still, the quantification 
of a net effect derived from p53, p63 and p73 may provide a perfectly sensible physiological 
parameter. 
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Activating the extrinsic apoptotic pathway via CD40 
An alternative to the selective activation of the intrinsic apoptotic pathway would be the 
selective induction of apoptosis in cancer cells by triggering the extrinsic or death receptor 
pathway. However, the massive hepatotoxicity of CD95/FasL (179) and the uncertain activity 
of clinically applicable Apo2L/TRAIL preparations (180) have so far prevented the 
translation of this approach into the clinic. Strategies to overcome these obstacles involve the 
regional delivery of Apo2L/TRAIL (181) and the directed killing of target cells via bispecific 
antibodies (182). Another, presumably safe option might be the triggering of CD40. While 
CD40 transduces survival signals in somatic cells, induction of apoptosis has been reported 
exclusively in transformed cell lines (183). Based on this rationale, expression and function of 
CD40 in malignant glioma cells were investigated (chapter 4).  
 
A further advantage of CD40L as a cancer therapeutic is that it may not only induce apoptosis 
in tumour cells. CD40L can also promote the priming of a potent antitumour immune 
response in the presence of apoptotic tumour cells (148, 184). Since glioma-derived inhibitory 
signals dominate tumour-host interactions in patients, the generation of apoptotic tumour cell 
material alone will probably be insufficient to trigger a productive anti-tumour immune 
response. It may further be necessary to provide additional immune stimulation and to 
overcome glioma-dependent immunosuppression. While a modest enhancement of anti-
lymphoma immune responses by CD40L has already been shown in a clinical trial (185), the 
potential targets for relieving glioma-dependent immunosuppression are less well defined. 
  
Glioma-induced T cell apoptosis via CD70/CD27 as a mechanism for immune escape 
In this context, chapter 5 of the present work describes a novel mechanism by which glioma 
cells may compromise anti-tumour immunosurveillance. The TNF family member 
CD70/CD27L (186) had previously thought to be expressed exclusively on activated B and T 
cells where it provides co-stimulatory signals to T cells and a strong activatory signal to NK 
cells. However, aberrant expression of CD70 on glioma cells can induce apoptosis of immune 
effector cells via its receptor CD27 that is constitutively expressed on T cells. Such a 
dichotomy is characteristic for members of the TNF family: TNF-α can activate NF-κB 
which then transmits survival signals and protects cells from apoptosis. However, if NF-κB 
signalling is inhibited, TNF-α becomes a strong pro-apoptotic stimulus (187). Also 
CD95/FasL can act both as a growth factor (188) and as a death signal (63) in tumour cells. 
CD40L (CD154) can induce apoptosis exclusively in cancer cells (183) and, apparently, 
 42 
CD70/CD27L only leads to the apoptotic elimination of non-transformed immune cells when 
it is expressed in the context of further immune-regulatory molecules expressed by malignant 
cells. This shows that the physiological outcome of TNF receptor signalling is fine-tuned by 
further input from related or interfering pathways.  
 
Glioma-dependent immunosuppression through expression of the non-classical MHC class I 
molecule HLA-G 
Some important determinants of the immunosuppressive milieu induced by glioma cells have 
been defined during the past few years´ research. It has become evident that tumour cells rely 
on more than one mechanism for securing their escape from the host’s immunosurveillance. 
An interesting candidate molecule that may provide an alternative strategy for the immune 
escape of malignant is the non-classical MHC class I molecule HLA-G (189). Membrane-
bound and soluble HLA-G are physiologically important for mediating foetal semi-allograft 
tolerance in the placenta. In the pathological condition of a tumour, they are also thought to 
promote immune tolerance, thus preventing an effective anti-tumour immune response (190). 
This and the following is work from joint projects with my colleagues where I contributed to 
both the intellectual framework and its experimental execution. The extent of my contribution 
is explained in the respective chapter (chapter 6). 
 
Transforming growth factor (TGF)-β as a principal target for the immunotherapy of 
malignant gliomas 
The strongest mediator of glioma-induced immunosuppression is TGF-β. TGF-β2 was named 
“glioblastoma-derived immunosuppressive factor” when it was discovered by Adriano 
Fontana in 1987 (191, 192). TGF-β is the cytokine with the strongest known 
immunosuppressive activity. While the direct effects of TGF-β on immune effector cells are 
well-documented (193) and have been further characterized in our group using the novel 
receptor kinase inhibitor SD-208 (chapter 7), its modulatory influence on other 
immunological pathways (explicitly, on the regulation of the expression of NKG2D and its 
ligands) is only now being recognized (chapter 8) (194). An intriguing aspect of these novel 
findings is that anti-TGF-β strategies do not only improve the compromised immune 
responses in the presence of glioma cells, but have also strong effects on growth, migration 
and invasion of glioma cells. Antagonizing TGF-β by  RNA interference (177, 178) also 
results in a massive upregulation of activatory NK and costimulatory T cell ligands on the 
surface of glioma cells, adding a further rationale to the concept of an anti-TGF-β glioma 
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therapy. By targeting TGF-β the relief of glioma-induced immunosuppression could be 
combined with the active induction of NK and T cell responses against cancer cells. Given the 
current lack of well-defined CTL epitopes for a peptide vaccination against glioma cells, this 
strategy may represent the most promising option for an immunotherapy of human 
glioblastoma. 
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II. CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent 
glioma cell death 
A related manuscript has been published in Oncogene. 2003 Nov 13;22(51):8233-45. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sequencing of p53 for this project (Table 2.1) was performed by Dr. Hiroko Ohgaki and 
Mrs. Marie-Anne Camus (International Agency for Research on Cancer, F-69372 Lyon 
Cedex 08, France). Thanks also go to Dr. Farzan Rastinejad (Cancer Drug Discovery 
Group, Pfizer Global Research and Development, Eastern Point Road, Groton, CT 
06340) who discovered CP-31398. He did not only supply CP-31398, but also gave 
helpful advice during many stages of this project. 
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Introduction 
 
Mutational inactivation of p53 is one of the most common genetic alterations in human 
cancers. The p53 gene encodes a 53 kD transcription factor which appears to require the 
integrity of at least three functional domains to exert its full transcriptional activity: the 
aminoterminal transcription activation domain, the central DNA binding domain and the 
carboxyterminal tetramerization/regulatory domain. The vast majority of mutations in 
the p53 gene in human cancers (>95%) affect the DNA binding domain (195). Whether 
functions other than transcriptional regulation are exerted by the wild-type p53 protein 
under physiological conditions has long remained controversial. Recent findings 
indicate that p53 can induce apoptosis in the absence of transcription, but still dependent 
on the functional integrity of the DNA binding domain (172, 173). 
 Fig. 2.1: p53 – domains and mutational frequency. A. Schematic representation of the
different domains of  p53. B. The relative positional frequencies of p53 mutations found in
cancer cell lines. (Diagrams modified from Cho et al., 1994) 
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The DNA binding domain of p53 is conformationally labile and is further destabilized 
in the majority of cancer-derived mutant p53 proteins. A novel type of anticancer agents 
which promote the proper folding of mutant p53 protein has recently been described 
(19). It is assumed that these agents act in a chaperone-like manner on newly 
synthesized p53 to promote and maintain a correctly folded conformation. The effects 
of one such compound, the styrylquinazoline CP-31398, were studied here in a panel of 
human malignant glioma cell lines with various genetic alterations of the p53 genes 
(Table 1). 
 
Table 2.1. Human malignant glioma cell lines: genetic p53 status, p53 reporter 
activity and sensitivity to CP-31398. 
Cell line Genetic p53 
status1 
p53 reporter 
activity [%] (196) 
CP-31398 
sensitivity (EC50, 
24 h) [µM] 
CP-31398 
sensitivity (EC50, 
4 h pulse) [µM] 
LN-18 238 Cys→Ser  1 (n.s.)2 12.6 ± 2.1 21.8 ± 3.5 
U138MG 273 Arg→His 
heterozygous 
9 19.2 ± 2.6 37.5 ± 3.8 
U87MG wild-type 36 11.2 ± 1.4 32.0 ± 2.1 
LN-428 173 Val→Met 
282 Arg→Trp 
0 17.9 ± 2.3 26.3 ± 2.6 
D247MG wild-type 77 12.6 ± 2.0 34.2 ± 3.1 
T98G 237 Met→Ile 0 10.1 ± 1.9 22.8 ± 2.5 
LN-319 175 Arg→His 1 (n.s.) 26 ± 3.4 34.7± 1.8 
LN-229 wild-type 100 14.1 ± 2.2 38.2 ± 4.2 
A172 wild-type 25 22.2 ± 2.6 35.1 ± 1.8 
U251MG 273 Arg→His 
homozygous 
0 16.8 ± 2.5 29.4 ± 3.3 
U373MG 273 Arg→His 
homozygous 
0 12.8 ± 1.7 31.6 ± 3.5 
LN-308 deletion 0 36 ± 4.2 > 120 
1see Methods; data correspond in essence to (17) and (15); however, LN-229 cells used 
here are homozygous wild-type (not heterozygous mutant) and U138MG cells used here 
are heterozygous with a mutation not previously described.   2n.s., not significant 
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Materials and Methods 
 
Materials and cell lines. CP-31398-01 (Lot #035035-106-02), prepared as described 
(19), was dissolved directly in medium. zVAD-fmk, obtained from Bachem 
(Heidelberg, Germany), was dissolved in dimethylsulfoxide (DMSO). AnxV-FITC was 
obtained from Pharmingen (Heidelberg, Germany), Fluo-3AM from Biorad (Munich, 
Germany). CHX, PI, ATA, PBN, 2´,7´-dichlorodihydrofluorescein diacetate (DCFH-
DA) and all other reagents, unless indicated otherwise, were purchased from Sigma (St. 
Louis, MO). zFA-fmk was from ESP (Livermore, CA), ALLN from Calbiochem (San 
Diego, CA), CA-074ME from Peptide Institute Inc. (Osaka, Japan). The human 
malignant glioma cell lines, kindly provided by Dr. N. de Tribolet (Lausanne, 
Switzerland), have been characterized (15, 197). Unlike LN-229 cells grown in other 
laboratories, the LN-229 cell line used for this study still harbours wild-type p53 (see 
Table 2.1). The cells were cultured in Dulbecco`s modified Eagle medium (DMEM) 
containing 10% foetal calf serum, 2 mM glutamine and penicillin (100 
IU/ml)/streptomycin (100 µg/ml). Viable cell counts were obtained by crystal violet 
staining. For the determination of EC50 values, the drug effects were monitored in serial 
dilutions (1:2) over a broad range of concentrations. Rat primary cerebellar granule 
neurons were prepared as described previously (198). 
 
p53 sequencing. Prescreening for mutations by polymerase chain reaction (PCR) and 
single strand conformational polymorphism (SSCP) analysis was carried out on exons 
5-8 of the p53 gene (14). Samples showing mobility shifts on SSCP were further 
analyzed by direct DNA sequencing. After PCR amplification with the same set of 
primers as used for SSCP, the PCR products were sequenced on a Genetic Analyzer 
(ABI PRISMTM 310, Perkin-Elmer Biosystems, Shelton, CT) using an ABI PRISM 
BigDye Terminator Cycle Sequencing Ready Reaction Kit. Primers for DNA 
sequencing were as follows: 5′-TCT GTC TCC TTC CTC TTC CTA C-3′ (sense) and 
5′-AAC CAG CCC TGT CGT CTC TCC A-3′ (antisense) for exon 5; 5′-ACA GGG 
CTG GTT GCC CAG GGT-3′ (sense) and 5′-AGT TGC AAA CCA GAC CTC-3′ 
(antisense) for exon 6; 5′-TGC CAC AGG TCT CCC CAA GG-3′ (sense) and 5′-GGG 
TCA GAG GCA AGC AGA GG-3′ (antisense) for exon 7; 5′-TCC TTA CTG CCT 
CTT GCT TC-3′ (sense) and 5′-TCT CCT CCA CCG CTT CTT GT-3′ (antisense) for 
exon 8. 
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p53 silencing. The p53 specific oligonucleotide sequences GATCCCCGACTCCAG 
TGGTAATCTACttcaagagaGTAGATTACCACTGGAGTCTTTTTGGAAA and 
TCGATTTCCAAAAAGACTCCAGTGGTAATCTACtctcttgaaGTAGATTACCAC
TGGAGTCGGG were obtained from Metabion (Munich, Germany) and cloned into 
Bgl II and Sal I-sites of the pSUPER vector (177), generously provided by Dr. Reuven 
Agami (Amsterdam, NL). The p53-specific parts of the sequence are depicted in bold 
letters and underlined. The resulting pSUPERp53 plasmid was stably cotransfected 
(10:1) with a pBABEpuro (199) plasmid and puromycin-resistant bulk transfectants 
were generated. Control transfectants were generated by co-transfecting pSUPER 
together with pBABEpuro. 
 
p53 and NF-κB  reporter assay. The cells were transfected with the PathDetect® p53 
and NF-κB cis-reporter gene plasmids (#219092 and #219077, Stratagene) using 
FuGene (Roche, Mannheim, Germany) (196). The p53-responsive enhancer is 
(TGCCTGGACTTGCCTGG)15, the NF-κB–responsive element is (TGGGGACTTTC 
CGC)5. Cotransfection with pFC-p53 which encodes human wild-type p53 was used as 
a positive control. The p53 null cell line, LN-308, was included as a negative control in 
all experiments. At 24 h after transfection, CP-31398 was added to some samples. 
Another 6 h later, the cells were washed and lysed using Reporter Lysis Buffer 
(Promega, Madison, WI). Following one freeze-thaw cycle, the lysates were transferred 
to a LumiNuncTM plate (Nunc, Roskilde, Denmark), Luciferase assay substrate 
(100 µl, Promega) was added automatically, and the luminescence was measured in a 
LumimatPlus (EG&G Berthold, Pforzheim, Germany). The background was subtracted 
from all values. 
 
Immunoblot analysis. The general procedure has been described (200). The cells were 
untreated or treated with CP-31398 as indicated and lysed. Soluble protein levels were 
analysed by immunoblot using 20 µg of protein per lane separated on 10-12% 
acrylamide gels (Biorad, Munich, Germany). After transfer to a nitrocellulose 
membrane, the blots were pretreated for 2 h with phosphate buffered saline (PBS) 
containing 5% skim milk and 0.05% Tween 20 and then incubated overnight at 4°C 
with the following antibodies: murine anti-human p53 monoclonal antibody Bp53-12 (2 
µg/ml), murine anti-mammalian p53 monoclonal antibody Pab240 (for the detection of 
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murine p53V135A) (2 µg/ml), rabbit anti-human p21 polyclonal antibody C-19 (2 µg/ml), 
rabbit anti-mammalian Bax polyclonal antibody N-20 (1 µg/ml), goat anti-mammalian 
β-actin polyclonal antibody I-19 (1 µg/ml), mouse anti-mammalian Mdm2 monoclonal 
antibody SMP14 (1 µg/ml), mouse anti-human Bcl-2 antibody 100 (2 µg/ml), rabbit 
anti-human bak polyclonal antibody G-23 (0.5 µg/ml), rabbit anti-mammalian caspase 
8 polyclonal antibody p20 (0.5 µg/ml) (all from Santa Cruz, Santa Cruz, CA), mouse 
anti-mammalian Bcl-xL monoclonal antibody 2H12 (2 µg/ml) (Pharmingen, 
Heidelberg, Germany), and mouse anti-human caspase 3 C31720 (1 µg/ml) 
(Transduction Laboratories, Lexington, KY). Mouse anti-human caspase 7 (clone 7-1-
10) and caspase 9 (clone 2-22) antibodies were generous gifts of Y. Lazebnik (Cold 
Spring Harbor, NY). Visualization of protein bands was accomplished using 
horseradish peroxidase (HRP)-coupled IgG secondary antibody (Sigma) and enhanced 
chemiluminescence (ECL) (Amersham, Braunschweig, Germany). Quantification was 
performed by multiplying the respective signal area with its mean intensity using Corel 
Photo-Paint 11 software (Corel Corporation, Ottawa, CA). 
 
Northern blot analysis. Denatured total RNA (10 µg) was loaded on a 1% agarose gel 
containing 6.7% formaldehyde. The RNA was separated at 100 V, transferred to a 
Hybond N+ membrane (Amersham, Freiburg, Germany) using capillary blotting and 
cross-linked in a UV stratalinker 1800 (Stratagene, La Jolla, CA) at 1200 J. Methylene 
blue staining was performed as a loading control. The membrane was preincubated for 2 
h in Church buffer at 65°C. The probes were constructed by isolating the respective 
cDNA sequences from expression plasmids. A cDNA encoding PUMA was generously 
provided by Dr. B. Vogelstein (Baltimore, MD), the NOXA cDNA was a generous gift 
of Dr. E. Oda (Tokyo, Japan). The respective full-length cDNAs were purified by gel 
extraction (Qiagen, Hilden, Germany) and labeled using 5 µl (~1.6 Mbq) dCTP and the 
Rediprime II random labelling system (Amersham). Filters were hybridized overnight at 
65°C in a hybridization oven with a rotisserie device using Church-buffer. Binding of 
radioactive probes was visualized using a PhosphoImager (FujiBasReader 1500, Fuji, 
Kangawa, Japan) and quantified using TINA software (Fuji). Loading was controlled by 
assessing ß-actin mRNA expression. 
 
Flow cytometry. For cell cycle analysis, the glioma cells were treated with CP-31398 as 
indicated, harvested, fixed and permeabilized overnight in ice-cold 70% ethanol 
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(Merck, Darmstadt, Germany). The cells were washed twice with PBS. RNA was 
digested with RNase A (Gibco Life Technologies, Paisley, GB). The DNA was stained 
with PI (50 µg/ml). Fluorescence was recorded on channel Fl-2A in a FACScalibur 
(Becton Dickinson, Heidelberg, Germany). Instrument settings were adjusted to move 
the G1 peak to 200 relative fluorescence units. Cells to the left of this peak appear to 
have a DNA content below 2n, indicative of cell death. Aggregated cells were detected 
in channel Fl-2W and gated out. 10,000 events per condition were recorded. Evidence 
for apoptosis was also obtained by AnxV-FITC staining which measures the exposure 
of phophatidylserine on the cell membrane. The cells were collected, washed with PBS 
and resuspended in a buffer containing 10 mM HEPES/NaOH, pH 7.4, 140 mM NaCl 
and 2.5 mM CaCl2. AnxV-FITC (1:100) and PI (50 µg/ml) were added. 
 
Free radical formation. The cells (2 x 105/well) were seeded in 6 well plates, adhered 
overnight and treated with CP-31398 or ethacrinic acid as a positive control. A solution 
of DCFH-DA in DMSO (stock: 2 mM) was added to a final concentration of 5 µM. 
After 15 min the cells were washed with ice-cold PBS, trypsinized and washed again 
with cold medium. The fluorescence originating from intracellular DCF (the oxidation 
product of DCFH-DA) was measured in channel Fl-1H in a Becton Dickinson 
FACScalibur. Dead cells were excluded by simultaneous staining with PI (50 µg/ml). 
 
Cell-free peroxide assay. CP-31398 was co-incubated in serum-free medium with 
serum, Fe2+ or PBN. Cell culture supernatant containing CP-31398 was also examined. 
The samples (20 µl) were collected at various times and ongoing reactions were stopped 
by addition of 180 µl 25 mM H2SO4. After a total incubation period of 30 min 200 µl 
reaction mixture containing 0.5 mM (NH4)2Fe(SO4)2, 200 µM xylenol orange and 200 
µM sorbitol in 25 mM H2SO4 were added to each well of the microtiter plate. The 
absorption at 540 nm was determined using a microtiter plate reader (Titertek Multiscan 
MCC, Flow Laboratories/ICN, Eschwege, Germany) 45 min later and compared with 
the absorbance read at standard concentrations of the peroxides (201, 202). 
 
Calcium assay. Fluo-3AM was reconstituted in DMSO and a 1:500 dilution was 
prepared in serum-free medium. Treated cells were washed and loaded with Fluo-3 AM 
for 30 min while still adherent. After further washing the cells were detached, 
 51
resuspended in PBS and analysed by flow cytometry. The signal from Fluo-3 bound to 
Ca2+ was detected in channel Fl-1H. Dead cells were gated out by PI (double) staining. 
DEVD-cleaving caspase activity. The cells (0.5 x 104) were seeded in 96 well plates, 
treated as indicated, lysed in 25 mM TrisHCl, pH 8.0, 60 mM NaCl, 2.5 mM EDTA, 
0.25% Nonidet-P40 for 10 min, and DEVD-amc was added at 12.5 µM. Caspase 
activity was assessed by fluorescence using a Millipore fluorimeter at 360 nm excitation 
and 480 nm emission wave lengths. 
 
Statistical analysis. Data are representative of experiments performed three times with 
similar results. Viability studies were performed using triplicate wells. Significance was 
assessed by t-test (p<0.05) or covariance analysis (ANCOVA). 
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Results 
 
CP-31398 is cytotoxic to human malignant glioma cell lines 
Light microscopic monitoring revealed that CP-31398-treated cells from all glioma cell 
lines rounded up and detached from the tissue culture plates. Trypan blue staining 
confirmed that the detached cells were dead. Cell death rather than inhibition of 
proliferation became also apparent on flow cytometry which showed accumulation of 
cell remnants in the sub-G0/1 peak (Fig. 2.2A). There was a dramatic loss of cells in the 
G2/M phase, suggesting that death occurred out of S-phase. However, synchronisation 
of LN-229 cells in S-phase by aphidicolin did not affect cell death induced by CP-31398 
(data not shown). Representative concentration response curves for LN-18, U87MG, 
LN-229 and LN-308 cells are shown in Fig. 2.2B. 
 
 
 
 
 
 
 Fig. 2.2. CP-31398 is cytotoxic to human glioma cell lines. A. LN-18 cells were untreated (top) or
treated with CP-31398 (9 µM) for 24 h (bottom) and studied by flow cytometry. B. The glioma cells
(LN-18, filled circles; U87MG; open circles, dashed lines; LN-229, open squares, dashed lines; LN-308,
filled squares) were treated with CP-31398 for 24 h. Survival was assessed by crystal violet staining. All
crystal violet data are expressed as mean percentages of survival and standard error of the mean (SEM,
n=3). 
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Next, the mode of cell death induced by CP-31398 was explored. p53 is supposed to 
induce apoptosis rather than necrosis, but cell death induced by a synthetic super-p53, 
CTS-1, was caspase-independent in glioma cells (203). Flow cytometry for annexinV-
FITC/propidium iodide (AnxV-FITC/PI) labelling revealed the exposure of 
phosphatidylserine on the cell membrane preceding the loss of membrane integrity 
detected by PI uptake (Fig. 2.3). Early apoptotic cells are AnxV-FITC-positive, but PI-
negative, and therefore move to the lower right quadrant. Fig. 2.3. CP-31398-induced cell death has features of apoptosis. LN-18 or LN-308 cells were left
untreated (left) or treated for 16 h with CP-31398 (12 µM) (right) and analysed for AnxV-FITC
binding and PI uptake by flow cytometry. Similar results were obtained for U87MG and T98G cells
(data not shown). 
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In contrast, almost no cells are PI-positive, but AnxV-negative (left upper quadrant). 
Asp-Glu-Val-Asp-7-amino-4-methylcoumarin (DEVD-amc) cleavage assays showed 
that even high concentrations of CP-31398 did not significantly increase caspase 
activity from baseline, as assessed in LN-18, T98G, LN-229 and LN-308 cells at 6 or 18 
h. In contrast, CD95 ligand (CD95L), as a positive control (204), induced prominent 
DEVD-amc cleavage in these cells (Fig. 2.4A). Accordingly, CD95L induced massive 
processing of caspases 3, 7, 8 and 9, whereas no effects of CP-31398 on caspase 8 and 9 
levels were observed in any cell line. In LN-18 and U87MG cells, a slight decrease in 
the levels of pro-caspase 3 was observed when the cells were treated with 36 µM of CP-
31398 for 16 h, and these conditions also induced cleavage of caspase 7 (Fig. 2.4B). 
However, the concentrations required for caspase cleavage were far above the EC50 
values for these cell lines (Table 2.1). Further, the time-point of caspase activation 
seemed to lie behind the point of commitment for cell death, suggesting that caspase 
activation is not essential for CP-31398-induced cell death. Accordingly, N-tert-butoxy-
carbonyl-Val-Ala-DL-Asp-fluoromethylketone (zVAD-fmk), a broad spectrum caspase 
inhibitor previously shown to inhibit CD95L- and drug-induced apoptosis in glioma 
cells (204), did not significantly modulate CP-31398 cytotoxicity in LN-18, LN-229, 
T98G, U87MG, U251MG, U373MG or LN-308 cells at concentrations up to 100 µM 
(Fig. 2.4C, data not shown). The viral preferential caspase 1 and 8 inhibitor, crm-A, 
which abrogates CD95-mediated apoptosis, had no effect on CP-31398 cytotoxicity 
either (data not shown). Neither had inhibition of calpains by N-tert-butoxy-carbonyl-
Phe-Ala-fluoromethylketone (zFA-fmk), N-acetyl-Leu-Leu-Nle-CHO (ALLN) or L-3-
trans-(prolylcarbamoyl)oxirane-2-carbonyl)-L-isoleucyl-L-proline methyl ester (CA-
074Me). Although no evidence was obtained for a role of caspases in CP-31398-
induced cell death, cytochrome c was released in LN-18, U87MG and T98G cells, but 
not in LN-308 cells, in response to CP-31398 (Fig. 2.4D, data not shown). It was also 
asked whether the ectopic expression of a bcl-xL transgene inhibited CP-31398-induced 
cell death. While T98G and LN-229 cells transfected with a bcl-xL transgene acquired 
resistance to CD95L-mediated apoptosis (61) (data not shown), Bcl-xL did not inhibit 
CP-31398 cytotoxicity (Fig. 2.4E). Immunoblot accordingly showed that cytochrome c 
release induced by CP-31398 was insensitive to Bcl-xL whereas cytochrome c release 
induced by CD95L was blocked (data not shown). 
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 Fig. 2.4. CP-31398-induced glioma cell death is largely caspase-independent. A. DEVD-amc cleavage was 
assessed at 6 (open bars) and 18 h (filled bars) after treatment with CP-31398 at 12 µM (LN-18) or 36 µM (LN-
308). CD95L (10 U/ml) in LN-18 cells was used as a positive control. B. LN-18, U87MG and LN-308 cells were 
treated for 16 h with CP-31398 (lanes 2-5: LN-18, lanes: 6-9 U87MG, lanes 10-13: LN-308, all treated with 0, 9, 
18, 36 µM CP-31398). Lane 1 shows LN-18 cells treated with CD95L (10 U/ml) for 6 h as a positive control. 
Caspase cleavage was assessed by immunoblot. C. LN-18 cells were treated for 24 h with increasing 
concentrations of CP-31398 (squares) or CD95L (triangles) in the absence (open symbols) or presence (filled 
symbols) of zVAD-fmk (100 µM). D. LN-18 cells were treated for 6 h with CD95L (lane 1, 10 U/ml) or CP-31398 
(lanes 2-5: 0, 9, 18, 36 µM). In lanes 6-9, LN-308 cells were treated with CP-31398 (0, 9, 18, 36 µM). Cytosolic 
fractions were assessed for cytochrome c (Cyt. c) and β-actin content by immunoblot. E. T98G neo (open squares), 
T98G Bcl-xL (filled squares), LN-229 neo (open triangles) or LN-229 Bcl-xL (filled triangles) cells were treated 
with CP-31398 for 24 h. Survival in C and E were assessed as in Fig. 2.2B. 
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Kinetic dissociation of p53-dependent and p53-independent effects of CP-31398 
Cytotoxicity data for CP-31398 in all glioma cell lines are summarized in Table 1. The 
EC50 for the induction of cell death at 24 h ranged from 10-36 µM. Prolonged exposure 
for 72 h did not significantly alter these data except for a reduction of the EC50 to 19 
µM in LN-308 cells (p<0.05, t-test). There was no correlation between the doubling 
times and the sensitivity to CP-31398 (p>0.05). Neither was there a difference in the 
sensitivity to CP-31398 of p53 mutant and p53 wild-type cell lines, defined genetically 
or functionally (Table 1). Also the expression level of p53 as determined by 
immunoblot and densitometric normalization to ß-Actin did not correlate with the 
sensitivity towards CP-31398-induced cell death. Although LN-308 cells, which lack 
p53 protein altogether, were the most resistant cell line, these cells were not fully 
resistant to CP-31398, clearly indicating that CP-31398 triggers a p53-independent cell 
death pathway. To confirm that part of the cytotoxicity of CP-31398 depends on p53, 
p53 synthesis was knocked down in the p53 wild-type cell line, LN-229, by siRNA 
technology. Transfection with pSUPERp53 encoding p53 siRNA (177) resulted in a 
massive down-regulation of p53 reporter gene activity (Fig. 2.5A) and protein level 
(Fig. 2.5B). No changes were observed in p63 or p73 protein levels (data not shown). 
Both assays showed that the suppression reached more than 98%. The p53-depleted 
cells were protected when exposed to moderate concentrations of CP-31398 (≤ 16 µM) 
for 24 h whereas no difference in sensitivity was observed at higher concentrations (Fig 
2.5C). This apparently low specificity appeared to be difficult to reconcile with the 
reported (19) safety and anti-tumour specificity of the agent in animals.  
 Fig. 2.5. Knockdown of p53 in LN-229 cells. A,B. LN-229 sublines bearing either a pSUPER control 
plasmid (left lane) or a pSUPERp53 construct (right lane) were generated. p53 expression and activity
were determined by reporter gene assay (A, filled bars) and immunoblot (B). Equal loading was assessed
by β-actin expression, luciferase production was further monitored by transfection with an NF-κB-Luc 
plasmid (A, open bars). C. LN-229 pSUPERp53 knock-down cells (filled squares) or LN-229 pSUPER 
control transfectants (open squares) were treated with CP-31398 for 24 h. 
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This led to the hypothesis that some non-specific effects occurred only with prolonged 
exposure not observed in vivo because of rapid metabolic clearing (t1/2 ≈ 2 h in mice). 
Therefore compared the data obtained with continuous exposure was compared with 
data obtained in pulse assays where CP-31398 was removed after certain time periods, 
but survival still assessed at 24 h. Drug washout experiments revealed that p53-
independent cytotoxicity, defined as the cytotoxicity observed in the p53 null cell line 
LN-308, did not become apparent until a minimum exposure of 6 h. In contrast, all p53 
mutant and p53 wild type cell lines showed cytotoxic effects already at 1-2 h (Fig. 
2.6A). Representative concentration curves for LN-18, U87MG, LN-229 and LN-308 
cells are shown in Fig. 2.6B. Similar curves for LN-229 pSUPER control transfectants 
and LN-229 pSUPERp53 cells are shown in Fig. 2.6C. The protection conferred by 
suppression of p53 turned out to be much more prominent when the cells were pulse-
treated for 4 h than when they were exposed continuously for 24 h. The EC50 values 
obtained in 4 h pulse assays ranged from 21.8 µM to 38.2 µM (Table 1). Importantly, 
these concentrations did not induce cell death in cultured postmitotic cerebellar granule 
neurons when CP-31398 containing medium was replaced by sister culture medium at 
4 h (data not shown).  
 
  
 
 
 
 
Fig. 2.6. Pulse exposure to CP-31398 enhances the selectivity of the agent for p53-bearing cell lines. A.
Glioma cells (LN-18, filled circles; U87MG; open circles; LN-229, open squares; LN-308, filled squares)
were pulse-treated with CP-31398 (48 µM). The agent was removed by washing at the indicated timepoints.
B. The same cell lines were treated with different concentrations of CP-31398 for 4 h. Survival was
assessed by crystal violet staining at 24 h. C. LN-229 pSUPERp53 cells (filled squares) or LN-229
pSUPER control transfectants (open squares) were treated and analysed as in B.  
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The modulation of p53 activity by CP-31398 was assessed by reporter assay. Fig. 2.7 
shows that either prolonged exposure for 20 h, or a 4 h pulse exposure with subsequent 
washing and further culturing for 16 h induced considerable p53 reporter gene activity 
in all cell lines except LN-308. (The liabilities of the reporter used here will be referred 
to in the next section of this thesis.) The endogenous p53 activity of LN-229 cells 
reaches the upper limit of detection in the assay and can thus not be induced any further 
by CP-31398. Thus short-term exposure effectively induces p53 activity and cell death, 
but appears to lack the non-specific effects seen in LN-308 cells with prolonged 
exposure. Still zVAD-fmk, crm-A or Bcl-xL were not protective even under the pulse 
assay conditions (data not shown).  
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UFig. 2.7. Induction of p53-like reporter gene activity by CP-31398. p53 activity was determined by
reporter gene assay and is given in % of the respective cell line cotransfected with pFC-p53 and the
reporter gene (filled bars, cells treated with CP-31398 at 12 µM for 20 h; open bars, cells pulse-
treated for 4 h at 18 µM and p53 reporter activity assessed 16 h later). o further assess the role p53 plays in cell death induced by CP-31398, the murine 
53V135A mutant was used. This mutant is temperature-sensitive, this is, silent and acting 
s a dominant-negative mutation at 38.5°C, but assuming wild-type conformation and 
enerating transcriptional activity at 32.5°C. This mutant was expressed in LN-308 and 
87MG cells (200). Reporter gene assays showed that p53V135A strongly decreased p53 
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activity in U87MG cells at 38.5°C, confirming its dominant-negative activity. At 
32.5°C, p53V135A exhibited strong transcriptional activity in both cell lines, consistent 
with the assumption of wild-type conformation. Conversely p53V135A was not 
completely silent at 38.5°C in LN-308 cells (2% in p53V135A-transfected LN-308 cells 
compared with essentially zero in hygro control transfectants) (Fig. 2.8A). CP-31398 (6 
h, 36 µM) increased p53 activity in U87MG hygro cells at both temperatures, and in 
U87MG p53V135A and LN-308 p53V135A at 32.5°C. The apparent failure of response in 
the dominant negative mutants at 38.5°C may be due to the large excess of already 
misfolded p53 protein. Conversely the highest concentration of CP-31398 induced p21 
in LN-308 p53V135A cells at 38.5°C (Fig. 2.8B), but not in LN-308 hygro control cells at 
either temperature (data not shown, see also Fig. 2.12). p53V135A-transfected LN-308 
cells shifted to 32.5°C revealed strong expression of p21 which was moderately 
increased by CP-31398.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig. 2.8. p53-dependent effects of CP-31398 in p53V135A-transfected glioma cell lines. A. LN-308
hygro control transfectants or p53V135A-transfected LN-308 or U87MG cells were maintained at 38.5°C
or shifted to 32.5°C for 24 h, and were then left untreated (open bars) or treated with CP-31398 (36 µM)
for 6 h (filled bars). p53 activity was determined by reporter gene assay and is given in % of the
respective cell line cotransfected with pFC-p53 and the reporter gene. B. p21 and β−actin levels were
determined by immunoblot at 6 h after exposure of LN-308 p53V135A cells to increasing concentrations
of CP-31398 at 38.5°C (left) or 32.5°C (right). Immunoblot bands were quantified and normalised to β-
actin signal intensity. 
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Ectopic expression of p53V135A at mutant conformation (38.5°C) did not alter the 
sensitivity of LN-308 cells to CP-31398 (data not shown). In contrast, expression of 
p53V135A in wild-type conformation conferred sensitization to CP-31398 over a broad 
range of concentrations (Fig. 2.9A). In U87MG cells, which carry wild-type p53 alleles, 
p53V135A inhibited the cytotoxicity of CP-31398 at 38.5°C (Fig. 2.9B), but had no effect 
at 32.5°C (data not shown).  
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Fig. 2.9. p53 gene transfer enhances CP-31398-induced cell death. A. Hygro control (open
circles) or p53V135A-transfected LN-308 (filled squares) cells were shifted to 32.5°C for 24 h and
then treated with CP-31398 for 24 h. B. Hygro control (open circles) or p53V135A-transfected
U87MG (filled squares) cells were treated with CP-31398 at 38.5°C for 24 h. Survival was
assessed by crystal violet staining. e kinetic difference between p53-dependent and p53-independent effects was 
nfirmed in LN-308 p53V135A and LN-308 hygro cells in 4 h pulse assays. Whereas 
-308 parental or hygro control transfectants were resistant to CP-31398 in the 4 h 
lse exposure assay, LN-308 p53V135A cells cultured at 32.5°C were sensitive to CP-
398 under these conditions (Fig. 2.10). Similarly, flow cytometry using AnxV-
TC/PI labelling showed a strong signal already at 6 h in U87MG, LN-18 and T98G 
lls, and also in LN-308 p53V135A cells at 32.5°C, whereas LN-308 hygro cells were 
ll unresponsive at this time (data not shown). 
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Fig. 2.10. Short-term exposure of p53V135A-transfected glioma cells to CP-31398. Hygro control
(open symbols) or p53V135A-transfected LN-308 (closed symbols) cells were either maintained at 38.5°C
(circles) or shifted to 32.5°C for 24 h (squares) and then pulse-treated (4 h) with CP-31398. Survival was
assessed by crystal violet staining.  
It has been suggested that CP-31398 cannot refold already misfolded mutant p53 
proteins, but rather enforces the assumption of a wild-type conformation in newly 
synthesized p53 proteins (19). Hence inhibition of protein synthesis should specifically 
prevent the p53-dependent cytotoxic effects of CP-31398. As predicted, cycloheximide 
(CHX), an inhibitor of protein synthesis, inhibited the cytotoxic effects of CP-31398 in 
LN-18, U138MG, U87MG, T98G and LN-229, but not in LN-308 cells (Fig. 2.11A, 
data not shown). Since CP-31398-induced cell death in LN-308 cells is necessarily p53-
independent, these data supported the idea that p53-dependent cell death induced by 
CP-31398 requires protein synthesis, most likely synthesis of p53 itself, whereas the 
p53-independent pathway can occur also in the presence of CHX. Consistent with this 
hypothesis, the sensitizing effects of p53V135A in transfected LN-308 cells at 32.5°C 
were nullified by CHX, whereas CHX had no effect on CP-31398-induced cell death in 
hygro control cells treated at 32.5°C (Fig. 2.11B). Altogether these data suggested that 
p53-dependent effects of CP-31398 can be examined at timepoints up to 6 h where non-
specific effects of the agent are still negligible or at least reversible. 
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 Fig. 2.11. CP-31398-dependent cell death requires protein synthesis. A. LN-18 or U87MG cells were
treated for 16 h with CP-31398 in the absence (open squares) or presence (filled squares) of CHX (10
µg/ml). M. LN-308 hygro (upper panel) or LN-308 p53V135A (lower panel) cells were shifted to 32.5°C
for 24 h and treated for 16 h with CP-31398 in the absence (open squares) or presence (filled squares) of
CHX (10 µg/ml). Survival was assessed by crystal violet staining.  
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CP-31398-induced effects on malignant glioma cells: the role of the p53 status 
 
 
Figure 2.12. 
Modulation of p53 
reporter activity, and 
p53, p21 and Mdm2 
protein accumulation 
by CP-31398. The cells 
were left untreated or 
treated with CP-31398 
(36 µM) for 6 h and 
assessed for p53 reporter 
activity. Values are 
given as fold increase 
over background (for 
mutant cell lines) or 
constitutional activity 
(for p53 wild-type cell 
lines). Lysates from 
untreated cells or from 
cells treated with CP-
31398 at 9, 18 or 36 µM 
for 6 h were assessed for 
the protein levels of p53, 
p21, Mdm2 and ß-Actin 
(upper panel). All signals 
were quantified, 
normalised to β-Actin 
content and expressed as 
fold increase over the 
respective untreated 
control (lower panel). 
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Next the effects of fixed concentrations of CP-31398 on p53 reporter activity and gene 
expression were compared in the panel of 12 glioma cell lines. CP-31398 induced 
changes in reporter gene activity at 6 h in all cell lines except LN-308 (p53 null) and 
LN-229 (maximal constitutive activity) (Fig. 2.12). The strongest effect of CP-31398 
was seen in LN-18 cells which carry a mutation (Cys→Ser) in codon 238. T98G cells, 
which carry a Met→Ile mutation in the neighbouring codon, 237, showed low p53 
activity in response to CP-31398. p53 activity was also induced in two other cell lines, 
LN-319 and LN-428, with mutations in codons 175 (Arg→His) and 173 (Val→Met) as 
well as 282 (Arg→Trp), respectively. The two cell lines mutated in codon 273 
(Arg→His), U251MG and U373MG, remained almost silent. There was no correlation 
between the induced activity in the reporter assay and the sensitivity to CP-31398 
defined by EC50 values over 24 h or in the 4 h pulse experiment (Table 2.1). Hence the 
type of p53 mutation may predict whether CP-31398 is able to induce p53 activity in a 
reporter assay, but not the cytotoxic effects of CP-31398. These data also indicate that 
some mutations within the DNA binding domain of p53, exemplified by U251MG and 
U373MG, are rather refractory to the action of CP-31398, as defined by p53 reporter 
assay. 
Next, the correlation between the p53 reporter assay data and the stabilization of p53 as 
determined by p53 protein accumulation on immunoblot analysis was investigated. CP-
31398 promoted the accumulation of p53 in all 5 cell lines retaining wild-type p53 
activity (U138MG, U87MG, D247MG, LN-229, A172) and in 4 of 6 p53 mutant lines 
(LN-18, LN-428, U251MG, U373MG). T98G and LN-319 cells, which showed 
enhanced activity in the reporter assay, did not show p53 accumulation in response to 
CP-31398. Conversely, U251MG and U373MG, which developed low p53 activity in 
the reporter assay, nevertheless showed marked accumulation of p53 protein. Thus p53 
stabilization and p53 activity in a reporter assay induced by CP-31398 do not 
necessarily coincide.  
The accumulation of p21 as a major p53 response protein was also monitored. The 
stabilization of p53 and the accumulation of p21WAF/CIP1 protein were concentration-
dependent and occur roughly in parallel. All 5 p53 wild-type cell lines accumulated p21 
in response to CP-31398. Similarly the 6 p53 mutant cell lines accumulated p21. LN-
308 cells again failed to respond. Physiologically the up-regulation of p53 is limited by 
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the p53-mediated accumulation of Mdm2 which targets p53 for proteasome-dependent 
degradation. Mdm2 accumulation was observed in response to CP-31398 in LN-18, 
U138MG, LN-428, LN-319, A172 and U251MG cells, but not in U87MG, D247MG, 
T98G, LN-229, U373MG and LN-308 cells. At the highest concentration of CP-31398 
used, Mdm2 levels decreased in all cell lines except U138MG, T98G, LN-308 and LN-
319 which  may in part be due to the stabilization of Mdm2 by p14arf (205). LN-319 and 
LN-308 cells are the only cell lines which show no deletion or mutation of the p14arf 
locus (15, 197). Thus in LN-319 cells the binding activity of p14arf may protect Mdm2 
from proteasomal degradation. Further, Mdm2 may bind to p53 in the presence of CP-
31398 while the ubiquitinylation and subsequent degradation of this complex are 
inhibited (206). Thus the effects seem to be complex and cell-type specific. 
 
Modulation of proapototic p53 response gene expression by CP-31398 
Changes in the expression of the proapototic p53-response genes NOXA (36) and 
PUMA (35, 207) were assessed by Northern blot. While the p53 null cell line LN-308 
did not respond to treatment with CP-31398 with the up-regulation of either mRNA, 
both genes were induced in LN-18, U87MG and LN-229 cells (Fig. 4). Quantification 
of the signals revealed that LN-18 cells showed only a slight induction of NOXA while 
the mRNA levels for PUMA were strongly up-regulated. In U87MG cells, on the other 
hand, induction of NOXA was much stronger. 
  
 
Figure 2.13. Modulation of NOXA and PUMA expression by CP-31398. LN-18, U87MG, LN-229 or LN-308
cells were untreated or treated with CP-31398 at 9, 18 or 36 µM for 6 h. Total cellular RNA was analysed for
NOXA and PUMA expression by Northern blot. Signal intensities were quantified using a Fuji PhosphoImager
and normalised to β-actin content. Gene induction is expressed as fold increase over the untreated control (open
bars: NOXA, filled bars: PUMA). 
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Modulation of Bcl-2 family protein expression by CP-31398 
 
 
 
Figure 2.14. Modulation 
of Bcl-2 family protein 
expression by CP-
31398. Lysates from 
untreated cells or cells 
treated with CP-31398 at 
9, 18 or 36 µM for 6 h 
were assessed for the 
protein levels of Bcl-xL, 
Bcl-2, Bax, Bak and ß-
Actin (upper panel). All 
signals were quantified, 
normalised to β-Actin 
content and expressed as 
fold increase over the 
respective untreated 
control (lower panel). 
 
 
 
 67
Changes in the expression of Bcl-2 protein family members have been attributed an 
important role in mediating p53-dependent apoptosis (38). Such changes include 
enhanced expression of proapoptotic proteins such as Bax and decreased expression of 
antiapoptotic proteins such as Bcl-2. Exposure to CP-31398 increased the levels of 
proapoptotic Bax in 9 of 12 cell lines (LN-18, U138MG, U87MG, T98G, LN-319, LN-
229, A172, U251MG and U373MG cells) (Fig. 2.14). Proapoptotic Bak levels increased 
in 4 of 12 cell lines (U138MG, LN-428, D247MG, T98G), but decreased in 4 cell lines 
(U87MG, LN-319, U251MG, U373MG). Antiapoptotic Bcl-2 levels decreased in 
response to CP-31398 in 4 of 12 cell lines (LN-18, U138MG, A172, U373MG), but 
increased in LN-319 and LN-308 cells. Antiapoptotic Bcl-xL levels decreased in 6 of 12 
cell lines (U138MG, U87MG, LN-428, T98G, A172, U373MG). These changes in Bcl-
2 family protein favoured induction rather than prevention of apoptosis, but were too 
heterogeneous to account for the cytotoxic effects of CP-31398. 
 
p53-independent CP-31398-induced cell death involves epiphenomenal free radical 
formation, is inhibited by aurintricarboxylic acid (ATA) and may be mediated by calcium 
cytotoxicity 
Free radical formation has been linked to p53-dependent and p53-independent types of 
cell death (32, 39). CP-31398 induced free radical formation in a concentration- and 
time-dependent manner in LN-18, LN-229 and LN-308 cells (Fig. 2.15A,B, data not 
shown). The analysis of free radical formation in LN-229 pSUPER and LN-229 
pSUPERp53 cells (Fig. 2.15C) as well as in LN-308 hygro and LN-308 p53V135A cells at 
38.5°C or 32.5°C showed no difference between p53V135A-transfected and hygro control 
cells (data not shown), suggesting that free radical formation induced by CP-31398 is 
p53-independent. Free radical formation was unlikely to be a mere indicator of cell 
death since it was observed as early as 30 min after exposure and since the increased 
CP-31398 sensitivity of LN-308 p53V135A cells compared with LN-308 hygro control 
cells at 32.5°C (Fig. 2.9A) did not translate into increased free radical formation. A 
peroxide assay performed with CP-31398 in medium or cell culture supernatant with 
various components being added (serum, Fe2+, phenol red) excluded the possibility that 
free radicals were produced by chemical interactions with CP-31398 in a cell-free 
system (data not shown). Free radical formation thus appeared to be part of the p53-
independent effects of CP-31398.  
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Fig. 2.15. CP-31398 induces free radicals in a p53-independent manner. A. LN-308 cells were
treated for 4 h with increasing concentrations of CP-31398 (untreated, filled histogram; 9 µM, solid,
thin line; 18 µM, solid, thick line; 36 µM, dotted line). The cells were loaded with the non-
fluorescent dye DCFH-DA and analysed by flow cytometry. The fluorescence originating from the
oxidized product DCF was recorded in channel Fl-1H. Dead cells were gated out by double staining
with PI. B. Shifts in mean fluorescence (SFI values) were calculated at 0.5, 1, 2, 4 or 6 h (9 µM,
open bars; 18 µM, grey bars, 36 µM, black bars). As a positive control, ethacrynic acid (100 µM)
induced an SFI of 2.6 at 30 min. C. LN-229 pSUPERp53 transfectants (lower panel) or LN-229
pSUPER control transfectants (upper panel) were left untreated (filled histograms) or treated for 6 h
with 18 µM CP-31398 (open histogram). Free radical formation was determined as in A, mean
fluorescence values are indicated in the diagrams. 
 
However, free radicals were not critical mediators of CP-31398-induced cell death since 
various antioxidants, including N-t-butyl-α-phenylnitrone (PBN) (1-100 µM) or N-
acetylcysteine (NAC) (1-100 µM) failed to inhibit CP-31398-induced cell death in LN-
18, T98G, LN-229, LN-308 hygro or LN-308 p53V135A cells (data not shown). As 
positive controls, the cytotoxic effects of ethacrinic acid (25 µM), cisplatin (50 µM) or 
betulinic acid (25 µM) were significantly reduced by PBN and NAC (208).  
 
Excessive calcium influx, or its liberation from intracellular stores, may provide a 
second messenger signal for apoptosis and trigger caspase-independent pathways 
including the formation of superoxide species (209). All of three cell lines examined 
(LN-18, LN-229, LN-308) cells showed a marked increase in [Ca2+]free, cytosolic at 6 h 
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after exposure to CP-31398. Down-regulation of p53 in LN-229 pSUPERp53 cells had 
no effect on calcium liberation (Fig. 2.16). Drug washout experiments revealed that the 
timepoint of calcium influx coincided with the onset of irreversible p53-independent 
effects (Fig. 2.6, data not shown). The increase in [Ca2+]free, cytosolic was prevented by 
coexposure to ATA (20 µM) (Fig. 2.16A).  
 
 
 
 
 
 
 
 
 
Fig. 2.16. CP-31398-induced cell death is preceded by an increase in the intracellular Ca2+ level.  
A. Free cytosolic calcium concentrations were determined in pSUPERp53 transfectants (lower panel) or
LN-229 pSUPER control transfectants (upper panel) by flow cytometry using the calcium-dependent
fluorescent probe Fluo3-AM. Untreated controls are shown as filled histograms, open histograms were
recorded after cells had been exposed to 18 µM CP-31398 for 6 h. Mean fluorescence values are indicated
in the diagrams. B. LN-229 cells were treated for 6 h with vitamin D (25 µM), CP-31398 (36 µM), ATA
(20 µM) or combinations thereof. Intracellular calcium liberation was determined as in A. 
 
 
 
ATA also attenuated CP-31398-induced cell death in all 12 cell lines (Fig. 2.17, data not 
shown) while the induction of p53 reporter gene activity was not inhibited by ATA in 
either cell line (data not shown). 
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Fig. 2.17. ATA protects against p53-independent effects of CP-31398. LN-18 or LN-308 cells were
treated with CP-31398 in the absence (open squares) or presence (filled squares) of ATA (20 µM) for
24 h. Survival was assessed by crystal violet staining.  
To further assess which pathway triggered by CP-31398 was affected by ATA, LN-308 
hygro and LN-308 p53V135A cells were compared at 38.5°C and 32.5°C. While CP-
31398-induced cell death was strongly inhibited by ATA in LN-308 hygro cells 
maintained at both temperatures and in LN-308 p53V135A cells at 38.5°C, ATA had only 
minor effects in LN-308 p53V135A cells kept at 32.5°C (Fig. 2.18A). Accordingly ATA 
did not protect when LN-308 p53V135A cells were pulse-treated with CP-31398 whereas 
CHX (10 µg/ml) blocked cytotoxicity under these conditions (Fig. 2.18B). 
 
 
 Fig. 2.18. ATA does not prevent the p53-dependent effects of CP-31398. A. LN-308 hygro or 
LN-308 p53V135A cells were treated with CP-31398 for 24 h in the absence (open bars) or presence 
(filled bars) of ATA (20 µM) at 38.5°C or 32.5°C. Data are expressed as EC50 and SEM at 24 h 
(**p<0.01, *p<0.05, t-test ). B. LN-308 p53V135A cells were shifted to 32.5°C for 24 h and pulse-
treated with CP-31398 for 4 h in the absence (open squares) or presence of ATA (20 µM, closed 
squares) or CHX (10 µg/ml, closed triangles). ATA was present during the whole course of the 
experiment whereas CHX was removed together with CP-31398.  
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Discussion 
 
Pharmacological agents which specifically activate p53-dependent cell death pathways 
in mutant p53-accumulating cancer cells would represent a major advance in the therapy 
of human cancers characterized by p53 mutations. The first such molecule to be 
characterized was CP-31398 (19), a second one, PRIMA-1, has recently been described 
(20). Here is shown that none of 12 human malignant glioma cell lines resists the 
cytotoxic effects of CP-31398 (Fig. 2.2, Table 1), a small molecule discovered in a 
screening for compounds that force mutant p53 variants into assuming a wild-type 
conformation (19). At the molar level, the range of EC50 concentrations of 10-40 µM 
compares well with current cancer chemotherapeutics used in the treatment of 
malignant glioma (197). CP-31398-induced cell death had light microscopic and 
biochemical (AnxV-FITC staining, Fig. 2.3) features of apoptosis, but is an unusual 
type of apoptosis in that caspases appeared to play no role and in that Bcl-xL was not 
protective (Fig. 2.4). The data summarized in Table 1 and Fig. 2.12 suggest that CP-
31398 converts the mutant conformation of p53 into a functional one when the mutation 
is located in the central DNA binding region (175). The blunted response obtained with 
this mutant in the reporter assay in U251MG and U373MG cells might relate to the fact 
that residue 273 directly contacts the DNA. A conformational stabilization of the 
backbone of the protein may well optimize the conformation of this mutant and thus 
DNA binding while efficient transcription of the target genes is still not initiated (210). 
However, U251MG and U373MG cells nevertheless showed a strong accumulation of 
p21 when treated with CP-31398 (Fig. 2.12), suggesting that the reporter assay poorly 
reflects the transcriptional activation at least of the p21 gene. In this regard, gene chip 
analysis revealed that most, but not all, p53 response genes are induced when mutant 
p53 is stabilized through CP-31398 (211). Further, in analogy to the protein data shown 
here (Fig. 2.12), these authors observed a repression of Mdm2 mRNA expression by 
high concentrations of CP-31398. Further, they assumed that differential patterns of 
responses of various p53 target genes might be responsible for the biological activity of 
CP-31398 since pro-apoptotic p53 response genes were induced much more potently 
than p53 targets mediating cell cycle arrest, e.g. cyclin G2, or negative feed back loops, 
e.g. Mdm2-dependent, ubiquitin-mediated proteasomal degradation. 
A comparative analysis of molecular events triggered by CP-31398 in different cell 
lines revealed at least two pathways of CP-31398-induced cell death, one being p53-
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dependent and one being p53-independent. The p53-dependent killing pathway is 
triggered within few hours and depends on new protein synthesis, presumably of p53 
itself (Fig. 2.6, 2.7, 2.11). The p53-independent pathway is associated with free radical 
formation, but free radical formation does not mediate cell death (Fig. 2.15). In contrast, 
p53-independent cell death involves delayed calcium release and is inhibited by ATA 
(Fig. 2.16-18), an agent that acts as a general inhibitor of Ca2+-dependent 
endonucleases, amongst various other effects. 
The specificity of these effects was ascertained both by p53 reconsitution (Fig. 2.8-11, 
Fig. 2.18) as well as by siRNA technology (Fig. 2.5,6,15,16). The relative resistance of 
p53 null LN-308 cells in the 4 h pulse assay (Fig. 2.10) indicates a central role for p53-
mediated cell death in that paradigm. That LN-229 p53 knock-down cells were not fully 
protected (Fig. 2.6) may be due to some residual p53 activity as well as to effects of CP-
31398 on other members of the p53 family, such as p63 or p73 (206). In fact, 
stabilization of p73 by CP-31398 was also detected (data not shown). 
The proximate cause of CP-31398-induced cell death remains obscure and may in fact 
differ among cell lines. Although proapoptotic Bcl-2 family proteins were induced in 
many cell lines, caspases did not mediate cell death, and glioma cells may tolerate high 
level Bax expression under certain conditions (64). Further candidate mediators of cell 
death include NOXA and PUMA which were also differentially induced in response to 
CP-31398 (Fig 2.13). That transcription-independent effects of p53 were responsible for 
cell death cannot be excluded (212, 213), but seemed unlikely since at the time, when 
the experiments were performed, transcription-independent cell death had not yet been 
proven to occur with wild-type p53 or naturally occurring p53 mutants in intact cells. 
However, recent reports (172, 173) have shed a new  light on this issue. 
A p53-independent killing pathway triggered by CP-31398 had previously been 
discussed (214), but not studied at a molecular level. Surprisingly, these authors were 
unable to identify physico-chemical evidence for the interaction between CP-31398 and 
the isolated free core domain of p53. Instead they speculated that CP-31398 acts merely 
as a DNA intercalator. However, they could not exclude that CP-31398 acts in a 
chaperone-like manner on newly synthesized p53 protein. This, however, is the mode of 
action previously proposed for CP-31398 (19). Further support for a direct interaction of 
CP-31398 and p53 comes from EMSA studies showing restoration of the sequence-
specific DNA binding ability of the 273 (Arg→His) p53 mutant by CP-31398 (206, 
215). 
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The present study illustrates the difficult task to design and develop specific agents free 
of unexpected side effects. Conversely CP-31398 used in the p53-dependent pulse 
assays (Fig. 2.6, Fig. 2.18) induced cell death in some cell lines more efficiently than 
gene transfer-mediated overexpression of wild-type p53 (unpublished observations), 
suggesting that CP-31398 may not merely hit p53, but also p53-related proteins such as 
p63 or p73 (176). Similar to the synthetic p53 homolog, chimeric tumour suppressor 1 
(CTS-1) (203), the p53-dependent cytotoxic effects of CP-31398 appeared not to be 
mediated by either death receptors, caspase activation or free radical formation. The 
proximate cause of death in glioma cells killed by p53-dependent pathways thus 
remains obscure. Future efforts of drug design aiming at optimizing CP-31398-related 
compounds will have to focus on the preservation of the p53-mediated effects, which 
are desirable and potentially therapeutic, and attenuation of p53-independent effects, a 
likely source of undesirable side effects. 
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III. p53 and its family members - reporter genes may not see the difference 
A related manuscript has been published in Cell Death & Differentiation.  
2004 Oct;11(10):1150-1152 
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by Prof. Gerry Melino, PhD (Medical Research Council, Leicester, UK) who also made 
helpful suggestions concerning the discussion of  the data. 
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Introduction 
 
Luciferase-coupled reporter genes are widely used to investigate the activity of 
transcription factors. However, there is little awareness that the promoter sequences 
contained in these vectors are not always specific. This report shows that both p63 and 
p73 activate Stratagene´s p53 PathDetect reporter plasmid, one of the most commonly 
used reporter genes. Thus data obtained using this system (or any similar one) should 
be interpreted with caution because they may not actually reflect p53 activity, but rather 
provide an integrated signal derived from different members of the p53 family. In the 
absence of p53 signalling, this reporter gene may be useful for the analysis of effects 
that depend on p63 or p73. 
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Materials and Methods 
 
Cell lines. The human malignant glioma cell lines, kindly provided by Dr. N. de 
Tribolet (Lausanne, Switzerland), have been characterized (15, 197). SV-FHAS non-
neoplastic astrocytes were kindly provided by D. Stanimirovic (Institute of Biological 
Sciences, National Research Council of Canada, Ontario, Ottawa, Canada). The cells 
were cultured in Dulbecco`s modified Eagle medium (DMEM) containing 10% foetal 
calf serum, 2 mM glutamine and penicillin (100 IU/ml)/streptomycin (100 µg/ml). 
 
Plasmids. The PathDetect® p53 cis-reporter gene plasmid, containing the p53-
responsive enhancer element (TGCCTGGACTTGCCTGG)15, was from Stratagene (La 
Jolla, Ca). pRL-CMV was obtained from Promega (Mannheim, Germany). pcDNA3-
HA-p53, pcDNA3-HA-p73α, pcDNA3-HA-p73β, pcDNA3-HA-p73γ, pcDNA3-HA-
p73δ, pcDNA3-HA-∆Np73β, pcDNA3-HA-p73αA156V, pcDNA3-HA-p73βA156V 
pcDNA3-HA-p73χA156V and pcDNA3-HA-p73δA156V have been described (216). 
pcDNA3myc-TAp63α, pcDNA3myc-TAp63β, pcDNA3myc-TAp63γ, pcDNA3myc-
∆Np63α, pcDNA3myc-∆Np63β and pcDNA3myc-∆Np63γ have been described 
(Boston, MA, USA) (217). 
 
p53 silencing. The p53 specific oligonucleotide sequences GATCCCCGACTCCAG 
TGGTAATCTACttcaagagaGTAGATTACCACTGGAGTCTTTTTGGAAA and 
TCGATTTCCAAAAAGACTCCAGTGGTAATCTACtctcttgaaGTAGATTACCAC
TGGAGTCGGG were obtained from Metabion (Munich, Germany) and cloned into 
Bgl II and Sal I-sites of the pSUPERpuro vector (177), generously provided by Dr. 
Reuven Agami (Amsterdam, NL). The p53-specific parts of the sequence are depicted 
in bold letters and underlined. The resulting pSUPERp53 plasmid was stably 
transfected (10:1) and puromycin-resistant bulk transfectants were generated. Control 
transfectants were generated by co-transfecting pSUPERpuro alone. 
 
Immunoblot analysis. The general procedure has been described (200). Soluble protein 
levels were analysed using 20 µg of cellular lysate separated on 10-12% acrylamide 
gels (Biorad, Munich, Germany). After transfer to a PVDF membrane, the blots were 
blocked and incubated with murine anti-human p53 monoclonal antibody Bp53-12 (2 
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µg/ml), goat anti-mammalian β−actin polyclonal antibody I-19 (1 µg/ml) (both from 
Santa Cruz, Santa Cruz, CA), mouse anti-mammalian p63 4A4 (217) or rabbit anti-
human p73 antiserum (Sanofi, Paris, France) (218). Visualization of protein bands was 
accomplished using horseradish peroxidase (HRP)-coupled IgG secondary antibody 
(Sigma) and enhanced chemiluminescence (ECL) (Amersham, Braunschweig, 
Germany). Quantification was performed by multiplying the respective signal area with 
its mean intensity using Corel Photo-Paint 11 software (Corel Corporation, Ottawa, 
CA). 
 
p53 reporter gene assay. Glioma cells were seeded into 96 well plates (6 x 
103cells/well) and left to adhere overnight, before they were co-transfected with 0.06 
µg of the PathDetect® p53 cis-reporter gene plasmid, 0.03 µg of the respective 
activator plasmid (or irrelevant DNA) and 0.01 µg of pRL-CMV, using FuGene 6 
(Roche, Mannheim, Germany). At 16 h after transfection, the cells were shifted to the 
respective temperature. Another 32 h later, the cells were washed and lysed using 
Reporter Lysis Buffer (Promega). The respective activities of firefly and renilla 
reniformis luciferase were determined sequentially using the firelite dual luminescence 
reporter gene assay (Perkin-Elmer, Rodgau-Jügesheim, Germany). Background was 
subtracted from all values and the counts obtained from the measurement of firefly 
luciferase were normalized with respect to pRL-CMV. 
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Results 
 
To study effects caused by p53 mutations (219), resulting in loss of functional p53 
activity (220, 221), and suppression of signalling from p53-related proteins such as p63 
or p73 (222, 223), a stable subline of LN-18 glioma cells was generated where the 
expression of the endogenous mutant p53 (238 Cys → Ser) (224) was suppressed by 
more than 90% by pSUPER siRNA technology (177). RNA interference targeting p53 
had no effects on the levels of p63 and p73 (Fig. 3.1 A). A transiently transfected 
pcDNA3-HA-p53 plasmid induced greater p53-Luc reporter gene activity in the p53-
depleted cells than in the control transfectants, consistent with a dominant negative 
effect of the endogenous p53 mutant (Fig. 3.1 B).  
 
 
 Figure 3.1:   siRNA-mediated 
downregulation of mutant p53 in LN-18 
glioma cells. A. LN-18 human malignant 
glioma cells were stably transfected with 
pSUPERpuro control (left) or pSUPERpuro 
p53 plasmid (right) and analysed for p53, 
p63, p73 or β-actin levels by immunoblot. 
B. LN-18 pSUPER puro control (left) or 
p53-knockdown cells (right) were seeded 
into 96 well plates (6 x 103cells/well) for 
24 h and then co-transfected with 0.06 µg of 
the PathDetect® p53 cis-reporter gene 
plasmid, 0.03 µg of pcDNA3-HA-p53 and 
0.01 µg of pRL-CMV. At 48 h after 
transfection, the cells were washed and 
lysed. The respective activities of photinus 
pyrsalis and renilla reniformis luciferase 
were determined sequentially. Background 
was subtracted from all values and the 
counts obtained from the measurement of 
firefly luciferase were normalized to pRL-
CMV. 
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Surprisingly, the mutant p53-depleted cells provided a significantly (Student’s t-test, 
p<0.01) increased p53-Luc signal (Fig. 3.2) even in the absence of wild-type p53 
transfection which, by definition, could not be derived from wild-type p53 in this cell 
line. 
 
 
 
 
 
 
 
Fig. 3.2. Induction of p53-like reporter gene activity by knock-down of mutant p53. LN-18
pSUPER puro control (left) or p53-knockdown cells (right) were transiently co-transfected with p53-
Luc and pRL-CMV alone. Luminescence was determined as in Fig.3.1B. 
Since we had previously demonstrated the expression of p73 in LN-18 cells (225), this 
p53-like reporter gene activity could possibly be derived from the de-repression of p73 
after the depletion of endogenous mutant p53. To assess whether the p53-luc reporter 
responds to p73, LN-308 cells which express neither p53 nor p73 (6,8) nor p63 by 
immunoblot (Fig. 3.3) were examined. 
 
 
 Fig. 3.3. LN-308 glioma cells do not
express p63 protein. LN-308 glioma cells
(left) and SV-FHAS non-neoplastic
astrocytes (right) were analysed for p63
and β-actin levels by immunoblot. The size
of the isoforms detected (corresponding to
TAp63β and ∆Np63γ) is indicated. 
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Co-transfection assays revealed that the transcriptionally most active p73β isoform was 
even a stronger activator of the reporter plasmid than p53 itself. p73δ was 
approximately as effective as p53. p73α and p73γ gave weaker, but still significant 
signals. Only the truncated p73∆Nβ remained transcriptionally silent (Fig. 3.4). 
 
 
 
 
 
 
 
 
 
Fig. 3.4. p53-like reporter gene activity can be induced by p73. LN-308 cells were co-transfected
with p53-Luc, pRL-CMV and plasmids encoding p53 or the different isoforms of p73 (pcDNA3-HA-
p53, pcDNA3-HA-p73α, pcDNA3-HA-p73β, pcDNA3-HA-p73γ, pcDNA3-HA-p73δ, pcDNA3-HA-
∆Np73). Photinus pyrsalis and renilla reniformis luciferase activities were determined as in Fig. 1
and the values for p53-Luc/pRL-CMV are expressed relative to pcDNA3-HA-p53. 
Similar experiments performed with p63 showed that TAp63β and TAp63γ were also 
strong inducers of reporter gene activity while TAp63α gave only a weak signal, most 
likely because of the rapid degradation of this isoform caused by the MDM-2 like 
activity of the α C-terminus (226). While the ∆Np63α and ∆Np63β isoforms remained 
transcriptionally silent, the ∆Np63γ isoform, which lacks the p53-homologous 
transcriptional activation domain at the N-terminus, induced strong reporter gene 
activity. This is consistent with this isoform being pro-apoptotic (217) and may be due 
to an additional C-terminal activation domain (227) which is repressed in the longer C-
termini of other isoforms (Fig. 3.5). The use of p63 plasmids encoding the murine and 
not the human protein does not weaken the findings since p63 is more than 99% 
conserved between mice and men, with consensus sites being identical. 
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Fig. 3.5. p53-like reporter gene activity can be induced by p63. LN-308 cells were co-transfected
with p53-Luc, pRL-CMV and plasmids encoding p53 or the different isoforms of p63 (pcDNA3myc-
TAp63α, pcDNA3myc-TAp63β, pcDNA3myc-TAp63γ, pcDNA3myc-∆Np63α, pcDNA3myc-
∆Np63β, pcDNA3myc-∆Np63γ). Photinus pyrsalis and renilla reniformis luciferase activities were
determined as in Fig. 1. Temperature-sensitive mutants of p53 such as murine p53V135A are widely used for the 
study of p53 function. A screening of a comprehensive p53 missense mutation library 
has revealed a huge number of temperature-sensitive mutations that could become 
valuable tools (228). A set of similar mutants has been described for p73 (229). 
Reporter gene analysis is ideally suited to assess their transcriptional activity under 
various conditions. All p73V156A mutants, the functional analogs to murine p53V135A and 
human p53V143A, were found to be highly temperature-dependent. While they were 
almost transcriptionally silent at 38.5°C, transcriptional activity increased by more than 
20-fold when the temperature was shifted to 32.5°C (Fig. 3.6). 
 
 
 
Fig. 3.6. The p73V156A mutant is temperature-sensitive. The cells were transfected as in A with the
V156A mutants of p73 (pcDNA3-HA-p73αA156V, pcDNA3-HA-p73βA156V pcDNA3-HA-p73χA156V and
pcDNA3-HA-p73δA156V) or the human p53V143A mutant. At 24 h after transfection, the cells were
shifted to 38.5°C (filled bars) or 32.5°C (open bars) and analysed 24 h later. 
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Finally, to confirm the inhibition of p63- and p73-induced p53-like reporter gene 
activity by mutant p53, the various p63 and p73 isoforms were transfected in pSUPER 
puro p53-transfected LN-18 cells or control transfectants. Overexpression of 
transcriptionally active plasmids reliably induced luciferase activity, suggesting that 
p63 and p73 signalling can occur in the presence of mutant p53 variants and may 
mainly depend on the relative abundance of p53-related transcription factors in the cell 
(230). Yet, when mutant p53 expression was suppressed by pSUPER puro p53, the 
signals obtained were up to ten-fold stronger than in the respective control cells. It 
should be noted that some residual mutant p53 was still present in the knock-down cell 
line (Fig. 1A). This may explain why p63α as well as the p73α and γ isoforms, which 
are weaker activators of the p53-Luc plasmid, are less well de-repressed from p53-
mediated suppression than the p73β and p73δ isoforms (Fig. 3.7) which induce stronger 
p53-like transcriptional activity (Fig. 3.4). Further, it was found that the p53-like 
reporter gene activity observed in the p53 knock-down cell line was abrogated by the 
∆Np63α, ∆Np63β and p73∆Nβ isoforms, confirming their dominant-negative action 
over the endogenous isoforms of p63 or p73. 
 
 
 
 
 
 Fig. 3.7. Presence of mutant p53 inhibits p63- and p73-dependent reporter gene activation. LN-18
pSUPERpuro p53-transfected cells (filled bars) or control transfectants (open bars) were transiently co-
transfected with p53-Luc, pRL-CMV and plasmids encoding the different isoforms of p63 and p73.
Luciferase activities were determined as in Fig. 3.2 and are expressed relative to the activity induced
by pcDNA-HA-p53 in LN-18 pSUPER puro p53 cells. 
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Discussion 
These data demonstrate that the PathDetect® p53 cis-reporter gene plasmid, a typical 
reporter for the measurement of p53 transcriptional activity, is also activated by p63 
and p73. This raises concerns about the specificity of p53-related data obtained by this 
and similar assays and suggests that often only integrated information on p53 and its 
family members is obtained. While several p53-dependent promoters including p21, 
bax, mdm2, gadd45 and cyclin G respond to p63 (231) and p73 (232) and thus resemble 
the artificial p53-responsive enhancer element (TGCCTGGACTTGCCTGG)15 
contained in the PathDetect® p53-Luc reporter, activation by all three family members 
is not a general characteristic of p53-dependent promoters. This is because only 6 of 36 
p53-induced transcripts were upregulated by tetracycline-dependent induction of p73α 
in DLD-1 colon cancer cells (233). Other promoters are activated by p63 and p73 only 
(234). Thus, the relative activity of p53, p63 and p73 isoforms appears to be promoter-
dependent, allowing for a finely differentiated cellular response. Further fine-tuning 
may occur in a cell-type specific way through the presence of co-factors like brn-3a, 
which shows synergy with p53 at the p21, but antagonism at the bax promoter (235). 
Other co-factors like MDM-2 (236), ASPP/iASPP (237) or PARC (238) show different 
(MDM-2) or yet unexplored interactions with the various p53 family members, adding 
further complexity. 
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IV.  Death receptor-mediated apoptosis in human malignant glioma cells: modulation by 
the CD40/CD40L system 
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Introduction 
 
CD40 is a member of the TNFR family which has been assumed to chiefly mediate 
antiapoptotic signalling, proliferation and differentiation in B cells (239, 240). The 
cognate ligand, CD40L, is mainly expressed on activated T cells and platelets (241). 
CD40L expression has also been described on macrophages, smooth muscle and 
endothelial cells (242). CD40 contains a cytoplasmic motif reminiscent of the death 
domain which mediates TNF-R- and CD95-dependent apoptosis. Accordingly, CD40 
mediates cell death in certain transformed cell lines, including neuroblastoma cells 
(243) and other tumour cells of mesenchymal and epithelial origin (244, 245). Given the 
lack of a proper death domain in CD40 homologous to that of CD95 or TNF-R, the 
mechanisms underlying the cytotoxic effects of CD40L mediated by CD40 ligation 
have not been resolved (246). It has been suggested that CD40 stimulation induces the 
production of membrane-anchored TNF-α which then engages TNF-R1 (p55) at the cell 
surface, thus triggering the death receptor-dependent pathway involving caspases 8 and 
3 (247). The synergistic cytotoxic effects of CD40 and TNF-R1 (p55) activation (183, 
245, 247, 248) as well as the protection from CD40L-induced apoptosis by antagonistic 
TNF-R1 (p55) antibodies (247) support this model. Alternatively, CD40 ligation may 
increase CD95L or TRAIL mRNA and protein levels (249, 250). 
Initiation of apoptosis via death receptors such as TNF-R, CD95, DR4/TRAIL-R1 or 
DR5/TRAIL-R2 by recombinant ligands or agonistic antibodies is currently being 
explored as a therapeutic approach to malignant gliomas (67, 251-253). A potential 
modulation of the sensitivity of malignant glioma cells to cytotoxic cytokines by the 
CD40/CD40L system would therefore be of clinical interest. 
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Materials and Methods 
 
Materials. Isoleucine zipper CD40L was generously provided by Immunex (Seattle, 
WN). Mouse monoclonal antibodies to human CD40 included mAb89 from 
Immunotech-Coulter (Marseille, France), 5C3 from BD Pharmingen (Heidelberg, 
Germany), HB14 from Caltag (Hamburg, Germany) and G28.5 (raised in the laboratory 
of H. Engelmann). Further antibodies were TRAP-1 mouse anti-human CD40L and 
4C10-5 mouse anti-human PARP from BD Pharmingen, mouse anti-human caspase 3 
and mouse anti human FADD (#C31720 and F33620, Transduction Laboratories, 
Lexington, KY), C5 and C15 mouse anti-human caspase 8 (generously provided by 
P.H. Krammer, Heidelberg, Germany), M3 mouse anti-human CD95 (American Type 
Culture Collection, Manassas, VA), goat anti-human Apo2L/TRAIL #AF-375 (R&D 
Systems, Wiesbaden, Germany), W27 mouse anti-human hsp-70 and rabbit anti-human 
CD95 FL-335 and C-20 (Santa Cruz, Santa Cruz, CA). Antibodies to TRAIL receptors 
1-4 were generously provided by H. Walczak (Heidelberg, Germany). Anti-TNF-R1 
(p55) antibody (H398) was generously provided by Dr. P. Scheurich (Stuttgart, 
Germany). The generation of the bispecific antibody constructs using switch variants of 
anti-human Apo-1 has been described (182). CHX was purchased from Sigma (St. 
Louis, MO), MG-132 and Bay 11-7082 from Calbiochem (Hamburg, Germany), PHA 
from Biochrom (Berlin, Germany) and zVAD-fmk and DEVD-amc from Bachem 
(Heidelberg, Germany). Human IFN-γ and TNF-α were obtained from Roche 
(Mannheim, Germany). Apo2L/TRAIL.0 was provided by A. Ashkenazi (Genentech, 
South San Francisco, CA). CD95L-containing supernatant was harvested from CD95L-
transfected N2A neuroblastoma cells (254). 
 
Cell lines. The human glioma cell lines, kindly provided by Dr. N. de Tribolet 
(Lausanne, Switzerland), have been characterized previously (197). The cells were 
maintained in DMEM containing 10% FCS and penicillin (100 IU/ml)/streptomycin 
(100 µg/ml). Primary human glioma cell lines were prepared from surgically obtained 
glioma specimens as described (253). The human ovary adenocarcinoma cell line EFO-
27 was obtained from the German Collection of Microorganisms (Braunschweig, 
Germany). Cells were cultured in RPMI 1640 containing 2 mM L-glutamine, 1 mM 
sodium pyruvate and amino acids with  addition of 20% FCS and penicilline (100 
IU/ml)/streptomycine (100 µg/ml). The hepatocellular carcinoma cell line Hep-G2 was 
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from the American Type Culture Collection (Manassas, VA). CD40L-transfected BHK 
cells and the respective neo control transfectants have been described earlier (183). 
Before use, these cells were fixed in paraformaldehyde and washed thoroughly. For the 
generation of stable CD40 transfectants, the cells were transfected with a pcDNA3 
control or a pcDNA3 CD40 plasmid generously provided by A. Eliopoulos 
(Birmingham, UK) (255). Transfection was carried out using FuGene transfection 
reagent (Roche). The cells were selected in medium containing 0.5 mg/ml neomycin 
(G418) (Calbiochem, Bad Soden, Germany). 
 
RT-PCR. Total RNA was extracted using the RNeasy RNA purification system (Qiagen, 
Hilden, Germany). RT-PCR for the detection of CD40 mRNA expression was 
performed according to standard procedures. The following primers were used with an 
annealing temperature of 62°C: 5´-CTCGCTATGGTTCGTCTGCCTC-3´ (42-63), 
5´-CTCCTGGGTGACCGGTTGGCA-3´ (839-818), 5´-CTGCCCAGTCGGCTTCTT 
CTC-3´ (482-502) and 5´-GAGAAGAAGCCGACTGGGCAG-3´ (502-482). CD95 was 
amplified at 59°C annealing using 5'-GAGACTCAGAACTTGGAAGGC-3' (133-153) 
and 5'-CTTTGCACTTGGTGTTG CTGG-3' (390-370). To test for expression of 
CD40L, 5´-CCATGAGCAACAACTTGGTAAC-3´ (479-500) and 5´-CACTTGGC 
TTGGATCAGTCAC-3´ (780-760) were used at 62°C annealing temperature. β-actin 
was amplified at 55°C using 5´-TGTTTGAGACCTTCAACACCC-3' (409-429) and 
5'-AGCACTGTGTTGGCGTACAG-3' (937-918). 
 
Northern blot. Denatured total RNA (10 µg) was loaded on a 1% agarose gel containing 
6.7% formaldehyde. The RNA was separated at 100 V, transferred to a Hybond N+ 
membrane (Amersham, Freiburg, Germany) using capillary blotting and cross-linked in 
a UV stratalinker 1800 (Stratagene, La Jolla, CA) at 1200 J. Methylene blue staining 
was performed as a loading control. The membrane was preincubated for 2 h in Church 
buffer at 65°C. The probe was constructed by cutting CD40 or CD95, respectively, from 
expression plasmids. The CD95 plasmid was obtained from N. Itoh (Osaka, Japan). The 
full-length gene sequences were purified by gel extraction (Qiagen, Hilden, Germany) 
and labeled using 5 µl (~1.6 Mbq) dCTP and the Rediprime II random labelling system 
(Amersham). Filters were hybridized overnight at 65°C in a hybridization oven with a 
rotisserie device using Church buffer. Binding of radioactive probes was visualized 
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using a PhosphoImager (FujiBasReader 1500, Fuji, Kangawa, Japan). Loading was 
controlled by assessing ß-actin mRNA expression. 
 
Immunoblot analysis. Cellular soluble proteins (20 µg/lane) were loaded on a 12% 
acrylamide gel (Biorad, Munich, Germany). Anti-TNF-R1 (p55) antibody H398 
recognizes an epitope that is only present under non-reducing conditions, otherwise β-
mercaptoethanol (5%) was added. After transfer to nitrocellulose (Biorad), the blots 
were blocked in PBS containing 5% skim milk and 0.05% Tween 20 and incubated 
overnight at 4°C with antibodies to CD40 (G28.5), CD95 (FL-335 and C-20), TNF-R1 
(p55), caspase 3 or caspase 8 (2 µg/ml). Visualization of protein bands was 
accomplished using HRP-coupled secondary antibody (Sigma) and ECL (Amersham). 
 
Immunoprecipitation. The cells (1.5 x 106/condition) were detached, washed in PBS and 
lysed for 30 min on ice in a buffer containing 10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 
1% NP40, 2 mM MgCl2, 2 µM EDTA, 1 µM pepstatin, 1 µM leupeptin and 0.1 mM 
PMSF. Lysates were centrifuged and pre-cleared on a shaker using protein A/G Plus 
sepharose (Santa Cruz). Cleared lysates were then divided for either direct loading or 
immunoprecipitation with 2 µg of antibody (30 min, 4°C, constant agitation). For pull-
down (4 h, 4°C, under shaking), protein A/G Plus sepharose was added. Precipitates 
were pelleted in a tabletop microcentrifuge. Pellets were washed three times in lysis 
buffer. Finally proteins were recovered by boiling for 5 min in 50 mM Tris-HCl, 
pH=6.8, 2% SDS, 0.1% bromphenol blue and 10% glycerol and loaded onto an agarose 
gel (12%). 
 
Flow cytometry. The cells were treated as indicated, detached with cell dissociation 
buffer (Gibco, Karlsruhe, Germany) and resuspended in flow cytometry buffer (PBS 
containing 1% bovine serum albumin and 0.01% sodium azide). The cells were stained 
with CD40 or CD40L antibodies (10 µg/ml) or appropriate isotype control antibodies. 
The SFI was defined as the ratio of mean fluorescence obtained with specific antibody 
divided by mean fluorescence obtained with the isotype control antibody. Intracellular 
staining was performed with the Cytofix/CytopermTM kit (BD Pharmingen). 
Alternatively the cells were permeabilized with ice-cold ethanol (70%) for 5 min. 
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Immunocytochemistry. The cells were seeded on coverslips (5 x 104 cells/well in a 24 
well plate), allowed to adhere overnight and stimulated with CD40L or G28.5 agonistic 
anti-CD40 antibody for the indicated time intervals. Incubations were terminated on ice 
and all further steps were performed at 4°C. The cells were washed twice in PBS and 
once in blocking buffer (PBS with 2% goat serum) before FITC-conjugated goat anti-
mouse secondary antibody (1:250, Sigma) was added. After three further washes, the 
cells were fixed in 4% ice-cold paraformaldehyde, mounted with Vectashield mounting 
medium (Vector Laboratories, Peterborough, UK), and analysed and photographed (at 
40x magnification) on a Leica DM IRBE inverted microscope (Leica, Wetzlar, 
Germany). 
For double-staining of CD40 and TNF-R1 (p55) the cells were fixed with 4% 
paraformaldehyde for 5 min, washed, blocked with normal goat serum (10% in PBS 
with 1% Triton X-100) and incubated for 2 h with antibodies against CD40 (G28-5, 
IgG1-κ, 5 µg/ml), TNF-R1 (p55) (H398, IgG2a, 5 µg/ml) or the respective isotype 
controls in PBS containing 1% serum and 0.1% Triton X-100. After washing with PBS 
visualization of bound antibodies was performed using isotype-specific goat anti-mouse 
IgG1-PE and goat anti-mouse IgG2a-Alexa Fluor 488 antibodies (Molecular Probes, 
Eugene, OR). Cross-reactivity was controlled by mismatched antibody pairing. Cells 
were analyzed by confocal laser scanning microscopy (LSM 510, Carl Zeiss, Jena, 
Germany). 
 
Immunohistochemistry. Cryosections (10 µm) of human glioblastomas (WHO grade 4) 
were fixed in acetone, air-dried, washed with TBS and stained with G28-5 anti-CD40 
antibody or control IgG1-κ (20 µg/ml). Avidin biotin complex (ABComplex, 
Dakopatts, Glostrup, Denmark) consisting of biotinylated anti-mouse secondary 
antibody and HRP-conjugated avidin was used at 1:400. Stainings were developed for 
1-2 min with diaminobenzidine. Nuclei were counterstained with haemalaun. Umbilical 
chord was taken as positive control. Normal human brain served as a negative control. 
 
Viability assay. The cells were seeded in 96 well plates at 104 cells/well and allowed to 
attach for 24 h. CD40L was added in fresh serum-free medium for up to 72 h. In some 
experiments, the cells were pretreated with IFN-γ or cotreated with CHX for 16 h. 
Viable cell counts were obtained by crystal violet staining. When paraformaldehyde-
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fixed BHK cells were used to deliver the apoptotic signal, the cells were removed by 
washing before the crystal violet stain was performed. 
 
Proliferation assay. The cells were pulsed for 24 h with [methyl-3H] thymidine (0.5 
µCi, Amersham), lysed and harvested with a cell harvester (Inotech, Dottikon, 
Switzerland). Incorporated radioactivity was bound to a glass fibre filtermat (Wallac, 
Turku, Finland). The filtermat was wetted with Ultima Gold Scintillation Cocktail 
(Packard, Dreieich, Germany) and radioactivity was determined in a Wallac 1450 
Microbeta Plus Liquid Scintillation Counter (Wallac, Turku, Finland). 
 
DEVD-amc-cleaving caspase activity. The cells (0.5 x 104) were seeded in 96 well 
plates, treated as indicated, lysed in 25 mM Tris-HCl, pH 8.0, 60 mM NaCl, 2.5 mM 
EDTA, 0.25% NP40 for 10 min, and the substrate DEVD-amc was added at 12.5 µM. 
Caspase activity was assessed by fluorescence using a Millipore fluorimeter at 360 nm 
excitation and 480 nm emission wave lengths. 
 
NF-κB and IL-8 reporter assay. The cells were transfected with the PathDetect® NF-
κB cis-reporter gene plasmid (#219077 Stratagene) or with an IL-8-luc construct 
generously provided by M. Kracht (Hannover, Germany) (256). The NF-κB–responsive 
element is (TGGGGACTTTCCGC)5. Transfection was performed using FuGene 
(Roche). Treatment with TNF-α (10 ng/ml, 6 h) (Roche) was used as a positive control. 
At 24 h after transfection, CD40L was added to some samples. Another 6 h later, the 
cells were washed and lysed using Reporter Lysis Buffer (Promega, Madison, WI). 
Following one freeze-thaw cycle, the lysates were transferred to a LumiNuncTM plate 
(Nunc, Roskilde, Denmark), Luciferase assay substrate (100 µl, Promega) was added 
automatically, and luminescence was measured in a LumimatPlus (EG&G Berthold, 
Pforzheim, Germany). The background was subtracted from all values. 
 
TNF-α ELISA. TNF-α concentrations in cell lysates and supernatants were determined 
by ELISA (Endogen, Woburn, MA). 
 
Generation of bispecific antibody fragments. Bispecific antibody fragments (bsFab2) 
were prepared by selective reduction and reoxidation of hinge region disulfide bonds as 
described (257). The reaction conditions prevent the formation of homodimers and 
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allow almost complete hybridization of modified Fab fragments of the parental 
antibodies. For this study, the IgG2A variant of the Apo-1 antibody (to CD95) (258) 
generously provided by P.H. Krammer (Heidelberg, Germany) was hybridized to 
antibodies directed to CD20 (L3B3, provided by Baxter, Munich, Germany) or CD40 
(G28.5). 
 
Statistical analysis. Data are representative of experiments performed three times with 
similar results. Viability studies were performed using triplicate wells. Significance was 
assessed by t-test (∗p<0.05, ∗∗p<0.01). 
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Results 
 
CD40 expression in human glioma cell lines 
CD40 mRNA expression was assessed in untreated or IFN-γ-stimulated (500 U/ml, 
48 h) glioma cells by RT-PCR (Fig. 4.1A) and Northern blot (Fig. 4.1B). The levels of 
mRNA varied considerably, however, some signal was detected in all cell lines by both 
methods. Immunoblot revealed a rather homogenous expression among the cell lines, 
suggesting that the regulation of CD40 protein levels does not only depend on CD40 
gene transcription, but is regulated posttranscriptionally as well (Fig. 4.1C). 
 
 
 
 
 
 
 
Fig. 4.1. Constitutive and IFN-γ-inducible CD40 expression in human glioma cell lines. The cells
were untreated or treated with IFN-γ (500 U/ml) for 48 h. CD40 expression was analysed by RT-PCR
(A), Northern blot (B) or immunoblot (C). The primers 5´-CTCGCTATGGTTCGT CTGCCTC-3´
(42-63) and 5´-CTCCTGGGTGACCGGTT GGCA-3´ (839-818) were used for RT-PCR for 28
cycles to allow for a semi-quantitative assessment. 
Surprisingly flow cytometry (of unpermeabilized cells) revealed that only 1 of 12 
glioma cell lines, U87MG, showed constitutive CD40 protein expression at the cell 
surface (Fig. 4.2A). Further, none of 5 primary polyclonal glioma cell cultures showed 
 93
constitutive CD40 expression at the cell surface (data not shown). The exposure to IFN-
γ resulted in enhanced CD40 mRNA expression assessed by Northern blot in 11 of 12 
cell lines (LN-18, U138MG, U87MG, LN-428, D247MG, LN-319, LN-229, A172, 
U251MG, U373MG, LN-308). At the total protein level determined by immunoblot, 
IFN-γ exposure increased CD40 levels in 5 of 12 cell lines (LN-18, U138MG, U87MG, 
LN-428, D247MG). The specificity of CD40 labelling was confirmed using lysates 
from CD40-transfected LN-18 glioma cells (Fig. 4.1C, right outer lane) and by 
competitive inhibition of labelling using lysates from CD40-transfected glioma cells 
(data not shown). At the cell surface, IFN-γ enhanced CD40 expression in U87MG 
cells, and induced low level CD40 expression in LN-18 and LN-229 cells (Fig. 4.2A,B).  
 
 
 
 
 
 
Fig.4.2 CD40 surface expression in human gliomas is inducible by IFN-γ. In A, LN-18,
U87MG and LN-229 cells are shown untreated (left) or IFN-γ-treated (right). Filled curves
indicate signal obtained with specific antibody, open curves indicate signal obtained with isotype
control antibody. Specific fluorescence indexes (SFI) are indicated in the graphs. B. Synopsis of
CD40 cell surface expression of untreated (open bars) or IFN-γ-treated (grey bars) glioma cells
expressed as SFI. Note that a value of 1 indicates the absence of CD40 expression (*p<0.05, t-test,
presence versus absence of IFN-γ). 
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To account for the discrepancy between the detection of CD40 in total cellular lysates, 
but not on the cell surface in most cell lines, several attempts were made to stain CD40 
intracellularly using flow cytometry, but none of the available antibodies (G28.5, 
mAb89, 5C3 and HB14) gave a signal when used for the flow cytometric analysis of 
cells permeabilized with Cytofix/Cytoperm reagents or with ethanol. Further, the 
pretreatment of the cells with 0.1% acetic acid in 0.15 M NaCl, which has been reported 
to free antigens from bound ligands (259), did not result in the surface staining of 
otherwise negative cell lines (data not shown). The possibility that glioma cells might 
produce a soluble CD40 molecule lacking the transmembrane domain corresponding to 
amino acids 194-215 or nucleotides 629-694 or release full-length CD40 into the cell 
culture supernatant was also considered. However, immunoblot analysis of supernatant 
protein and a transmembrane region-spanning RT-PCR failed to support these 
possibilities (Fig. 4.1A). Instead, glioma cells appeared to express exclusively full-
length CD40 while various alternatively spliced isoforms were detected in PBMC (260) 
(data not shown). CD40L RNA and protein were not detected in any glioma cell line as 
assessed by RT-PCR and flow cytometry, using PBMC as a positive control (see Table 
1). 
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Table I. Death ligand expression in human malignant glioma cells 
 
 TNF-αa CD95Lb Apo2L/TRAILc CD27Ld CD40Le 
LN-18 - + + + - 
U138MG - + + + - 
U87MG - + nd + - 
LN-428 - + + + - 
D247 - + nd + - 
T98G - + + - - 
LN-319 - + + + - 
LN-229 - + nd + - 
A172 - + nd + - 
U251MG - + + + - 
U373MG - + + + - 
LN-308 - + + + - 
aELISA and bioassay (261), bRT-PCR, immunoblot or flow cytometry (204, 262-264), cRT-
PCR and immunoblot (265), dNorthern blot, immunoblot and flow cytometry (261), eRT-PCR 
and flow cytometry (this study) (nd no data) 
 
 
 
CD40 expression in primary human glioblastoma tissue 
Cryosections from glioblastoma patients were stained for CD40 expression. While post 
mortem sections from patients with no reported neurological diseases or symptoms (further 
designated as normal brain tissue) showed no CD40 immunoreactivity (Fig. 4.3A), all 
glioblastoma samples showed CD40 expression ranging from scattered positive cells to over 
30% of CD40-expressing cells (Fig. 4.3B). Both cell surface and intracellular staining was 
observed (Fig. 4.3C), suggesting that CD40 protein is not restricted to the outer cell 
membrane in glioma cells in vivo either. CD40-positive cells were identified as tumour cells 
by morphological criteria in all samples. Strong expression was also detected on tumour-
associated blood vessels. 
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Fig. 4.3. Human glioblastomas 
express CD40 in vivo.  
Frozen tissue sections were 
immunostained with the CD40-
specific mAb G 28.5 or isotype 
control. A. Umbilical cord 
(upper panel) and normal brain 
tissue (#636/02II, lower panel) 
(x200). Endothelial cells of 
blood vessels in the umbilical 
cord are CD40-positive 
(positive control).  
 
 
 
 
 
 
 
 
B. Umbilical cord (upper panel) 
and glioblastoma section 
(#551/02, lower panel) (x 200, 
overview).  
 
 
 
 
 
C. For better visualization of 
tissue structure, glioblastoma 
sections (#551/02, upper panel; 
#1110/02, lower panel) stained 
with the CD40-specific mAb G 
28.5 or isotype control were 
photographed under polarised 
light (x400). 
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Human glioma cell lines are refractory to CD40L-mediated signalling 
To assess the death signalling properties of CD40 expressed on glioma cells, untreated 
and IFN-γ-stimulated EFO-27 ovarian adenocarcinoma cells were treated with 
isoleucine zipper CD40L which is cytotoxic to lymphoma and epithelial ovarian 
carcinoma cells (266, 267). While unstimulated cells were almost unresponsive (a small 
effect was observed in a 72 h cytotoxicity assay – data not shown), cell death was 
readily induced in IFN-γ-pretreated EFO-27 and Hep-G2 cells (Fig. 4.4A and data not 
shown). Apoptosis was greatly enhanced by inhibition of protein synthesis with 
cycloheximide (10 µg/ml for 16 h) (Fig. 4.4A). However, U87MG glioma cells were 
refractory to soluble CD40L at concentrations up to 10 µg/ml (Fig. 4.4B). This 
resistance was not overcome when the cells were pretreated with IFN-γ, or cotreated 
with CHX, or both (Fig. 4.4C). CHX alone reduced cell density by about 20% within 
16 h, due to growth arrest, but not cytotoxic effects as demonstrated by LDH release 
assays (data not shown). IFN-γ alone had no effect on cell density in these experiments. 
Neither did the pharmacological NFκB inhibitor, Bay 11-7082, sensitize U87MG cells 
to the cytotoxic properties of CD40L.  
 
 
  
 
 
In line with this, flow cytometry revealed that stimulation with CD40L did not 
alter the cell surface expression of CD95, TNF-R1 (p55) or TRAIL receptors 1-4 in
these cells  
 
 
Fig. 4.4. CD40-expressing glioma cells are refractory to CD40L-induced cell death. A. Untreated
(open symbols) or IFN-γ (48 h, 500 U/ml)-stimulated (closed symbols) EFO-27 cells (104/well) were
treated with CD40L in the absence (rhomboids) or presence (triangles) of CHX (10 µg/ml). Cell density
was assessed at 16 h by crystal violet staining. The data are expressed relative to cells exposed to
vehicle, CHX, IFN-γ or their combination alone. B,C. Untreated (B) or IFN-γ (48 h, 500 U/ml)-
stimulated (C) U87MG cells (104/well) were treated with CD40L in the absence (squares) or presence
(triangles) of CD95L with (filled symbols) or without (open symbols) CHX (10 µg/ml). Cell density
was assessed at 16 h by crystal violet staining and is expressed in % of the untreated control. Note that
either CD95L or CHX, and both in synergy, reduced cell density, but that these effects were unaffected
by CD40L.  
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Similarly, IFN-γ-treated LN-18 and LN-229 cells did not acquire sensitivity to CD40-
mediated cell death (data not shown). Alternatively, CD40L-transfected BHK cells, or 
the respective neo control transfectants (183) were used to deliver a death signal to 
unstimulated or IFN-γ-stimulated glioma cells, in the absence or presence of CHX. 
However, membrane-bound CD40L was unable to induce apoptosis either. In IFN-γ-
treated or untreated LN-18, U87MG or LN-229 cells, there was no synergy of CD40L 
with death ligands such as CD95L (Fig. 4.4B,C) or Apo2L/TRAIL (data not shown). 
Also the resistance of U87MG and LN-229 cells to TNF-α induced apoptosis was not 
overcome by CD40L (data not shown). Further, soluble or membrane-bound CD40L did 
not induce NF-κB or IL-8 reporter gene activity in naïve U87MG (Fig. 4.5B, data not 
shown) or in IFN-γ stimulated LN-18, U87MG or LN-229 cells (Fig. 4.5C, data not 
shown) whereas untreated or IFN-γ stimulated Hep-G2 cells responded readily (Fig. 
4.5A). Treatment with TNF-α (10 ng/ml), on the other hand, resulted in a 4-10-fold 
activation of these reporter genes in all cell lines. Finally [methyl-3H] thymidine 
incorporation by these cell lines was not altered by treatment with CD40L whereas the 
reagent induced massive B cell proliferation (data not shown). 
 
 
 
 
 
 
 
 
 
 
Fig. 4.5. CD40-expressing glioma cells are refractory to CD40L-induced signalling A.
Untreated (shaded bars) or IFN-γ (48 h, 500 U/ml)-stimulated (filled bars) Hep-G2 cells (104/well)
were treated with CD40L (1 µg/ml) or TNF-α (10 ng/ml) as a positive control. NF-κB reporter
activity was assessed at 6 h. Data are expressed as fold induction compared with untreated control
cells (open bars). B. NF-κB and IL-8 reporter activity were measured in untreated U87MG cells or
cells treated with CD40L (1 µg/ml) (shaded bars) or TNF-α (10 ng/ml) (filled bars) for 6 h. Data
are expressed as in A. In C, IFN-γ (48 h, 500 U/ml)-stimulated LN-18, U87MG and LN-229 cells
were examined as in A for NF-κB reporter activity (*p<0.05, **p<0.01, t-test). 
 99
Gene transfer mediated overexpression of CD40 confers sensitivity to CD40L-induced cell 
death 
Given these data, CD40 function or the signal transduction pathway triggered by CD40 
may be disabled in glioma cell lines. Consequently it was attempted to generate U87MG 
and LN-18 sublines stably overexpressing CD40 using plasmid-mediated gene transfer. 
Whereas LN-18 CD40 transfectants showed high expression of CD40 (Fig. 4.6A), no 
stable overexpression was achieved in U87MG cells. Soluble and membrane-bound 
CD40L induced NF-κB and IL-8 reporter activity in CD40-transfected LN-18 cells (Fig. 
4.6B, and data not shown), indicating that the signalling cascade was intact and that the 
physiological levels of CD40 expressed on naïve U87MG or IFN-γ-treated U87MG, 
LN-18 or LN-229 glioma cells were insufficient to transmit a signal. Further, CD40L 
was cytotoxic to CD40-transfected LN-18 cells, and its cytotoxicity was strongly 
enhanced by CHX (Fig. 4.6C).  
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.6. CD40-transfected LN-18 cells are susceptible to CD40L-induced apoptosis. A. CD40
expression in CD40-transfected LN-18 cells was assessed by flow cytometry (see Fig. 1D for
comparison). B. NF-κB (open bars) or IL-8 (filled bars) reporter gene activity were measured in
CD40-transfected LN-18 cells after stimulation (6 h) with CD40L (1 µg/ml), BHK neo or BHK
CD40L cells (at a 4:1 ratio of BHK:LN-18 cells) or TNF-α (10 ng/ml). C. CD40-transfected LN-18
cells (104/well) were treated with increasing concentrations of CD40L in the absence (open squares)
or presence (filled squares) of CHX (10 µg/ml), or CHX and zVAD-fmk (50 µM) (open triangles) for
16 h. The data are expressed relative to cells exposed to vehicle, CHX, zVAD-fmk or their
combination alone.  
Since CD40 does not contain a proper death domain, CD40-dependent apoptosis has 
been attributed to the recruitment of other TNF family receptors. These receptors do not 
only need to trimerize, instead, super-aggregation induced by cross-linked ligands (268) 
may be required for the induction of apoptosis (269). Thus CD40-transfected LN-18 
cells were examined for the “capping” of TNF receptor family members after 
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stimulation with trimeric CD40L or agonistic CD40 antibody (270). While no 
aggregation of TNF-R1 (p55), CD95 or TRAIL-R 1 or 2 was detected after treatment 
with CD40L (data not shown), clustering of CD40 itself was observed, beginning at 5 
min after stimulation and peaking at 45-60 min (Fig. 4.7). In contrast to the cytotoxicity 
of CD40L in the absence or presence of CHX (Fig. 4.6C), CD40 clustering was 
insensitive to the pan-specific caspase inhibitor zVAD-fmk (data not shown). 
 
  
 
 
 
 
Fig. 4.7. CD40L induces clustering of CD40 on LN-18 CD40 cells. CD40-transfected LN-18 cells (5
x 104/well) were stimulated with agonistic G28.5 anti-CD40 antibody (10 µg/ml) for 0 min (top), 10
min (middle) or 60 min (bottom) before the cells were put on ice for life-staining using FITC-labeled
goat anti-mouse secondary antibody. The cells were fixed for 5 min in 4% paraformaldehyde. Staining
was visualized under a Leica DM IRBE microscope and photographed (40x).  
 
The role of caspases in CD40L-induced cell death was further investigated using 
activity assays and immunoblot. There was a concentration-dependent induction of 
DEVD-amc cleavage at 6 h after exposure to CD40L in CD40-transfected LN-18 cells 
(Fig. 4.8A), but not in LN-18 neo cells, which, however, were sensitive to CD95L or 
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Apo-2L/TRAIL. Further, the processing of caspases 8 and 3 into the active fragments 
p18/caspase 8 and p17/caspase 3 and the cleavage of PARP into the 85 kDa and 25 kDa 
fragments characteristic for apoptosis was promoted by CD40L in CD40-transfected 
LN-18 cells but not in control transfectants (Fig. 4.8B and data not shown). Induction of 
apoptosis by TNF-α or TNF-α plus CD40L was included as a positive control. 
 
 
Fig.4.8. CD40L-induced cell death is caspase-dependent. A. DEVD-amc cleavage was assessed in lysates
from CD40-transfected (filled bars) or mock-transfected (open bars) LN-18 cells at 6 h after treatment with
CD40L. CD95L (50 U/ml) and Apo2L/TRAIL (0.2 µg/ml) were included as controls. B. The processing of
caspases 8 and 3 and PARP was investigated at 6 h after treatment of CD40-transfected LN-18 cells with
TNF-α (2 ng/ml) or CD40L (0.008, 0.04, 0.2, 1.0 µg/ml) alone or in combination (2 ng/ml TNF-α and 0.04
µg/ml CD40L). β-actin was included as a loading control. 
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Gene transfer mediated overexpression of CD40 confers resistance to CD95L-induced cell 
death 
LN-18 is among the most sensitive cell lines to CD95-mediated apoptosis (253). 
Interestingly, CD95L-treated CD40-transfected LN-18 cells exhibited only little DEVD-
amc cleavage (Fig. 4.8A) and did not respond with massive cell death (Fig. 4.9A). In 
contrast, their sensitivity towards Apo2L/TRAIL remained unaltered (Fig. 4.9B). A 
clonal artefact was excluded because bulk transfectants from three different 
transfections showed the same pattern of selectively induced resistance to CD95L, but 
not Apo2L/TRAIL (data not shown).  
 
 
 
 
 
Fig. 4.9. CD40 overexpression modulates CD95-mediated apoptosis. LN-18 neo control (open
squares) or CD40-transfected LN-18 cells (filled squares) were treated with CD95L (A) or
Apo2L/TRAIL (B). Survival was assessed at 24 h by crystal violet staining. 
Flow cytometry for CD95 and DR5 revealed a loss of CD95 expression whereas DR5 
was still expressed at a rather high level (Fig. 4.10). The expression of the other 
Apo2L/TRAIL receptors remained also unchanged (data not shown).  
 
Fig. 4.10. CD40 overexpression leads to decreased surface expression of CD95/Fas. CD95 or
DR5/TRAIL-R2 expression in LN-18 neo or CD40-transfected LN-18 cells were assessed by flow
cytometry. SFI values are indicated. 
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This suggests that glioma cells were selected against high co-expression of CD95 and 
CD40. This issue was addressed by transient transfection assays using LN-18 and 
U87MG cells. Whereas the generation of stable CD40-overexpressing sublines had 
failed in U87MG cells, transient transfection was feasible: at 36 h after transfection, 60-
70% of the cells showed enhanced CD40 expression at the cell surface. Interestingly, 
more than 50% of these cells had down-regulated CD95 expression (Fig. 4.11A). 
Coexposure to zVAD-fmk did not alter these results, indicating that cells expressing 
both receptors at high levels are not simply deleted by apoptosis (Fig. 4.11A, right 
panel). Similar results were obtained in LN-18 cells, and ectopic expression of the viral 
caspase inhibitor, crm-A, also failed to prevent the loss of CD95 at the cell surface of 
CD40-transfected LN-18 cells (data not shown). When cells from the same transfection 
were gated for CD40-overexpressing cells and for cells expressing CD40 at the 
endogenous level only, the groups showed prominent differences in CD95 expression, 
assessed either at the level of specific fluorescence index (SFI) values or of calculating 
the percentages of CD95-negative cells in the respective groups (Fig. 4.11B). 
 
 
 
 
 
 
 
 
 
Fig.4.11. Transient transfection with CD40 results in reduced CD95/Fas surface expression. A.
U87MG cells were transiently transfected with pcDNA3 neo (left panel) or pcDNA3-CD40 (middle and
right panel). In the right panel, zVAD-fmk was added (100 µM). The cell surface expression of CD40
and CD95 was analysed at 36 h by flow cytometry. The percentages of cells in each quadrant are
indicated in the graph. In the isotype controls, ≥ 97% of the cells were in the lower left quadrant (data
not shown). B. U87MG cells from D were separately gated for non-transfected, this is, CD40-negative
(open bars) and transfected cells (filled bars). U87MG control transfectants were also included as a pool
(grey bars). CD95 expression was then quantified for the respective groups by histogram analysis. Data
are expressed as SFI (left panel) or as percentages of CD95-negative cells (right panel) (*p<0.01, t-test).
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To assess whether the protein level of CD95 was absolutely diminished in CD40-
transfected LN-18 cells or whether the receptor was internalized, immunoblots for 
CD95 were also performed. Fig. 4.12A shows a striking reduction in total cellular CD95 
levels in CD40-transfected LN-18 cells compared with LN-18 neo cells. In contrast, 
CD95 mRNA levels were unaltered (Fig. 4.12B), suggesting that CD95 protein levels 
were regulated at the posttranslational level. In fact, exposure to the proteasome 
inhibitor, MG-132, for 16 h almost restored CD95 protein levels in CD40-transfected 
LN-18 cells (Fig. 4.12C), suggesting that the forced expression of CD40 promoted the 
increased proteasomal degradation of CD95.  
 
 
 
 
 
 
 
 
 
Fig. 4.12. CD40-dependent down-regulation of CD95 expression is due to increased proteasomal
degradation. A,B. Total cellular levels of CD95 protein and mRNA in LN-18 neo or CD40 cells were
determined by immunoblot using antibody FL-335 (A) or RT-PCR (B). β-actin expression was assessed
as a loading control. C. Total cellular levels of CD95 were determined by immunoblot in LN-18 neo
(left) or CD40-transfected LN-18 (right) cells after 16 h treatment with MG-132 at 0, 0.33 or 1 µM.
Proteasome inhibition was verified by hsp-70 protein accumulation. 
 
To exclude the possibility of CD95 mRNA being induced under conditions of 
proteasome inhibition (271), Northern blots were also performed to assess the CD95 
mRNA levels in response to MG-132 (Fig. 4.12D). These actually showed a slight 
decrease in CD95 mRNA expression, quantified in Fig. 4.12E. Thus the accumulation 
of CD95 upon proteasome inhibition was most likely due to the prevention of 
proteasomal degradation. 
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Fig. 4.13. Proteasome inhibition does not increase CD95 mRNA expression. A. CD95 mRNA levels
were assessed by Northern blot in LN-18 neo (left) or CD40-transfected LN-18 (right) cells after 16 h
treatment with MG-132 at 0, 0.33 or 1 µM. Total cellular β-actin mRNA levels were measured as a
loading control (lower panel). B. CD95 mRNA levels from A were quantified using a PhosphoImager and
normalized to β-actin mRNA signals. 
 
D40 interacts with TNF-α-dependent signalling 
roapoptotic effects of CD40L have been proposed to be mediated by CD95 (250) or 
NF-R1 (p55) (247) in different cell types. The sensitivity of CD40-transfected LN-18 
lls to TNF-a alone was unaltered. However, in contrast to the negative results for 
D95L (Fig. 3A,B), coexposure revealed strong synergy between CD40L and TNF-a in 
D40--transfected LN-18 cells, but not in the neo control transfectants (data not 
own), both in the absence (Fig. 4.14A) and presence of CHX (Fig. 4.14B). The 
ncentrations of CD40L required for this effect were subtoxic when applied on their 
n (see Fig. 4.6), and cell death was sensitive to zVAD-fmk (data not shown). 
 
  
 
 
Fig. 4.14 CD40L-mediated signaling affects TNF-R1-dependent cell death. A,B. CD40-transfected
LN-18 cells (104/well) were treated with TNF-α in the absence (open symbols) or presence (closed 
symbols) of subtoxic concentrations of CD40L (0.04 µg/ml in A, 0.0016 µg/ml in B). In B, CHX (10 
µg/ml) was added to all wells. Survival was assessed at 16 h by crystal violet staining. 
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Ligation of CD40 did not trigger endogenous TNF-α production by glioma cells since 
ELISA did not reveal TNF-α in supernatants or lysates from treated CD40-transfected 
LN-18 cells, using PBMC stimulated with PHA (5 µg/ml) as a positive control (Table 
1). Neither did blockade of TNF-R1 (p55) (247) or CD95 (250) or neutralization of 
TRAIL/Apo2L (248) confer protection against CD40L-induced cell death while 
apoptosis mediated by the respective ligands was blocked in CD40-transfected LN-18 
cells (shown for TNF-α and CD95L in Fig. 4.15). 
 
 
 
 
 
 
 
Fig. 4.15. Blocking of TNF-related death receptors does not inhibit CD40-mediated apoptosis.
CD40-transfected LN-18 cells (104/well) were treated with CD95L (100 U/ml), TNF-α (1 ng/ml) or
CD40L (1 µg/ml) in the presence of 10 µg/ml of either control antibody (open bars) or M-3 anti-
CD95 (shaded bars) or H398 anti-TNF-R1 (p55) antibody (black bars). Survival was assessed by
crystal violet staining at 24 h (**p<0.01, t-test).
 
The constitutive cell surface expression of TNF-R1 (p55) in CD40-transfected LN-18 
cells was somewhat increased. Interestingly, however, TNF-R1 (p55) surface expression 
was down-regulated in CD40-transfected LN-18 cells after treatment with CD40L, but 
not in the neo control cells (Fig. 4.16). This effect was seen as early as 2 h after 
exposure. Accordingly, addition of TNF-α to LN-18 CD40 cells that had been pre-
exposed to CD40L did not increase CD40-mediated cell death any further.  
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Fig. 4.16. TNF-R1 surface expression is reduced after treatment with CD40L. TNF-R1 (p55)
expression levels at the cell surface were analysed by flow cytometry in LN-18 control transfectants
(upper panel) and in CD40-transfected LN-18 cells (lower panel) before (left) or 6 h after (right)
exposure to CD40L (0.5 µg/ml). The SFI values are indicated in the upper right.  
Immunoblotting showed that the overall expression levels of TNF-R1 (p55) remained 
unchanged (Fig. 7E), suggesting that TNF-R1 (p55) was internalised rather than 
degraded (272). It should be noted that immunoblots for TNF-R1 (p55) commonly yield 
more than one band, probably due to glycosylation and ubiquitination (273). 
 
 
These data suggested an intracellular interaction between CD40 and TNF-R1 (p55). 
Fig. 4.17. Total cellular TNF-R1 expression is unaltered after treatment with CD40L. Total cellular
TNF-R1 (p55) content was assessed in CD40-transfected LN-18 cells before (lane 1) or 2 h, 4 h or 8 h (lanes
2-4) after exposure to CD40L (0.5 µg/ml). β-actin was included as a loading control. 
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Immunocytochemistry showed co-localization of CD40 and TNF-R1 (p55) (Fig. 4.18). 
 
 
 
 
 
 
 
 
Fig. 4.18. TNF-R1 (p55) and CD40 co-localize. Untreated, paraformaldehyde-fixed CD40-transfected
LN-18 cells were stained for both CD40 (red staining) and p55 TNF-R1 (green stain) and analyzed by
confocal microscopy. Shown are stainings for CD40 (upper left), p55 TNF-R1 (upper right) and their
respective overlay (lower left). Co-localization is indicated by yellow patches. A control staining with
the respective isotype antibodies is shown in the lower right panel. 
 
Further, CD40 and TNF-R1 (p55) could be co-immunoprecipitated (Fig. 4.19A). In 
contrast, no interaction of CD40 with CD95 was detected, neither in LN-18 neo control 
transfectants nor in unstimulated or CD40L-stimulated CD40-transfected LN-18 cells 
(Fig. 4.19B, data not shown). Yet, TNF-R1 (p55) was pulled down with anti-CD95 
antibody in stimulated CD40-transfected LN-18 cells, suggesting that treatment with 
CD40L initiates some kind of crosstalk between TNF-R1 (p55) and CD95. Anti-FADD 
and anti-caspase 8 blots showed that these molecules form an integral part of the DISC 
formed after stimulation via CD95. However, small but detectable amounts of these 
molecules were also pulled down when the apoptotic process was triggered by CD40L. 
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The specificity of all signals was confirmed by IgG controls (data not shown) and 
immunoblots from the respective lysates. Due to the much lower amounts of specific 
protein contained in the lysates, exposure times were not always the same for the input 
and the precipitate, e.g. for TNF-R1 (p55) and CD95/Fas in Fig. 4.19B.  
 
 
 
  
 
 
 
 
 
 
 
 
 
Fig. 4.19. CD40 interacts with TNF-R1 (p55) and induces crosstalk between death receptors in
CD40-transfected LN-18 cells. A. The interaction of CD40 and TNF-R1 (p55) was analysed in CD40-
transfected LN-18 cells by immunoprecipitation with anti-TNF-R1 (p55) (H-398) or anti-CD40 (G28.5)
antibodies followed by immunoblot with either antibody. An IgG control was used to exclude non-
specific pull-down or bands originating from antibody fragments. The respective lysates are shown on the
left. B. The interactions of the TNF family receptors TNF-R1 (p55), CD95 and CD40 were further
explored by immunoprecipitation using anti-CD95 (FL-335) or anti-CD40 antibodies and subsequent
immunoblotting with anti-CD40 (G28.5), anti-CD95 (FL-335), anti-TNF-R1 (p55) (H398), anti-FADD
(F33620) or anti-caspase 8 (C15) antibodies  (lanes 4 and 5, CD40-transfected LN-18 cells; lanes 6 and 7,
CD40-transfected LN-18 cells stimulated with 1 µg/ml CD40L for 1 h). Controls include lysates from
unstimulated and stimulated CD40-transfected LN-18 cells (lanes 1 and 2) and immunoprecipitates from 
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An interaction between CD40 and TNF-R1 (p55) was also observed in U87MG cells. 
However, there was no interaction of CD40 or TNF-R1 (p55) with CD95 in this cell 
line, not even after stimulation (Fig. 8D). Accordingly, U87MG cells did not die in 
response to the treatment with TNF-α alone or TNF-α plus CD40L (Fig. 8E). 
 
 
 
 
 
 
Fig. 4.20. CD40 interacts with TNF-R1 (p55) and does not induce crosstalk in U87MG cells.
A. Immunoprecipitation was performed as in 4.19, using wild-type U87MG cells stimulated with
CD40L (1 µg/ml, 1 h). B. U87MG cells (104/well) were treated with increasing concentrations of
TNF-α in the absence (open symbols) or presence (closed symbols) of CD40L (1 µg/ml). CHX (10
µg/ml) was added to all wells. Survival was assessed at 16 h by crystal violet staining. 
 
Bispecific CD40xCD95 antibodies promote cell death signalling in U87MG cells  
A crosstalk between CD40 and CD95 was enforced in U87MG cells using a bispecific 
antibody to these two antigens. This antibody was cytotoxic to U87MG cells. A similar 
construct directed to CD20 and CD95 had no such effect. CD40xCD95 antibody-
induced cell death was enhanced by CHX (Fig. 4.21A) and blocked by zVAD-fmk (data 
not shown). Addition of a five-fold excess of anti-CD95 Fab fragment, anti-CD40 or 
CD40L prevented cell death (data not shown). The construct was almost equally 
effective in IFN-γ-stimulated LN-18 cells which show lower expression of CD40, but 
are more susceptible to CD95-mediated apoptosis. In contrast, uninduced (CD40-
negative) LN-18 cells were not killed by the CD40xCD95 antibody. Neither did the 
construct induce cell death in IFN-γ-stimulated LN-229 cells which are much less 
susceptible to CD95L-induced apoptosis than LN-18 cells (Fig. 4.21B).  
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Fig. 4.21. CD40/CD95 bispecific antibodies induce apoptosis in U87MG cells. A. U87MG cells
(104/well) were treated with CD20xCD95 (squares) or CD40xCD95 (triangles) bispecific antibodies in
the absence (open symbols) or presence (filled symbols) of CHX (10 µg/ml) for 16 h. B. IFN-γ (48 h,
500 U/ml)-stimulated LN-18 (open bars), U87MG (black bars) or LN-229 (shaded bars) cells (104/well)
were treated with CD40L, CD20xCD95 or CD40xCD95 antibodies (1 µg/ml), or with CD95L (50
U/ml), all in the presence of CHX (10 µg/ml), for 16 h. 
 
Further, the CD40xCD95 antibody induced DEVD-amc cleavage in U87MG cells in a 
concentration-dependent manner, and this was blocked by zVAD-fmk (Fig. 4.22A). 
Immunoblot analysis also revealed the processing of caspases 8 and 3 in response to the 
antibody (Fig. 4.22B), showing that the bispecific CD40xCD95 antibody kills glioma 
cells in a fashion similar to the respective natural ligands. 
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Fig. 4.22. Apoptosis by CD40xCD95 bispecific antibody is caspase-dependent. A. DEVD-amc cleavage was
assessed in lysates from U87MG cells at 6 h after co-exposure to CHX (10 µg/ml) and CD40L (2 µg/ml),
CD20xCD95 (2 µg/ml) or CD40xCD95 (0.8 µg/ml and 2 µg/ml, in the absence or presence of zVAD-fmk at 100
µM). CD95L (10 U/ml) was included as a positive control. In A-C, all values were normalised to control cultures
containing vehicle or CHX alone. B. U87MG cells were treated for 6 h with CD20xCD95 (1 µg/ml) or
CD40xCD95 (1 µg/ml) bispecific antibodies or with CD95L (50 U/ml) as a positive control in the presence of
CHX (10 µg/ml). Cleavage of caspases 8 and 3 was assessed by immunoblot. Neither CHX alone nor CD40L
nor any of the monospecific antibodies induced caspase 8 or 3 cleavage (data not shown). 
 
 
 
 
 
 
 
 113
Discussion 
 
The TNF receptor family member, CD40, is thought to promote proliferation, survival 
and differentiation in B cells (239, 240). The survival-promoting activity of CD40 has 
been attributed to the transcriptional activation of c-IAP via TRAF 2-5 (274) and the 
NF-κB-dependent induction of c-FLIP (275) and A20 (244). In dendritic cells CD40 
provides a strong stimulatory signal that may overcome a pre-induced tolerance to 
tumour antigens (276). Pro-apoptotic effects of CD40 signalling seem to be restricted to 
tumour cells (277).  
The biological significance of aberrant CD40 expression in cancer cell lines has 
remained obscure and the mechanism of CD40 triggering the death receptor-dependent 
apoptotic pathway is still somewhat enigmatic (246). A role for CD40 in tumour cell 
survival, growth and neo-vascularization has been proposed for Kaposi sarcoma cells 
(278). CD40-expressing tumour cells have also been suggested to impair immune cell 
function (279). A role of CD40/CD40L interactions in normal or diseased human brain 
has not been clearly defined either. For instance, it has remained controversial whether 
mouse astrocytes can be induced to express CD40 (280) or not (160). T helper type 1 
cells expressing CD40L may induce IL-12 release in CD40-expressing microglial cells 
in the mouse (281). CD40 expressed on neuronal cells has been suggested to mediate 
death in the absence of ligand binding, similar to TNF-R p75 (282). CD40 is also 
expressed by normal neurons of the adult mouse brain and, based on in vitro studies and 
analysis of CD40-deficient mice, may serve a protective function here (283). 
The present study shows that CD40 is expressed by human glioma cells in vitro and in 
vivo (Fig. 4.1, 4.2, 4.3). In malignant glioma cell lines, CD40 is uniformly expressed at 
the RNA (Fig. 4.1 A,B) and protein level, as assessed by immunoblot (Fig. 4.1C). 
Interestingly, differences in CD40 mRNA levels did not translate into according 
differences in total CD40 protein, indicative of posttranslational regulation of protein 
levels, e.g. at the level of protein degradation. In contrast to the uniform CD40 
expression in glioma cell lysates, flow cytometry showed that only one cell line 
(U87MG) expressed CD40 at the cell surface constitutively (Fig. 4.2A), and two more 
cell lines were induced to do so by IFN-γ treatment (Fig. 4.2B). There was no evidence 
for the release of soluble CD40 by the glioma cell lines. These data indicated that a 
possible function of CD40 in glioma cell lines would have to be largely a ligand-
independent, intracellular one. Since CD40 contains a pre-ligand-binding assembly 
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domain (PLAD) (284), ligand-independent receptor assembly is likely to occur. It is, 
however, not clear whether this may result in ligand-independent signalling. 
Under conditions where CD40 was expressed at the cell surface, several assays failed to 
document signal-transducing activity, including assessment of viability or NF-κB or 
IL-8 reporter gene activity in glioma cells exposed to soluble CD40L or CD40L-
expressing effector cells (Fig. 4.4, 4.5, data not shown). In wild-type glioma cell lines, 
no indications for synergistic induction of apoptosis by CD40L and TNF-α, CD95L or 
Apo2L/TRAIL were found, nor was any modulation of the respective receptor levels 
observed (Fig. 4.4, data not shown). This was not only true for long-term established 
glioma cell lines, but also short passage polyclonal glioma cell cultures (data not 
shown). These negative data were confirmed when membrane-bound CD40L expressed 
on BHK cells was used instead of recombinant CD40L to trigger CD40. Still, it cannot 
be excluded that CD40 exerts effects on growth, apoptosis, and cytokine secretion in 
vivo that are rapidly lost when the cells are cultured in vitro. Such an effect has already 
been described for epithelial ovarian carcinoma cells (285).  
To decide whether the level of CD40 was insufficient to transduce a signal or whether 
the signalling cascade triggered by CD40L was essentially disabled in glioma cells, LN-
18 sublines expressing high levels of CD40 were generated (Fig. 4.6 A). These cells 
acquired sensitivity to CD40L-induced promoter activity and cell death (Fig. 4.6 B,C). 
Further, CD40L-induced cell death resembled death ligand-induced apoptosis of glioma 
cells in several ways: CHX-mediated inhibition of protein synthesis potentiated cell 
death (Fig. 4C), the broad spectrum caspase inhibitor, zVAD-fmk, was protective and 
cell death involved clustering of receptor (CD40) molecules (Fig. 4.7), the proteolytic 
activation of caspases 8 and 3 and PARP cleavage (Fig. 4.8). 
Interestingly, forced expression of CD40 resulted in the loss of CD95 protein 
presumably via proteasomal degradation (Fig. 4.9, 4.10). A synergy of CD40 and CD95 
in the induction of apoptosis has been reported (250). Thus the possibility of a negative 
selection pressure preventing co-expression of CD40 and CD95 at high levels was 
investigated. However, down-regulation of CD95 resulting from forced ectopic 
expression of CD40 occurred even in the presence of the broad-spectrum caspase 
inhibitor zVAD-fmk as well as in crmA-transfected glioma cells, strongly arguing 
against an apoptotic deletion of cells co-expressing both receptors at high level (Fig. 
4.11). Further, earlier experiments had shown (204) that glioma cells are resistant to 
suicidal or fratricidal killing by glioma-cell bound CD95L. In any case, the loss of 
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CD95 in CD40-transfected cells with the concomitant resistance to CD95-dependent 
apoptosis renders the possibility of endogenous CD95 mediating CD40L-induced cell 
death unlikely. There were no such interactions with the Apo2L/TRAIL receptor system 
(data not shown). 
Interestingly, exposure of CD40-transfected LN-18 cells to proteasome inhibitors 
restored CD95 protein levels to that found in control transfectant (Fig. 4.12). At the 
same time, CD95 mRNA levels were slightly diminished (Fig. 4.13). While the 
contribution of further mechanisms cannot be excluded, CD95 is likely to be subjected 
to increased proteasomal degradation when high levels of CD40 are present. This might 
be due to CD40 and CD95 competing for a rate-limiting step of receptor transport and 
integration into the cell membrane, thus redirecting CD95 to degradation.  
In contrast, CD40L showed strong synergy with TNF-α in inducing apoptosis (Fig. 
4.14). Since CD40 does not contain a death domain, a role for endogenous TNF-R 
mediating CD40-induced apoptosis has been proposed on the basis of the following 
observations: Both CD40 and TNF-R1 (p55) use common signalling pathways 
including TRAF-2, TRAF-6, p38-MAPK, NF-κB and AP-1. Further, co-exposure to 
CD40L and TNF-α synergistically induces apoptosis on various cell types whereas 
preexposure to either one induces resistance to further doses of TNF. Interestingly, 
CD40-transfected HeLa cells are protected from CD40L-induced apoptosis by 
neutralizing antibodies to TNF or TNF-R1 (p55). In this cell line, stimulation with 
CD40L even induced TNF-α mRNA synthesis and protein production (247). However, 
the authors also postulated a TNF-α-independent interaction between TNF-R1 (p55) 
and CD40. 
A role for endogenous CD95 mediating CD40-induced apoptosis was also assumed 
since biliary epithelial cells upregulated CD95L mRNA in response to CD40L and were 
protected from CD40-dependent apoptosis by Nok-1 anti-CD95L antibody (249, 250). 
The same authors observed an up-regulation of TNF-α, CD95L and Apo2L/TRAIL 
mRNA and achieved various degrees of protection by neutralization of any of these 
cytotoxic ligands in CD40-transfected HeLa cells (248).  
Our study of glioma cells does not support the model of a delayed and attenuated CD40-
dependent apoptosis via the production of membrane-anchored cytotoxic ligands which 
then engage their respective receptors on the cell surface resulting, in autocrine or 
fratricidal apoptotic deletion. Apart from the absence of TNF-α and the failure of 
blocking experiments with TNF-, CD95- and Apo2L/TRAIL-specific antibodies (Fig. 
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4.15), the suggested mechanism requires synthesis of mRNA and protein. However, 
inhibition of protein synthesis by CHX led to a dramatic sensitization towards CD40-
mediated apoptosis (Fig. 4.6C), even when the cells where pre-exposed to CHX (data 
not shown). Thus CD40-transfected LN-18 cells exposed to CD40L die through a 
mechanism that does not require protein synthesis and that is probably independent of 
other TNF-related ligands. 
Concomitant with cell death, TNF-R1 (p55) expression at the cell surface decreased 
(Fig. 7D), presumably due to internalization (Fig. 4.17) which would be characteristic 
for TNF-R1 (p55)-mediated apoptosis (272). Immunoprecipitation studies demonstrated 
an interaction between TNF-R1 (p55) and CD40 both in control cells and in resting 
CD40-transfected cells (Fig. 4.19). While a direct physical interaction between these 
molecules seems unlikely, they may both be incorporated into a larger complex 
containing common adaptor molecules. Then stimulation of CD40 might lead to the 
removal of a protective protein from TNF-R1 (p55), thus enabling the formation of an 
activated TNF-R1 (p55) complex. Alternatively, following CD40 engagement, an 
adaptor protein might be recruited that organizes TNF-R1 (p55) aggregation. Finally, 
the clustering of CD40 itself will induce proximity of molecules that interact with 
CD40, including TNF-R1 (p55). Thus clustering of TNF-R1 (p55) by “induced 
proximity” is most likely to occur, but may have escaped detection due to the 
internalization of this receptor.  
After stimulation, immunoprecipitation with anti-CD95 antibody also revealed an 
interaction with TNF-R1 (p55), suggesting an intracellular crosstalk between these two 
receptor complexes. Assuming that CD40 stimulation induces the formation of an 
activated TNF-R1 complex, an interaction with CD95 may then be mediated by some 
common adaptor molecules. While this is still speculative, the fact that TNF-R1 (p55) 
and CD95 use the same executors of cell death and some common adaptor molecules 
adds plausibility to this proposed crosstalk (286). In particular, FADD and caspase 8 are 
common to and essential for both the TNF-R1 (p55) and the CD95 signalling pathways 
(287, 288). TNF-R1 (p55) signalling even is promiscuous with regard to TRADD and 
FADD, including heterodimers of both, which may provide a molecular basis for the 
observed involvement of components from both the p55 TNF-R1 and the CD95 
apoptotic pathways (289). 
Interestingly, TNF-R1 does not directly interact with caspase 8 or FADD. Neither are 
caspase 8 and FADD incorporated into a membrane-bound, TNF-induced receptor 
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signalling complex (290). Instead, caspase 8 and FADD are recruited to a second, 
intracellular complex (187) that is formed after or upon dissociation from the 
internalized TNF-R1 (p55). This complex apparently contains most essential 
components of the CD95-related DISC apart from CD95 itself. Thus, already a weak 
interaction of this complex with CD95 could account for the small amounts of FADD 
and caspase 8 that were co-precipitated with CD95 from CD40-transfected LN-18 cells 
after stimulation with CD40L. Accordingly, a CD95-related DISC immunoprecipitation 
yielded much larger amounts of FADD and caspase 8. While the various complexes and 
potential intermediates involved in this signalling pathway clearly require further 
exploration, the involvement of both TNF-R1 (p55) and CD95 in a cell type-specific 
manner might reconcile the divergent observations concerning the further death 
receptors involved in CD40-mediated apoptosis. 
Finally bispecific antibodies targeting CD95 and CD40 had specific activity against 
glioma cells that was not seen with a similar antibody targeting CD95 and CD20 and 
that required the expression of CD40 at the cell surface (Fig. 4.21, 4.22). These data 
indicate that endogenous CD40 expressed at the cell surface does participate in cell 
death signalling, albeit under specific circumstances. Further, these observations shed 
novel light on antibody-mediated triggering of receptors in that bispecific antibodies 
would a priori not be predicted to have the steric properties of activating death receptors 
at endogenous expression levels (48, 291). In view of the fact that glial cells or neurons 
of normal brain appear not to express CD40 (see Figure 4.3), a bispecific antibody 
would seem a reasonably safe way to activate the death receptor pathway on glioma 
cells in the absence of neurotoxicity. Thus, the demonstration of tumour cell 
cytotoxicity mediated by bispecific antibodies against a death receptor and a second 
antigen preferentially expressed on tumour cells opens up new perspectives for the 
development of innovative cancer therapies based on selective death receptor activation 
in tumour cells. 
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V. Identification of CD70-mediated apoptosis of immune effector cells as a novel 
immune escape pathway of human glioblastoma 
 
A manuscript based on this project has been published in 
 Cancer Res. 2002 May 1;62(9):2592-9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For help with this project, thanks go to Dr. Gundram Jung (Department of 
Immunology, Institute for Cell Biology, University of Tübingen, 72076 Tübingen) 
who introduced me to the immunological techniques employed in this project. Dr. 
Ivan Radovanovič (at that time in Adriano Aguzzi´s group in the Institute of 
Neuropathology, University of Zürich, 8091 Zürich, Switzerland) performed all 
immunohistochemical stainings. CD70 expression in glioma cells was found when 
Huatao Huang and Hiroko Ohgaki (International Agency for Research on Cancer, 
69372 Lyon, France) performed a cDNA array using mRNA from untreated and 
irradiated glioma cells prepared by my colleague Andreas Rimner. 
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Introduction 
 
Human glioblastoma is a highly lethal brain tumour which kills affected patients by 
local destructive growth. Although glioblastoma cells display virtually all features of 
aggressive neoplastic cells, including resistance to multiple apoptotic stimuli and 
strong migratory and invasive properties, these tumours hardly ever metastasize 
outside the central nervous system. This clinical observation, as well as ample 
evidence of altered immune function in glioblastoma patients, has raised the hope 
that immunological approaches may lead to a therapeutic breakthrough in the 
management of glioblastoma (155). Glioblastoma-mediated immunosuppression has 
been attributed to various mechanisms, including the release of immunosuppressive 
TGF-β (292), CD95L-dependent maintenance of immune privilege (63, 264, 293), 
interference with IL-2-mediated T cell activation (294) and the release of as yet 
unidentified soluble factors (295, 296). 
CD70 (297), a cell surface protein, is the ligand for CD27, a type I glycoprotein and 
member of the TNF receptor family (298). CD70 is expressed by cells of the 
lymphoid lineage, notably activated B (299) and T cells (300, 301), but not resting 
lymphocytes. CD27 is expressed constitutively by T, B (302) and NK cells. A 
reciprocal expression pattern for CD27 and CD70 has been described (303). 
CD70/CD27 interactions may play an important role in the maturation and activation 
of B (304, 305), T (306) and NK (307) cells. CD8-positive T cells may be activated 
via CD70 whereas T helper cells remain largely unaffected (308). Direct inhibitory 
effects on the generation of plasma cells (309) and on T cell activation (310) have 
also been reported. CD27 costimulation may induce CD45 RA+ CD4+ T cells with 
regulatory function, resulting in a down-regulation of the immune response (311). 
CD27 can also mediate apoptosis (49). The immune system of CD27 knockout mice 
shows impaired T cell memory, but no further immunodeficiency (312). A more 
severe phenotype was observed in CD70-transgenic mice which show chronic T cell 
activation associated with depletion of the B cell compartment and of naive and 
CD27-positive T cells. When aged 6-8 months, CD70 transgenic mice die from T 
cell immunodeficiency (313, 314). 
Some lymphoproliferative diseases are associated with reduced CD27 expression 
while CD70 expression is elevated (315, 316). CD27 was not detected on the 
affected CD3 cells in 20 of 21 patients suffering from lymphoproliferative disease of 
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granular lymphocytes whereas the nontransformed cells expressed CD27 
constitutively (317). In contrast, CD70 was induced by malignant transformation in 
these patients. Here, the aberrant expression of CD70 by human malignant glioma 
cells is shown in vitro and in vivo and a role for CD70/CD27 interactions in 
mediating immune escape in this type of cancer is delineated. 
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Materials and Methods 
 
Cell culture and reagents. The human malignant glioma cell lines LN-18, U138MG, 
U87MG, LN-428, D247MG, T98G, LN-319, LN-229 (the p53 wild-type subline), 
A172, U251MG, U373MG and LN-308, kindly provided by Dr. N. de Tribolet 
(Lausanne, Switzerland), and SKN-LE and SKN-BE human neuroblastoma cells 
(American Type Culture Collection, Rockville, MD) were cultured in 75 cm3 Falcon 
plastic flasks using DMEM supplemented with 1% glutamine (Gibco Life 
Technologies, Paisley, Great Britain), 10% FCS (Biochrom KG, Berlin, Germany) 
and penicillin (100 IU/ml)/streptomycin (100 µg/ml). U87MG cells were transfected 
with the dominant-negative p53V135A mutant by electroporation (200). The CD70-
transfected murine pre B-cell line 300-19 and control-transfected 300-19 B cells 
carrying a neo control plasmid, kindly supplied by Dr. S. Jacquot (Rouen, France), 
were maintained in RPMI 1640 (Gibco) with 10% FCS, G418 (250 µg/ml) and 15 
µM β-mercaptoethanol. All cell lines were routinely tested for contamination with 
mycoplasma by DAPI staining (Sigma, Deisenhofen, Germany). Where indicated, 
the cells were irradiated while adherent using a Gammacell 1000 Elite (Nordion, 
Ontario, Canada). Radiation was applied as a single dose at a central dose rate of 
approximately 9 Gy/min. The pan-specific caspase inhibitor zVAD-fmk was 
purchased from Bachem (Heidelberg, Germany). Lomustine was kindly provided by 
Medac (Hamburg, Germany). Cycloheximide and propidium iodide were purchased 
from Sigma (St. Louis, MO). AnnexinV-FITC was obtained from Pharmingen 
(Heidelberg, Germany), human recombinant TNF-α from Roche (Mannheim, 
Germany). The following antibodies were used: M-T271 mouse anti-human CD27, 
FITC-labeled, and unlabeled BU69 mouse anti-human CD70 (Ancell, Bayport, MN), 
HNE.51 mouse anti-human CD70 (Dakopatts, Glostrup, Denmark), C-20 goat anti-
human CD70 (Santa Cruz, Santa Cruz, CA), Ki-24 mouse anti-human CD70, NOK-1 
mouse anti-human CD95L (Pharmingen) and MAB1835 mouse anti-human TGF-β 
(R&D Systems, Wiesbaden, Germany). All cell lines were tested for the cell surface 
expression of costimulatory molecules using FITC-labeled antibodies to CD40, 
CD80, CD86, and CD154 (Pharmingen). The cell lines were also analysed for HLA-
A2 expression using the murine BB7.2 antibody raised in the laboratory of H.G.R.. 
Maxisorp plates used for antibody immobilization were obtained from Nunc 
(Roskilde, Denmark). 
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cDNA Array analysis. The Atlas Human Cancer 1.2 Arrays (Clontech, Palo Alto, 
CA, USA) were used to screen for alterations of gene expression by irradiation in 
U87MG and T98G cells. Details for cDNA probe synthesis, array hybridization and 
quantitation were described previously (318). The irradiated to control ratio of at 
least 1.5 in expression was considered as up-regulation and a ratio of less than 0.67 
in expression was considered as down-regulation after irradiation. 
 
Northern blot analysis. Total RNA was extracted using the RNeasy RNA 
purification system (Qiagen, Hilden, Germany). Denatured total RNA (10 µg) was 
loaded on a 1% agarose gel containing 6.7% formaldehyde. The RNA was separated 
at 100 V, transferred to a Hybond N+ membrane (Amersham, Freiburg, Germany) 
using capillary blotting, and cross-linked in a UV stratalinker 1800 (Stratagene, La 
Jolla, CA) at 1200 J. Methylene blue staining was performed as a loading control. 
The membrane was preincubated for 2 h in Church buffer at 65°C. The probe was 
constructed by PCR-amplifying nucleotides 192-535 from a human CD70 expression 
vector, kindly provided by M.R. Bowman (Cambridge, MA), using CD70-specific 
primers (5´-CTT GGT GAT CTG CCT CGT GG-3´ up and 5´-GCA GCA GGC 
TGA TGC TAC G-3´ down). Purified PCR product (40 ng) was labeled using 5 µl 
(~1.6 Mbq) dCTP and the Rediprime II random labelling system (Amersham). Filters 
were hybridized over night at 65°C in a hybridization oven with a rotisserie device 
using Church buffer. Binding of radioactive probes was visualized and quantified 
using a PhosphoImager (FujiBasReader 1500, Fuji). Signals were normalized to ß-
actin mRNA expression. RNA from the 12 glioma cell lines under investigation was 
also probed for CD27 expression using a sCD27 probe amplified from human CD27 
cDNA (ATCC, Manassas, VA). The primers used were 5´-GGG AAT TCT TGG 
AGG TGC TAA CT-3 up and 5´-ATG GGC CCC GAA TAA AAT CGG AGC-3 
down (319). 
 
Immunoblot analysis. CD70 protein levels were analysed by immunoblot using 20 
µg of protein per lane on a 10% acrylamide gel (Biorad, Munich, Germany). After 
transfer to nitrocellulose (Biorad) the blots were blocked in PBS containing 5% skim 
milk and 0.05% Tween 20 and incubated overnight at 4°C with 2 µg/ml of CD70 
antibody (C20). Visualization of protein bands was accomplished using horseradish 
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peroxidase-coupled anti-goat IgG secondary antibody (Sigma) and enhanced 
chemiluminescence (ECL) (Amersham). 
 
Flow cytometry. Glioma cells were detached non-enzymatically using cell 
dissociation solution (Sigma). The cells were preincubated in PBS with 2% bovine 
serum albumin and incubated with FITC-labeled CD70 antibody (BU69, 20 µg/ml in 
PBS/BSA) or isotype-matched mouse IgG-FITC as a control. Fluorescence was 
measured in a Becton Dickinson FACScalibur (Heidelberg, Germany). Specific 
fluorescence indexes (SFI) were calculated by dividing mean fluorescence obtained 
with specific antibody by mean fluorescence obtained with control antibody. To 
validate the data, experiments were repeated with additional monoclonal CD70 
antibodies (HNE.51 and KI-24). To examine the cells for CD27 expression, M-T271 
antibody was used under the same conditions. 
 
Immunohistochemistry. Cryosections (0.7 mm) of human gliomas were fixed in 
acetone and blocked with normal rabbit serum and bovine serum albumin. All 
samples were stained with three different CD70 antibodies (Dakopatts, Pharmingen, 
Santa Cruz) at dilutions of 1:25 to 1:100. All antibodies gave comparable results at 
all tested dilutions. A biotinylated anti-mouse or anti-goat secondary antibody 
(Zymed) was used at 1:150. Avidin biotin complex was added, and the staining was 
developed with diaminobenzidine. Human tonsils were taken as positive control. 
Normal human brain (temporal lobe) served as a negative control. 
 
T cell reaction against allogeneic glioma cells. To suppress glioma cell proliferation, 
the cells were incubated in serum-free medium for 24 h, irradiated at 200 Gy and 
maintained in serum-free medium for another 24 h. Although doses in excess of 10 
Gy are sufficient to suppress colony formation in all glioma cell lines examined here 
(131), the high dose of 200 Gy was necessary to prevent proliferation within the 1-5 
days of the experiments and to suppress [methyl-3H] thymidine incorporation in 
assays where this incorporation was used to assess immune cell proliferation in the 
presence of glioma cells. PBMC were isolated from healthy donors by density 
gradient centrifugation (Biocoll, Biochrom KG) and characterized for their HLA-A 
isotype. Monocytes were depleted by adhesion and differential centrifugation. To 
obtain purified T cells, the samples were depleted of B cells and monocytes using the 
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LymphoKwik TTM reagent (One Lambda Inc., Canoga Park, CA). The purity of this 
population was controlled by flow cytometry using anti-human CD3-PE (Becton 
Dickinson). HLA-A2-negative T cells or PBMC (105/well) were cocultured with 104 
irradiated HLA-A2-positive glioma cells in 96 well plates in triplicates. In order to 
minimize interference of CD70 antibody with CD70 expressed by activated immune 
cells, the glioma cells were preincubated with CD70 antibody for 2 h and washed 
twice with PBS. After 4 days, the cells were pulsed for 24 h with [methyl-3H] 
thymidine (0.5 µCi, Amersham). The cells were harvested with a cell harvester 
(Inotech, Dottikon, Switzerland) and incorporated radioactivity was bound to a glass 
fibre filtermat (Wallac, Turku, Finland). The filtermat was wetted with Ultima Gold 
Scintillation Cocktail (Packard, Dreieich, Germany) and radioactivity was 
determined in a Wallac 1450 Microbeta Plus Liquid Scintillation Counter (Wallac, 
Turku, Finland). 
 
Chromium release assay. The glioma cells were seeded into 25 cm2 flasks such that 
the number of cells reached 106 per flask 24 h later. The cells were serum-deprived 
and irradiated at 200 Gy. After repeated washing and preincubation of the glioma 
cells with CD70 or control antibodies, 1.5 x 107 PBMC were added in 5 ml RPMI 
containing 10% FCS. The cells were cocultured for 5 days. PBMC from the same 
isolation were maintained in culture without glioma cells in parallel. On day 3, PHA 
(10 µg/ml) (Biochrom) was added to one group of PBMC. On day 5, PBMC were 
collected and counted. The supernatants were collected for cytokine measurements. 
Glioma cells were detached, suspended in medium (1 ml) and labeled by addition of 
50 µCi 51Cr (#NEZ147, NEN, Boston, MA). The PHA-stimulated PBMC were also 
labeled. The labeled allogeneic glioma cells (104 per well) were incubated either 
alone (spontaneous release) or with effector PBMC from the cocultures at 
effector:target ratios of 10:1, 20:1, 40:1 or 80:1. The maximum 51Cr release possible 
was determined by addition of NP-40 (100% lysis). To determine autoreactivity, 
labeled activated PBMC (105 per well) were incubated with numbers of effector 
PBMC equivalent to those used for the lysis of the glioma cells. After 4 h, 50 µl of 
the supernatant were transferred to a Luma-PlateTM-96 (Packard, Dreieich, 
Germany), dried overnight and measured. Lysis was calculated as [cpm (effector 
cells) - cpm (spontaneous)] / [cpm (NP-40) - cpm (spontaneous)] x 100%. To 
examine the killing of immune cells by glioma cells, 104 glioma cells were seeded in 
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a 96 well plate. One day later, 105 labeled PBMC were added. Both PHA-stimulated 
and non-stimulated PBMC were tested. Supernatants were collected 18 h later and 
assayed as above. 
 
TNF-α bioassay. L-M cells (5 x 104 per well) were seeded in 96 well plates. One day 
later the serum-containing medium was replaced by 100 µl serum-free DMEM 
containing cycloheximide (20 µg/ml). The supernatants from PBMC or glioma cells 
or cocultures were diluted to a volume of 100 µl and added. Survival was assessed 16 
h later by crystal violet staining. These data were confirmed by ELISA for human 
TNF-α (Endogen, Woburn, MA). 
 
Determination of sCD27. Cell culture supernatants were analysed for sCD27 by 
sandwich ELISA (CLB, Amsterdam, Netherlands) according to the manufacturer’s 
instructions. 
 
Detection of DNA fragmentation and apoptosis. PBMC were stained with FITC-
labeled antibodies to CD4, CD8, CD14, CD19 or CD56, fixed and permeabilized in 
ice-cold 70% ethanol. RNA was digested with RNase A (Gibco). DNA was stained 
with propidium iodide (50 µg/ml). FACScalibur settings were adjusted so that the 
G1-peak measured in channel Fl-2A moved to 200 relative fluorescence units. Cells 
to the left of this peak have less than 2n chromosomes signifying loss of DNA. 
Aggregated cells were detected in channel Fl-2W and gated out. Given the strong 
adherence of glioma cells and the excess of PBMC in these assays, contamination of 
PBMC populations with glioma cells was negligible as controlled by staining of 
lymphocyte subpopulations and size. PBMC apoptosis was also analysed by 
AnnexinV-FITC staining. The cells were collected, washed and resuspended in a 
buffer containing 10 mM HEPES/NaOH, pH 7.4, 140 mM NaCl and 2.5 mM CaCl2. 
AnnexinV-FITC (1:100) and propidium iodide (50 µg/ml) were added. When 
analysis of lymphocyte subsets was desired, PBMC were first incubated with CD4-
PE, CD8-PE, CD14-PE, CD19-PE or CD56-PE monoclonal antibodies. 
 
Statistical analysis. Data are representative of experiments performed three times 
with similar results. Viability studies were performed using triplicate wells. 
Significance was assessed by t-test (∗p<0.05, ∗∗p<0.01). 
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Results 
 
Human malignant glioma cell lines express CD70 mRNA and protein in vitro and 
CD70 protein in vivo 
U87MG and T98G cells were screened for changes in gene expression in response to 
irradiation. In U87MG cells, the Clontech Atlas cDNA array revealed that 42 genes 
were induced and 36 were down-regulated 1 h after irradiation. At 4 h after irradiation, 
15 genes were up- and 10 down-regulated. In T98G cells, the expression of 27 genes 
was up-regulated and 66 genes were down-regulated 1 h after irradiation, while 6 genes 
were up- and 22 down-regulated at 4 h after irradiation. Genes known to be induced by 
irradiation, e.g. p21, were up-regulated in U87MG cells after 1 h (1.4-fold) and 4 h 
(2.6-fold) irradiation. T98G is a p53 mutant cell line and p21 levels did not change with 
irradiation in these cells. Surprisingly, CD70 antigen mRNA was found in both control 
and irradiated U87MG cells. Whereas no change in CD70 expression was observed at 1 
h after irradiation, there was a 5.7-fold increase 4 h after irradiation (Fig.5.1). CD70 
mRNA was not detectable in T98G cells with or without irradiation. 
 
 
Fig. 5.1. cDNA array 
autoradiographs showing up-
regulation of CD70 in U87MG cells 
after irradiation. Five µg of DNase-
treated total RNA isolated from non-
irradiated U87MG cells (A) and from 
U87MG cells 4 hrs after irradiation (6 
Gy) (B), respectively, were reverse-
transcribed into cDNA in the presence 
of [α-32P]-dATP separately, and 
hybridized to Clontech Atlas Human 
Cancer 1.2 Arrays. Note that CD70 
antigen (indicated by an arrow) 
expression was up-regulated 4h after 
irradiation. 
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Northern blot analysis revealed that 11 of 12 malignant glioma cell lines expressed 
CD70 mRNA (Fig. 5.2A). T98G cells were negative. High levels of CD70 mRNA were 
detected in U138MG, D247MG, LN-319 and U373MG cells. Immunoblot analysis 
confirmed that CD70 mRNA was translated into CD70 protein (Fig. 5.2B). Flow 
cytometry showed that the protein was expressed at the cell surface (Fig. 5.2C). 
Quantitative data for CD70 mRNA expression and CD70 protein levels are provided in 
Table I. There was strong correlation between CD70 mRNA expression and CD70 
protein expressed at the cell surface (r = 0.9594, p < 0.0001). Two human 
neuroblastoma cell lines, SKN-BE and SKN-LE, did not show CD70 protein 
determined by flow cytometry and immunoblot analysis (data not shown).  
 
 
Table 5.1. CD70 expression in human glioma cell lines.a 
 
 CD70/ß-actin 
mRNA ratio
CD70 protein 
[SFI] 
LN-18 0.0146 1.3 
U138MG 0.1925 10.3 
U87MG 0.0604 2.7 
LN-428 0.0479 2.5 
D247MG 0.0888 3.9 
T98G 0.0048 1.1 
LN-319 0.2747 15.5 
LN-229 0.0317 1.9 
A172 0.0288 1.5 
U251MG 0.0479 6.4 
U373MG 0.4613 31.7 
LN-308 0.0167 3 
 
aCD70 mRNA expression assessed by Northern blot analysis is expressed as ratios of 
optical density values normalized to ß-actin (Fig. 5.2A). CD70 protein quantified by 
flow cytometry is expressed as SFI values (Fig. 5.3B). 
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 Fig. 5.2. CD70 expression in human glioma cells. (A). Total RNA was analysed for the expression
of CD70 or ß-actin mRNA. B,C. CD70 protein levels were determined by immunoblot (B) and flow
cytometry (C). B shows CD70 migrating at 55 kD. C shows representative flow cytometry profiles for
CD70-negative T98G cells (left), CD70-positive U373MG cells (middle) and CD70-transfected 300-
19 cells (right) (bold profile, CD70 antibody; dotted profile, control antibody) (see also Table 1, right
column).  
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Among 12 human glioblastoma specimens, 5 were positive for CD70. A representative 
sample is shown in Fig. 5.3A. Among 4 anaplastic astrocytomas examined, 3 showed 
CD70 expression (Fig. 5.3B). Morphological features led to the identification of CD70-
expressing cells as tumour cells rather than tumour-infiltrating host cells. Normal brain 
sections revealed no CD70-expressing cells (Fig. 5.3C). 
 
 
 
 
 
Fig. 5.3. CD70 expression in human gliomas in vivo. CD70 expression was assessed by 
immunocytochemistry in glioblastoma (A), anaplastic astrocytoma (B), normal brain (C) or tonsil, as a
positive control (D, magnification 200x in A,B and 100x in C,D). 
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p53-independent modulation of CD70 expression in human malignant glioma cell lines 
by irradiation  
Since irradiated glioma cells were used for the ensuing immunological studies, it was 
also determined whether radio-inducibility is a general feature of CD70 expression in 
human glioma cells. All 12 cell lines were irradiated at 6 Gy and assessed for CD70 
mRNA and protein levels. CD70 mRNA levels increased in 8 cell lines, CD70 
protein expression at the cell surface in 7 cell lines (Fig. 5.4). The increase in CD70 
mRNA in LN-319 cells, which express high levels of CD70 constitutively, did not 
result in enhanced CD70 protein expression. The highest increase in CD70 protein 
expression was 89% in U87MG cells (Fig. 5.4C). Kinetic analyses in U87MG and 
LN-229 cells showed that the maximum cell surface expression was found at 6 h 
after irradiation. 
 
 
 
Fig. 5.4 CD70 expression by
glioma cells is enhanced by
irradiation. A. The cells were
untreated or irradiated at 6 Gy.
RNA was isolated 4 h later and
CD70 mRNA levels were
quantified by Northern blot.
(B,C). CD70 protein in
untreated or irradiated cells (6
Gy, 4 h) was quantified by flow
cytometry, shown
representatively in B for
U87MG cells. The isotype
control was not shifted after
irradiation at 6 Gy. The
numbers indicate the mean
fluorescence values used to
derive the SFI values. In (C),
the induction of CD70
expression is expressed as
percentages as determined by
Northern blot analysis (relative
intensities corrected for ß-actin)
and flow cytometry
(SFI6Gy/SFI0Gy – 1). 
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To assess whether CD70 is also induced at lower doses of irradiation, U87MG and 
LN-308 cells were irradiated at 1, 3 or 6 Gy. The SFI were 2.7 at 0 Gy, 3.6 at 1 Gy, 
4.9 at 3 Gy and 5.1 at 6 Gy in U87MG cells, and 3.0 at 0 Gy, 3.4 at 1 Gy; 3.5 at 3 Gy 
and 3.5 at 6 Gy in LN-308 cells (data not shown). Irradiation of U373MG, U138MG 
or T98G at 200 Gy resulted in the same changes in CD70 expression detected by 
flow cytometry as irradiation at 6 Gy (data not shown). U87MG, the first cell line 
identified to respond to irradiation with enhanced CD70 expression, is wild-type for 
p53 (196). However, the irradiation-induced increase in CD70 expression was 
unaffected by ectopic expression of a dominant-negative p53 mutant, p53V135A (31), 
confirming that p53 does not mediate the induction of CD70 after irradiation. 
Conversely, the nitrosourea lomustine, a cytotoxic agent which induces p53 
expression in U87MG cells, did not modulate CD70 expression, confirming that 
enhanced CD70 expression is not a nonspecific response to genotoxic stress (data not 
shown). 
 
No autocrine effects of CD70 expression in human glioma cells 
To investigate possible autocrine effects of the CD70/CD27 system (320) in glioma 
cells, the glioma cell lines were screened for the expression of CD27 mRNA using 
Northern blot, RT-PCR and flow cytometry. None of the methods revealed the 
expression of CD27 in either of the 12 cell lines, using PBMC as a positive control. 
Further, ligation of CD70 with specific antibody in LN-18, U138MG, U87MG, 
T98G or U373MG cells had no effect on the proliferation or survival of the glioma 
cells. These data remained negative, even with immobilisation of the CD70 antibody 
on a Nunc Maxisorp surface or crosslinking by a secondary antibody. These overall 
negative data (not shown) provided no evidence for autocrine or backward signalling 
of the CD70 system in human glioma cells. 
 
CD70-mediated inhibition of alloreactivity by human glioma cells 
None of the 12 glioma cell lines expressed B7.1 (CD80), B7.2 (CD86) or CD40L 
(CD154) (see also section 4 of this thesis). The cell lines used for the ensuing 
immunological experiments (T98G, U138MG, U373MG) were also negative for 
CD40 and MHC class II expression, but all three expressed the MHC class I 
molecule HLA-A2 at high levels. First the alloproliferative response of HLA-A2-
negative PBMC or T cells to the glioma cells was examined. The Ki-24, HNE.51 and 
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BU69 antibodies to CD70 have all been described as blocking antibodies (Vth 
Workshop on Leucocyte Typing). When tested in parallel, these antibodies uniformly 
enhanced the alloproliferative response to the CD70-positive cell lines, U138MG and 
U373MG, but not the alloproliferative response to the CD70-negative cell line, T98G 
(Fig. 5.5A). Since the effects were most prominent with the Ki-24 antibody, an 
azide-free preparation of this antibody (10 µg/ml) was chosen for all ensuing 
functional experiments. Consistent with this inhibitory effect of CD70, PHA-induced 
T cell proliferation (Fig. 5.5B) or PBMC proliferation in a mixed lymphocyte 
reaction (MLR) (Fig. 5.5C), were inhibited much stronger by U138MG and 
U373MG cells than by T98G cells, and this inhibition was partly relieved by the 
CD70 antibody. The broad spectrum caspase inhibitor, zVAD-fmk, mimicked the 
effects of CD70 antibody in the MLR (Fig. 5.5C). 
 
 
 
 
Fig. 5.5 Modulation of alloreactivity to 
glioma cells by CD70. (A-C). Irradiated 
glioma cells were preincubated with isotype 
control antibody (open bars) or CD70 
antibody (Ki-24) (black bars) (10 µg/ml) for 2 
h. In (A), the glioma cells were seeded in 96 
well plates (104/well) and 105 T cells were 
added in a total volume of 150 µl RPMI 
containing 10% FCS. [Methyl-3H] thymidine 
(0.5 µCi/well) was added on day 4 for 16 h. 
[Methyl-3H] thymidine incorporation was 
measured by liquid scintillation counting. In 
(B), PHA (10 µg/ml) was added to all wells. 
In (C), 105 irradiated HLA-A2-positive 
stimulator PBMC were cocultured with 105 
HLA-A2-negative responder PBMC and 104 
irradiated glioma cells. Data in (A-C) are 
expressed as cpm determined by liquid 
scintillation counting (*p<0.05, **p<0.01, 
CD70 antibody or zVAD-fmk compared with 
isotype control antibody). 
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CD70-mediated induction of PBMC apoptosis by glioma cells 
The number of viable PBMC was decreased by a factor of 1.8-2.6 after the coculture 
with U138MG and U373MG cells compared to T98G cells. This cell loss was 
prevented by CD70 antibody, by sCD27 or zVAD-fmk (Fig. 5.6 A). In PBMC 
cocultured with U138MG and U373MG cells, the number of AnnexinV-positive 
cells was significantly reduced by CD70 antibody or sCD27. No such effect was seen 
in PBMC cocultured with T98G cells (Fig. 5.6 B). Flow cytometry confirmed cell 
loss by apoptosis: the percentage of PBMC in the sub-G1-peak was significantly 
reduced by CD70 antibody and sCD27 after coculture with U138MG and U373MG 
cells, but not after coculture with T98G cells. zVAD-fmk (100µM) exerted a 
protective effect in cocultures with all three cell lines (Fig. 5.6 C). The protection 
afforded by CD70 antibody or sCD27 was similar to that achieved with zVAD-fmk.  
 
 
 
 
 
 Fig. 5.6. CD70-expressing glioma cells kill PBMC in a CD70-dependent manner. (A) Irradiated 
(200 Gy) glioma cells were preincubated with isotype control antibody, CD70 antibody (10 µg/ml) or
sCD27 (50 U/ml) for 2 h and washed twice in PBS before PBMC were added. Alternatively, zVAD-
fmk (100 µM) was added at 0 h. The number of viable PBMC was assessed 5 days later by trypan blue
exclusion. (B) The percentage of AnnexinV-positive PBMC was determined after coculture conditions 
as in (A). (C) After coculture with glioma cells, the PBMC were fixed, permeabilized and stained with 
propidium iodide. Cells to the left of the G1-peak show loss of DNA indicative of apoptosis.  
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Induction of apoptosis was strong in CD4-positive and CD8-positive T cells, which 
constitute the major subpopulations after 5 day coculture, whereas no significant 
effect was found for CD56-positive cells. As expected, the effect was only apparent 
in the CD27+ subset. 
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5Fig. 5.7.  CD70-dependent apoptosis affects CD27+ cells from the CD4+ and CD8+ subset. 
Survival rates of CD4+, CD8+ T cells, of CD56+ NK and NKT cells and of pooled CD27+-
lymphocyte subpopulations were determined by AnnexinV-FITC-staining following 5 days of 
coculture with irradiated glioma cells. he hypothesis that glioma cells kill PBMC (reversed lysis) was confirmed in a 
directed 51Cr release assay. The coincubation of 51Cr-labeled resting or PHA-
timulated PBMC with the glioma cells resulted in the release of 51Cr. Lysis was 
uch more prominent with U138MG and U373MG cells than with T98G cells. 
VAD-fmk decreased the lysis of PBMC in cocultures with all three cell lines (Fig. 
.8 A). Similar results were obtained in PHA-activated PBMC (Fig. 5.8 B). 
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Fig. 5.8. CD70-expressing glioma cells kill PBMC in a caspase- and CD70-dependent manner.A.
PBMC were labeled with 51Cr. Following coculture with non-irradiated glioma cells (105 PBMC, 104
glioma cells/well) for 18 h, 51Cr was determined in the supernatant. Assays were performed in the
presence of an isotype-matched control antibody (10 µg/ml), Ki-24 CD70 antibody (10 µg/ml),
sCD27 (50 U/ml) or zVAD-fmk (100 µM). (B) As in A, but PBMC (5 x 104) were activated by
incubation with PHA (10 µg/ml) for 24 h (*p<0.05, **p<0.01, coculture in the presence of Ki-24
CD70 antibody, sCD27 or zVAD-fmk compared to coculture plus control IgG, t-test). 
After longer stimulation with PHA (48 h), about 25% of all cells underwent 
spontaneous apoptosis which was prevented by zVAD-fmk. The spontaneous 51Cr 
release by PHA-stimulated PBMC, but not by resting PBMC, in the absence of 
glioma cells was also reduced by CD70 antibodies or sCD27. These effects in the 
51Cr release assay may be mediated by interactions of the reagents (CD70 antibody, 
sCD27) with CD70 expressed on the activated immune cells. 
In line with this concept, PHA stimulation greatly enhanced the cell surface 
expression of CD70 (Fig. 5.9 A). In contrast, the expression of CD27 remained 
largely unchanged for 24 h (data not shown), but was considerably decreased among 
CD4-, CD8- and CD56-positive cells after 48 h (Fig. 5.9 B). No cells expressed both 
CD27 and CD70. 
 
 
 
  
Fig. 5.9. CD 27 and CD70 expression by lymphocyte subsets. The expression of CD27 (A) and
CD70 (B) by lymphocyte subsets (CD4-, CD8-, CD14-, CD19- and CD56-positive cells) under
resting conditions (open bars) or 48 h after stimulation with 10 µg/ml PHA (filled bars) was assessed
by double-staining with FITC- and PE-labeled antibodies. 
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Corresponding to the larger number of surviving PBMC, the number of remaining 
U138MG and U373MG stimulator cells determined by crystal violet staining was 
decreased by a factor of 1.7 to 2.5 after 5 days of cocultures when CD70 antibody or 
sCD27 were present (data not shown). However, Fig. 5.10 shows that the lytic 
activity of the surviving PBMC was unaffected by pre-exposure of the glioma cells 
to CD70 antibodies, demonstrating that PBMC surviving the challenge of glioma 
cell-induced CD70-mediated apoptosis were fully functional (Fig. 5.10). 
 
 
 
 
 
 
 
 
 
Fig. 5.10. Surviving PBMC from co-cultures with glioma cells display CD70-independent lytical
activity. The lytic activity of PBMC stimulated with glioma cells was determined by 51Cr release. Prior
to the stimulation period (5 days), glioma cells were incubated with a non-specific isotype control
antibody or Ki-24 CD70 antibody (10 µg/ml) for 2 h. During the effector period (4 h), no antibody was
present. The lytic activity of the remaining viable PBMC is given for various effector:target (E:T) ratios
with the number of 51Cr-labeled target cells kept constant. 
To further confirm the specificity of the effects mediated by CD70 expressed on 
glioma cells, similar experiments were performed in the absence of glioma cells, but 
in the presence of agonistic CD27 antibodies. These experiments revealed induction 
of apoptosis in resting PBMC and in the MLR, and apoptosis was blocked by zVAD-
fmk (Fig. 5.11 A,B). The proportion of apoptotic PBMC detected by flow cytometric 
analysis of DNA content remained at an almost constant level for 5 days. Since 
apoptotic cells are likely to be cleared by macrophages in culture (321), the actual 
number of dying cells may be considerably higher than the level of approximately 
20% found at a given time point. The amount of 51Cr released by resting and 
activated PBMC was significantly increased by the CD27 antibody compared with 
an isotype control antibody (data not shown).   
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 Fig. 5.11. CD70-mediated apoptosis of PBMC cocultured with glioma cells is mimicked by 
agonistic CD27 antibody. A. Resting PBMC were cultured in the presence of non-specific IgG or 
agonistic CD27 antibody (10 µg/ml), without or with zVAD-fmk (100 µM), for 48 h. Dead cells were 
quantified by flow cytometry as in Fig. 4C. In (B), 105 irradiated HLA-A2-positive stimulator PBMC 
were cocultured with 105 HLA-A2-negative responder PBMC and 104 irradiated glioma cells. On day 
4, [methyl-3H] thymidine (0.5 µCi/well) was added. [Methyl-3H] thymidine incorporation was 
measured 16 h later by liquid scintillation counting. poptotic PBMC detected by AnnexinV-FITC staining or DNA loss (sub G0-peak) 
ere further characterised by staining with specific antibodies. Subset analysis 
vealed that several CD27-positive subsets, in particular CD19-positive, CD4-
ositive and CD8-positive cells, were affected (data not shown).  
able 5.2. TNF-α release by cocultures of PBMC and glioma cells.a 
TNF-α [pg/ml] 
PBMC alone PBMC + T98G PBMC + U138MG PBMC + U373MG
    
ontrol 
ntibody 
160 ± 32 992 ± 49** 73 ± 74 152 ± 49 
i-24 CD70 
ntibody 
34 ± 86 947 ± 8** 665 ± 62**++ 615 ± 62**++ 
CD27 148 ± 111 894 ± 74** 714 ± 123**++ 652 ± 111**++ 
VAD-fmk 174 ± 37 1128 ± 37**+ 689 ± 49**++  775 ± 62**++  
 
PBMC activation in coculture with glioma cells was also monitored at the level of  
aPBMC (1.5 x 107) were cultured alone or cocultured with 1.5 x 106 irradiated T98G, U138MG or U373MG
cells in 5 ml RPMI/10% FCS for 5 days. TNF-α release was determined by L-M bioassay (**p<0.01,
coculture compared to PBMC alone; ++p<0.01, compared to coculture plus control IgG, t-test). 
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TNF-α release into the supernatant (Table II). TNF-α release was enhanced by CD70 
antibody in cocultures containing U138MG and U373MG cells but not in cocultures 
containing T98G cells. The addition of zVAD-fmk levels elevated TNF-α under all 
conditions. There was no TNF-α release by glioma cells cultured in the absence of 
PBMC or in the presence of IFN-γ (100 U/ml) (data not shown). As in other 
experiments, PBMC from some donors were strongly activated by T98G cells 
whereas PBMC from other donors hardly responded to this cell line. This donor-
specific variability was less pronounced with U138MG and U373MG cells. 
Importantly, TNF-α release from PBMC in cocultures with T98G was never affected 
by the addition of CD70 antibody or sCD27 whereas these reagents produced 
consistent effects in the other two cell lines. Appropriate control experiments 
revealed that CD70/CD27-mediated PBMC apoptosis was not mediated by 
CD95/CD95L interactions or TGF-ß since neutralizing antibodies to CD95L or TGF-
ß failed to rescue the loss of PBMC in experiments corresponding to Figures 5.6 and 
5.8. The antibodies were used at concentrations previously shown to block human 
CD95L (204) and TGF-ß (292). 
 
CD70-expressing glioma cells induce the release of sCD27 from PBMC and decrease 
CD27 expression 
The detection of sCD27 in normal human serum (322) indicates that this molecule 
may have immune regulatory properties. The PBMC preparations used here showed 
levels of 5 U/ml at day 5 as determined by ELISA. None of the 12 glioma cell lines 
produced sCD27 when cultured alone, consistent with the failure to detect CD27 
mRNA by RT-PCR and Northern Blotting (see above). Coculture with U138MG or 
U373MG cells significantly enhanced the levels of sCD27 in the supernatant 
whereas no such effect was seen with T98G cells. CD70 antibody and zVAD-fmk 
inhibited this effect (Fig. 5.12A). sCD27 is generated by proteolytic cleavage of 
membrane-bound CD27 (323) after triggering of T cells by antigen (322, 324). 
Hence CD27 expression at the cell surface of the remaining PBMC was also 
investigated after 5 day coculture. While no change in CD27 expression resulted 
from coculture with T98G cells, the CD70-positive cell lines U138MG and U373MG 
induced a reduction of CD27 expression at the surface of the remaining PBMC. The 
number of PBMC with high CD27 expression decreased from 50.7% to 10.9% after 
coculture with U373MG cells, suggesting that, after contact with CD70-expressing 
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glioma cells, CD27 is cleaved, released and not re-incorporated into the cell 
membrane, providing another response of PBMC to CD70-expressing glioma cells, 
in addition to apoptosis (Fig. 5.12B). 
 
 
Fig. 5.12. CD70-expressing glioma 
cells promote sCD27 release by 
PBMC. (A) PBMC (1.5 x 107) were 
cultured alone or cocultured with 1.5 x 
106 irradiated glioma cells for 5 days. 
Glioma cells were preincubated with 
control IgG or CD70 antibody (10 
µg/ml) for 2 h; alternatively, zVAD-fmk 
(100 µM) was added during coculture. 
sCD27 levels in the supernatant were 
determined by ELISA (*p<0.05, 
**p<0.01, compared to control IgG). (B)
CD27 expression was assessed by flow 
cytometry using M-T271 CD27 
antibody: in PBMC cultured alone for 5 
days (upper panel), cocultured with 
U373MG cells preexposed to control 
antibody (middle panel) or to CD70 
antibody (lower panel). 
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Discussion 
 
The present study identifies CD70 as a novel candidate molecule mediating immune 
escape of human malignant gliomas. The induction of CD70 expression by irradiation 
exemplifies how radiotherapy might suppress antitumour immune responses. This 
observation therefore has implications for the orchestration of multimodality cancer 
therapy in the clinic. Endogenous expression of CD70 had not been reported previously 
in nonlymphoid cancer cells, but has simultaneously been confirmed by another group 
(325). CD70 was identified as a radio-inducible gene in U87MG glioma cells (Fig. 5.1). 
CD70 expression turned out to be rather common among human malignant glioma cell 
lines (Fig. 5.2 A-C) Immunohistochemical stainings confirmed that CD70 was also 
expressed by neoplastic glial cells in vivo (Fig. 5.3). CD70 expression was specifically 
induced by irradiation in glioma cells (Fig. 5.4), but not in neuroblastoma cells. 
Irradiation-induced CD70 expression did not require wild-type p53 activity and was not 
merely a response to genotoxic stress since cytotoxic agents such as lomustine did not 
modulate CD70 expression. In contrast to the expected result, CD70 expressed by 
glioma cells induced immunosuppression rather than immune stimulation in 
alloreactivity assays in vitro (Fig. 5.5). Several lines of experimental evidence disclosed 
that CD70 expressed by glioma cells promoted apoptosis in the PBMC population (Fig. 
5.6, 5.8, 5.11). The shedding of CD27 by PBMC may represent an escape mechanism 
from glioma cell-induced, CD70-dependent apoptosis (Fig. 5.12). The role for 
CD70/CD27 interactions in T, B and especially in NK cell activation has raised 
interesting perspectives for the immunotherapy of cancer (326, 327). For instance, 
virus-mediated CD70 gene transfer into mouse colon carcinoma cells enhanced T cell 
responses and induced antitumour immunity (328). Further, in a mouse model using 
CD70-transfected MHC class I-deficient RMA-S tumour cells, CD70 expression 
enhanced primary, NK cell-mediated tumour rejection in vivo as well as tumour-
specific T cell memory against secondary tumour challenge (329). However, since all 
investigated glioma cell lines express large amounts of MHC class I (131), this NK 
cell-dependent response is likely to be inhibited. Further, T cell activation and 
apoptosis are complex processes that do not only depend on primary signals but also on 
secondary factors. This complex regulation seems to be necessary, given the need of 
rapidly controlling immune reactions under different and rapidly changing conditions 
(30). Many molecules can thus exert both stimulatory as well as proapoptotic effects on 
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the immune system (330). The costimulatory role of CD70 has been well characterized 
(331). However, CD70-induced apoptosis mediated by the proapoptotic protein Siva 
has also been demonstrated (49, 332). Recent findings suggest that Siva antagonizes the 
pro-survival function of Bcl-xL and activates the mitochondrial (intrinsic) apoptosis 
pathway (333, 334). The present study provides ample evidence that CD70 expressed 
by glioma cells evokes immune inhibition rather than immune stimulation (Fig. 5.5-5.8) 
and thus contrasts with several previous studies aiming at exploiting immune 
stimulatory properties of CD70 (326-329). It is commonly assumed that cells 
undergoing malignant transformation can potentially be cleared by the immune system. 
In order to escape from the surveillance of the immune system, most tumours down-
regulate costimulatory molecules and instead express molecules with immune 
inhibitory function, including TGF-β or CD95L. Such processes of selection a priori 
argue against a possible costimulatory role of CD70 expressed on glioma cells. It is 
well conceivable that (yet unidentified) immunosuppressive factors expressed by 
glioma cells interfere with CD27-mediated, NF-κB-dependent costimulatory signalling, 
while the apoptosis pathway via Siva may not be inhibited. Impaired CD70 signalling 
may occur when the level of sCD27 is abnormally high. This has been reported for the 
blood and cerebrospinal fluid of patients suffering from various autoimmune diseases 
(335-338). One might therefore speculate that high concentrations of sCD27 
administered into a postsurgical glioma cavity might promote local antiglioma 
immunity. 
Expression and functional activity of CD70 in a solid nonlymphoid tumour represents 
one of two novel and unexpected findings of this study. The second major observation 
was the radioinducibility of CD70 in glioma cells in vitro which led to its identification 
by cDNA array analysis. Human glioblastomas are commonly irradiated in 1.8-2 Gy 
fractions to a total dose of 54-60 Gy. Since single doses of 6 Gy were used here to 
assess the effects of irradiation in most experiments (Fig. 5.4), future studies will need 
to determine whether lower dose fractionated irradiation will also induce CD70 
expression in vitro and whether similar effects can be demonstrated in vivo. This study 
defines a possible pathway by which fractionated radiotherapy may create a locally 
immunosuppressed environment in human glioblastomas. CD70 expression maintained 
by radiotherapy may thus interfere with immune responses to the tumour during the 
weeks of radiotherapy. It is tempting to speculate that irradiation-induced CD70 
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expression might be particularly counterproductive in human cancers known to be 
immunogenic, such as malignant melanoma or renal cell carcinoma. 
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VI. Expression of the non-classical MHC class I molecule HLA-G in human gliomas: 
an alternative strategy of immune escape 
This work has been published in the Journal of Immunology 2002 May 1;168(9):4772-80. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is based on an idea from Dr. Heinz Wiendl (Group of Neuro-Immunology, 
Department of Neurology, University of Tübingen, Medical School, Tübingen) who also lead 
the project. The immunohistochemical stainings were performed by Dr. Antje Bornemann and 
Prof. Dr. Richard Meyermann in the Institute of Brain Research, University of Tübingen, 
Germany. Dr. Valeska Hofmeister and Prof. Dr. Elisabeth H. Weiss (Institute of 
Anthropology and Human Genetics, Ludwig Maximilians University, Munich, Germany) 
confirmed the expression of HLA-G by RT-PCR, Western and Northern Blotting. I generated 
the glioma cell transfectants (Fig. 6.5) that were used in this manuscript and guided the 
functional immunological experiments shown in Fig. 6.6, 6.7, 6.9, 6.10, 6.11, 6.12 that were 
largely carried out by Meike Mitsdörffer. Thanks also go to Drs. M. McMaster (University of 
California, San Francisco) and D. Geraghty (Fred Hutchinson Cancer Research Center, 
Seattle) for kindly providing anti-HLA-G mAbs. 
 144 
Introduction 
The escape from immune surveillance is thought to be a prerequisite for the development of 
clinical cancer. A failure of the immune system to recognize and eliminate tumour cells may 
be caused by the absence of tumour antigens and by the non-reactivity or non-recognition of 
tumour antigens because of insufficient costimulation, anergy, tolerance or 
immunosuppression. Human glioblastoma is a highly lethal tumour which is paradigmatic for 
its ability to suppress effective antitumoral immune responses. Two pathways of glioblastoma 
associated-immune suppression that have attracted a lot of attention are the release of the 
immunosuppressive cytokine TGF-β (155) and the expression of CD95L (253), both acting on 
lymphoid cells (reviewed in (63)). 
Major histocompatibility complex (MHC) class Ia expression is frequently altered in a variety 
of malignancies. These alterations may have a decisive influence on the immune response and 
on the metastatic capacity of the tumours (e.g. (339)). HLA-G is a ”nonclassical” MHC class I 
molecule (class Ib) structurally related to classical MHC class Ia (HLA-A, -B, -C) which – in 
contrast to class Ia molecules – exhibits a limited tissue distribution: first detected on 
extravillous cytotrophoblast cells (340), it has now been recognized that HLA-G is also 
expressed by thymic epithelial cells (341), cytokine-activated monocytes (342), inflamed 
muscle and myoblasts (343) and some tumours (e.g. (344)). 
In contrast to HLA class Ia molecules, HLA-G is characterized by a limited polymorphism 
and the transcription of alternatively spliced mRNAs that encode at least seven different 
isoforms, including membrane-bound HLA-G1, -G2, -G3, -G4 and soluble HLA-G5 
(formerly HLA-sG1), -G6 (formerly HLA-sG2), -G7 proteins (reviewed in (190)). HLA-G 
binds CD8 and a restricted repertoire of peptides and might therefore act as a peptide-
presenting molecule (345-348). However, HLA-G has so far chiefly been regarded as a 
mediator of immune tolerance because it protects target cells from NK cytolysis through 
direct or indirect interaction with several inhibitory receptors expressed on NK cells (349-
351). Further, HLA-G can also modulate antigen-specific lysis through interaction with 
surface molecules expressed on cytotoxic CD8 T cells (352, 353). Expression of HLA-G has 
therefore been proposed to allow immune escape in tumours. 
In this section, the expression and functional activity of HLA-G in glioblastoma cells is 
reported. The negative immune regulatory effects of HLA-G on different effector lymphocyte 
populations studied here in models of primary and secondary immune responses supports the 
idea of HLA-G-dependent suppression of T cell responses representing a novel immune 
escape pathway of human glioblastoma. 
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Material and Methods 
Antibodies and reagents 
The following antibodies were used: 87G (IgG2b, anti-HLA-G1; kindly provided by D. 
Geraghty), 4H84 (mIgG1, anti-HLA-G; kindly provided by M. McMaster); MEM-G/9 
(mIgG1, anti-HLA-G; Exbio, Prague, Czech Republic); BFL1.1.2 (mIgG2b, anti-HLA-G; 
Immunotech, Marseille, France); W6/32 (mIgG2a, anti-HLA-A, -B, -C, -C, -G, -E and β2 
microglobulin (β2m); Biozol, Eching, Germany); L243 (mIgG2a, anti-HLA-DR), BB7.2 
(mIgG2b, anti-HLA-A2; ATCC; Rockville, MD); RPA-T4 (mIgG1κ anti-CD4 FITC- and PE-
labeled), HIT8A (mIgG1κ, anti-CD8 PE-labeled), AnnexinV-FITC (Pharmingen, Heidelberg, 
Germany); B9.11 (mIgG1, anti-CD8 FITC-labeled) N901 (NKH-1; mIgG1, anti-CD56 PE-
labeled) (Immunotech); goat anti-mouse F(ab)2 fragment (Dianova, Hamburg, Germany), 
peroxidase (hrp)-labeled rabbit anti-human β2microglobulin (DAKO Diagnostika, Hamburg, 
Germany). The antibodies were titrated for flow cytometry and used at concentrations 
indicated (usually 20 µg/ml) in the functional assays. Soluble CD95L was obtained from 
CD95L-transfected murine N2A neuroblastoma cells (354). Propidium iodide was purchased 
from Sigma (St. Louis, MO). 
 
Cell culture 
The human malignant glioma cell lines LN-18, U138MG, U87MG, LN-428, D247MG, 
T98G, LN-319, LN-229, A172, U251MG, U373MG and LN-308, kindly provided by Dr. N. 
de Tribolet (Lausanne, Switzerland), and SV40 FHAS non-neoplastic astrocytes (kindly 
provided by A. Muruganandam, Ottawa, Canada) were cultured in 75 cm3 Falcon plastic 
flasks using DMEM supplemented with 1% glutamine (Gibco Life Technologies, Paisley, 
Great Britain), 10% foetal calf serum (FCS) (Biochrom KG, Berlin, Germany) and penicillin 
(100 IU/ml)/streptomycin (100 µg/ml) (Gibco). The JEG-3 human choriocarcinoma cell line 
and the K-562 human erythroleukemia cell line (ATCC) were maintained in RPMI 1640 
supplemented with 1 mM sodium pyruvate, penicillin (100 IU/ml)/streptomycin (100 µg/ml) 
and 10% FCS. Cells were routinely tested for contamination with mycoplasma. Where 
indicated, the cells were irradiated using a Gammacell 1000 Elite (Nordion, Ontario, Canada).  
 
Immunohistochemistry 
Tumour biopsy specimens were surgically removed from 4 patients with glioblastoma (grade 
IV WHO) (male, age range 32-64 y, mean 46y) and one patient with anaplastic oligo-
astrocytoma (grade III WHO) (female, 42 y). Frozen sections 10 µm thick were cut, fixed in 
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acetone, and immunostained with anti-HLA-G antibody (87G, BFL1.1.2). The reaction 
product was visualised with the streptavidin-biotin method (reagents from DAKO) using 
diaminobenzidine (Serva, Heidelberg, Germany) as an electron donor. As control tissue 
placenta was used.  
 
HLA-G transfectants 
HLA-G transfectants were obtained as described elsewhere (352, 355). In brief, HLA-G1 
(encoding the full-length HLA-G transcript) and HLA-G5 (coding for the secreted HLA-G 
heavy chain) plasmids were generated by cloning HLA-G1 and HLA-G5 cDNAs into a GFP 
vector (pIRES2-pEGFP; Clontech, Palo Alto, CA). GFP vector transfectants (pIRES2-
pEGFP) were used as controls. Transfection was done using Effectene® transfection reagent 
(Qiagen, Hilden, Germany). Cells were selected in media containing 0.5 mg/ml neomycin 
(G418, Calbiochem, Germany). The following transfectants were used in the study: K-562-
HLA-G1, U87MG-pIRES2-EGFP (referred to as U87MG-pEGFP), U87MG-HLA-G1, 
U87MG-HLA-G5.  
 
Peripheral blood mononuclear cells (PBMC) and purified lymphocyte populations 
PBMC were isolated from the peripheral blood of normal healthy volunteers by density 
gradient centrifugation using Biocoll Separating Solution (Biochrom KG). Cells were 
analyzed for their HLA-A2 isotype by flow cytometry. CD4 and CD8 T cells were purified by 
positive selection with CD4 or CD8 Microbeads (Miltenyi Biotec, Bergisch Gladbach, 
Germany). NK cells were isolated by an NK cell-negative isolation kit (Dynal, Biotech, 
Hamburg, Germany). The purity of the isolated subpopulations used in the experiments was > 
95% as determined by flow cytometry. 
 
Flow cytometry 
Adherent cell lines were collected after treatment with cell dissociation buffer (Gibco) at 
37°C for 5 min. JEG-3, K-562-HLA-G1 or K-562 cells were used as positive and negative 
control cell lines for HLA-G or MHC expression when indicated. Cells were washed with 
PBS containing 0.1% bovine serum albumin (BSA) and 0.1% sodium acide and blocked with 
human immunoglobulins (Alphaglobin, Grifols, Langen, Germany) for 10 min at 4°C. After 
one washing step, the unlabeled first antibody was added at the final concentration. Isotype 
control monoclonal antibodies (mAbs) were used at the same concentration as the primary 
antibody. Incubation was done on ice for 30 min, followed by two washes. Goat anti-mouse 
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IgG (F(ab)2-PE (5 µg/ml, Sigma) or IgG (F(ab)2- di-chlorotriazinyl-fluoresceine (DTAF) (10 
µg/ml, Dianova) were used as secondary antibodies. After washing, propidium iodide (PI) 
was added to the cells at a final concentration of 0.02 µM. PI-positive (nonviable) cells were 
excluded from analysis. Specific fluorescence indexes (SFI) were calculated by dividing mean 
fluorescence obtained with specific antibody by mean fluorescence obtained with isotype 
control antibody. Analysis of PBMC and lymphocyte subsets was performed similarly. Cells 
were blocked with human immunoglobulins and stained either with directly labeled antibodies 
or the respective combinations of an unlabeled first antibody and a fluorescent secondary 
antibody. Flow cytometry was performed using a FACSCalibur (Becton Dickinson, 
Heidelberg, Germany).  
 
Detection of apoptosis by AnnexinV binding 
PBMC or purified lymphocyte subsets undergoing apoptotic cell death were analysed by 
staining with FITC-labeled AnnexinV (Pharmingen). After various incubation times with the 
glioma cells, lymphocytes were collected, washed with PBS and resuspended in a buffer 
containing 10 mM HEPES/NaOH, pH 7.4, 140 mM NaCl and 2.5 mM CaCl2. Then 
AnnexinV-FITC and PI were added. Following incubation for 30 min the cells were analysed 
by flow cytometry. When analysis of lymphocyte subsets was desired, PBMC were first 
incubated with respective PE-labeled cell surface antibodies (CD4-PE, CD8-PE, Pharmingen, 
CD56-PE; Imunotech) before the AnnexinV staining was performed. 
 
Primary alloreactive proliferation 
To suppress the proliferation of stimulator cells, glioma cells were incubated in serum-free 
medium for 24 h, irradiated at 50 - 200 Gy and maintained in serum-free medium for another 
24 h. Cells were detached using cell dissociation solution (Gibco), counted and seeded in 
RPMI medium. HLA-A2-mismatched responder PBMC (105) were coincubated with 104 
irradiated glioma cells in a total volume of 100 µl. The assay was performed in 96-well plates 
in triplicates. PBMC without glioma cells, glioma cells without PBMC, and PHA-stimulated 
PBMC (10 µg/ml) were used as controls. After 4 days, the cells were pulsed for 24 h with 0.5 
µCi of [methyl-3H] thymidine (Amersham-Pharmacia Biotech, Freiburg, Germany). Cells 
were harvested with a cell harvester (Inotech, Dottikon, Switzerland) and the incorporated 
radioactivity was bound to a glass fibre filtermat (Wallac, Turku, Finland). The filtermat was 
wetted with Ultima Gold Scintillation Cocktail (Packard, Dreieich, Germany) and 
radioactivity was determined in a Wallac 1450 Microbeta Plus Liquid Scintillation Counter. 
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Secondary alloreactive immune response (51Cr release assay) 
To test for lytic activity of primed cytotoxic T cells after coculture with HLA-A2-mismatched 
glioma cells (U87MG-pEGFP, U87MG-HLA-G1, U87MG-HLA-G5) for 5 days, a 51Cr 
release assay was performed. Growth-suppressed glioma cells were seeded into 25 cm2 flasks 
to a density of 106 cells. HLA-A2-mismatched PBMC (1.5 x 107) were added in 5 ml RPMI 
containing 10% FCS. Cells were cocultured for 5 days. Glioma cells (106) were labeled by 
addition of 100 µCi 51Cr (#NEZ147, NEN, Boston, MA) in 1 ml and 104 labeled glioma cells 
were seeded as target cells in a U-shaped 96-well plate. Primed alloreactive cytotoxic 
lymphocytes obtained after 5 days of coculturing were removed and added to the labeled 
target cells at different effector:target ratios (ranging from 10 to 80) in a volume of 100 µl. 
After coincubation for 4 h, 50 µl of the supernatant were transferred to a Luma-PlateTM-96 
(Packard), dried overnight and measured. To correct for spontaneous release of 51Cr, a control 
of labeled target cells in medium only was included (0% specific lysis). The maximum 51Cr 
release possible was determined by addition of NP-40 (100% lysis). Lysis was calculated as 
[cpm (effector cells)-cpm (spontaneous)]/[cpm (NP-40)-cpm (spontaneous)] x 100%. 
 
Primary alloreactive lysis (51Cr release) 
Primary alloreactive lytic damage of glioma target cells by HLA-A2-mismatched 
lymphocytes was measured in a 51Cr release assay. Target glioma cells were radioactively 
labeled and seeded into 96-well U-bottom wells as described above. For blocking 
experiments, glioma cells or HLA-G transfectants were preincubated with specific antibodies 
or the corresponding isotype control antibodies. After incubation for 1 h at 37°C, crosslinking 
by a secondary antibody (goat anti-mouse F(ab)2 fragment, 10 µg/ml, Dianova) was 
performed to immobilize the antibody on the glioma cells. Effector cells (PBMC, CD4, CD8, 
NK cells) were added at effector:target ratios ranging from 1 to 100 in a total volume of 
100 µl. After coincubation for 8 h, 50 µl of the supernatant were transferred to a Luma-
PlateTM-96 (Packard), dried overnight and measured. In experiments using purified NK cells, 
incubation was done for 4 h. To correct for spontaneous 51Cr release, a control of labeled 
target cells in medium only was included (0% specific lysis). The maximum 51Cr release 
possible was determined by addition of NP-40 (100% lysis).  
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Soluble HLA-G (sHLA-G) ELISA.  
Secreted HLA-G molecules were measured as total soluble HLA-class I molecules in the 
culture supernatants. MHC class I antibody (W6/32, concentration 5 µg/ml, volume 100 µl) 
was coated onto a 96-well microtiter plate (Nunc) and incubated over night at 4°C. After three 
washes with PBS containing 0.05% Tween 20 (PBS-Tween), the plate was saturated with 
250 µl of PBS containing 2% BSA. After incubation for 2 h at 37°C, the plate was washed 
three times with PBS-Tween. Cell culture supernatants (100 µl) were added to each well at 
various dilutions and incubated for 2 h at 37°C. Plates were washed another three times with 
PBS-Tween and hrp-labeled rabbit anti-mouse β2m antibody (dilution 1:500, volume 100 µl) 
was added. After incubation for 1 h at 37°C and washing three times with PBS-Tween, 100 µl 
of ortho-phenyl-diamine peroxidase substrate was added (Abbott Diagnostics, Wiesbaden-
Delkenheim, Germany) for 30 min at room temperature avoiding exposure to light. The 
reaction was stopped by addition of 50 µl of 2 M H2SO4. The concentration was estimated 
from the absorption measured at 490 nm (triplicate wells) on a ELISA microplate reader 
(Wallac). 
 
Reverse transcription and amplification 
First strand DNA synthesis of 1 µg total RNA primed with oligo(dT)12-18 (Amersham 
Pharmacia Biotech) and ExpandTM Reverse Transcriptase (Boehringer, Mannheim, Germany) 
was done according to the manufacturer's recommendations (356). One µl of cDNA was 
amplified using the following primer pairs  which coamplify the HLA-G isoforms HLA-G1, -
G2/4, and –G3: Ex1 (5‘-CAAGGATGGTGGTCATGGCG-3‘) and Ex6/3‘UT (5‘-
CAGCTGTTTCACATTGCAGCCTG-3‘), 60°C annealing temperature, 40 cycles. PCR 
products were analyzed on 1.5% agarose gels containing ethidium bromide or on 8% native 
polyacrylamide gels followed by silver staining (357). 
 
DNA probes and Northern blot analysis 
RNA was isolated with the TriPure Isolation reagent (Boehringer, Mannheim). 20 µg of total 
RNA were separated on 1.2% formaldehyde agarose gels, transferred to Hybond-N+ 
membrane (Amersham Pharmacia Biotech) in 20x SSC over night and cross-linked by baking 
at 80°C for 2 h. The filters were hybridized with 10 ng/ml specific digoxigenin-labeled probe 
and detected as described (355). Hybridization probes specific for HLA-G transcripts were 
derived from the 3'- untranslated regions and were generated by PCR and incorporation of 
digoxigenin-labeled dideoxyuridine triphosphate (Boehringer Mannheim). The 486 bp HLA-
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G probe was labeled from a subcloned 287 bp amplificate with the primers M13 (-20) and 
M13 reverse. The 440 bp HLA-B probe was generated from the subcloned 3‘UT Pvu II/Pst I 
fragment using SP6 and T7 primers. To detect HLA-G transcripts in HLA-G transfectants, a 
787-bp HLA-G4 probe was generated by PCR using the primer pair Ex1 and Ex6/3'UT (358). 
 
Immunoblot analysis 
Cells were lysed for 30 min at 4°C in lysis buffer (20 mM Tris-HCl pH 7.5, 1% Triton X100, 
2% trasylol) (Bayer, Leverkusen, Germany), 1 mM phenylmethyl sulfonylfluoride (PMSF, 
Sigma). After removal of cellular debris by centrifugation, protein content of the lysates was 
quantified using a Micro-Bradford assay (24). Lysates equivalent to 100 µg of protein were 
separated by 10% SDS-PAGE and transferred onto nitrocellulose membranes (Schleicher and 
Schuell, Dassel, Germany) using standard blotting techniques. HLA-G heavy chains were 
detected with the mAb 4H84 and the ECL Western blotting analysis system (Amersham 
Pharmacia). 
 
Statistical analysis 
All data are representative of experiments performed at least three times with similar results. 
Significance was assessed by two sided t-test (*p<0.05, **p<0.01). 
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Results 
HLA-G expression in human glioma cell lines  
Twelve human glioma cell lines were tested for HLA-G mRNA expression in the absence or 
presence of IFN-γ by Northern blotting using a probe specific for all HLA-G isoforms (Fig. 
6.1). Six glioma cell lines transcribed HLA-G constitutively (U251MG, U373MG, D247MG, 
T98G, LN-428, A172). The presence of different alternative splicing patterns were confirmed 
by RT-PCR specific for transmembraneous and soluble isoforms of HLA-G (data not shown). 
After stimulation with IFN-γ, HLA-G transcripts became detectable in 10 of the 12 glioma 
lines (Fig. 6.1). Only U87MG and LN-308 cells were refractory to IFN-γ-mediated induction 
of HLA-G expression. PCR analysis paralleled these observations, confirming strong up-
regulation of different HLA-G isoforms after IFN-γ induction (data not shown). 
 
 
Fig. 6.1: Human glioma cells express HLA-G mRNA. HLA-G mRNA levels were assessed by Northern
blot analysis. A total of 20 µg of total RNA from untreated (-) or IFN-γ- treated (+) cells (500 U/ml; 48h)
(12 different glioma cell lines) was separated on a formaldehyde agarose gel and hybridized with HLA-G
specific probes. The amount of RNA loaded is visualized by ethidium bromide staining of the 28S rRNA
(lower panel). The human choriocarcinoma line JEG-3 was used as a positive control. 
 
 
 
 
 
To test whether the transcripts detected were translated into protein, flow cytometry was 
performed using the anti-HLA-G mAbs 87G and MEM-G/9. A weak membrane expression of 
HLA-G was observed in 4 of 12 untreated glioma cell lines (U373MG, LN-319, T98G, A172) 
(Fig. 6.2). After stimulation with IFN-γ, HLA-G membrane expression increased and was 
detectable in 8 of the 12 tested glioma cell lines, using a cutoff SFI value of 1.3 (Fig. 6.2).  
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Fig. 6.2. Human glioma cells express HLA-G protein. MHC class I, class II and HLA-G expression by
human glioma cell lines in the absence or presence of IFN-γ was determined by flow cytometry. The cell
lines were incubated for 48 h with or without IFN-γ (500 U/ml), stained either with the MHC-class I
reactive mAb W6/32 (HLA-A,-B,-C,-G,-E+ß2-m), the MHC-class II reactive mAb L243 (HLA-DR) or
the HLA-G specific mAb 87G (HLA-G1). JEG-3 choriocarcinoma were used as positive control, K-562
as negative control (not shown). The numbers in the upper right corner indicate SFI values. A SFI value
of 1.3 was considered positive. Data are representative of 4 independent experiments with similar results.
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The expression of class I (HLA-A, -B, -C mAb W6/32; HLA-A2 mAb BB7.2) and class II 
(HLA-DR; mAb L243) molecules was assessed in parallel, showing that all glioma cells 
expressed HLA-class I molecules constitutively. IFN-γ enhanced the surface expression of 
MHC class I in all cell lines except A172. The MHC class II DR-molecule was expressed 
constitutively in 4 of 12 glioma cell lines. IFN-γ induced HLA-DR in all except 2 cell lines 
(LN-308, U138MG). The human SV40-transformed astrocytic cell line SV40-FHAS did not 
show HLA-G RNA or protein expression in the absence or presence of IFN-γ (data not 
shown). 
 
HLA-G expression in human brain tissue 
Immunohistochemistry detected HLA-G expression in 4 of 5 brain tumours. Up to 50% of 
tumour cells expressed HLA-G in 3 of the 4 tested glioblastomas and in one anaplastic oligo-
astrocytoma (Fig. 6.3; staining shown here with mAb BFL1.1.2 and mAb 87G). Positive cells 
were evenly scattered throughout the specimens. One glioblastoma was negative for HLA-G 
with all tested antibodies. 
 
 
  
 
 
 
 
Fig. 6.3: Analysis of HLA-G expression in vivo. Frozen tissue sections of a glioblastoma (A, C and D)
and term placenta as control (B) were immunostained with the HLA-G-specific mAb BFL1.1.2. (A, B),
mAb 87G (C) or IgG-isotype control (D) About 50% of tumor cells expressed HLA-G (glioblastoma, 32
year old male, A magnification x 185, C, magnification x 420). Positive cells were evenly scattered
throughout the specimen. Isotype control (D) of glioblastoma is shown at magnification x 420.
Endothelial cells of three blood vessels (asterisks) in placenta control tissue are HLA-G-positive  (B,
magnification x 395). 
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Expression of HLA-G in glioma cells protects from alloreactive lytic killing 
To elucidate the functional relevance of constitutive and inducible HLA-G expression by 
glioma cells, different alloreactivity assays were performed. Freshly isolated PBMC were 
used as effector cells and incubated with HLA-A2-mismatched glioma targets that had 
previously been cultured in the absence or presence of IFN-γ. The relevance of HLA-G 
molecules for the protection of glioma cells from alloreactive lysis was shown by 
preincubating glioma cells with HLA-G specific antibody 87G (Fig. 6.4). HLA-G expressed 
on U373MG and T98G participated in the protection of glioma cells against direct cytolytic 
activity of PBMC as recorded in a 8 h 51Cr-release assay. The MHC class I specific antibody 
W6/32 was used as a control. Although W6/32 blocks alloreactive lysis by MHC class I 
restricted CD8 T cells, the observed net effect on PBMC lysis in the presence of W6/32 was 
an increase in specific lysis. MHC class I expression regulates NK cell lysis via interaction 
with killer inhibitory receptors, therefore blocking MHC class I might have facilitated lysis by 
NK cells present within the PBMC population. Since W6/32 crossreacts with HLA-G and the 
negative immune regulatory molecule HLA-E part of the observed effects of this antibody on 
lysis may have been mediated by an interaction with HLA-E. In U87MG, a glioma cell line 
lacking HLA-G expression, neutralization with 87G had no significant influence on lysis by 
alloreactive PBMC (data not shown). 
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Fig. 6.4: HLA-G expressed on human glioma cells inhibits lysis by alloreactive PBMC. T98G or
U373MG glioma cells were cultured in the absence or presence of IFN-γ (500 U/ml) for 48 h and used as
targets. Target cells were preincubated either with 87G, W6/32 or isotype control antibody for 1 h. Freshly
purified HLA-A2-mismatched PBMC were added as effector cells at different effector:target (E:T) ratios
(shown 50:1). Data are expressed as percentages of specific lysis recorded in a 8 h 51Cr-release assay
(*p<0.05, **p<0.01 compared with isotype control antibody). Data are representative of 3 independent
experiments with similar results. 
 
 
Gene transfer of HLA-G1 or -G5 into HLA-G negative glioma cells 
To elucidate the effects of the 2 major isoforms HLA-G1  and HLA-G5 on antitumoral 
immune responses, HLA-G transfectants of a HLA-G-negative glioma line (U87MG) were 
generated. Transfectants showed high levels of HLA-G expression as documented by 
immunoblot, flow cytometry, and ELISA for soluble HLA-G (Fig. 6.5). The forced 
expression of HLA-G isoforms did not alter the expression levels or inducibility by IFN-γ of 
classical MHC class I or MHC class II molecules as determined by flow cytometry (data not 
shown). 
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Fig. 6.5: Expression of HLA-G1 and HLA-G5 after gene transfer into U87MG glioma cells. A: The
transfectants were examined by immunoblot analysis using the 4H84 mAb specific for the denatured HLA-
G heavy chain. JEG-3 choriocarcinoma cells and K-562-HLA-G1 were used as positive controls. The HLA-
G protein migrates at 39 kDa. B: Cell surface expression of HLA-G1 protein in the HLA-G transfectants
was assessed by flow cytometry using the HLA-G specific antibodies 87G (left) and MEM-G/9 (right) and
BFL1.1.2 (not shown). Filled profiles indicate specific fluorescence, open profiles correspond to the isotype
control (IgG2b) for HLA-G. C: Levels of sHLA-G released into the supernatant by U87MG, U87MG-HLA-
G5 and U87MG-HLA-G1 transfectants were determined by ELISA. Data are expressed as arbitrary units
corresponding to the optical density measured at 490 nm. Data are representative of at least 3 independent
experiments with similar results. 
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Gene transfer of HLA-G1 or -G5 into U87MG glioma renders glioma cells resistant to 
primary alloreactive lysis 
 
Gene transfer of HLA-G1 and HLA-G5 rendered U87MG cells less susceptible to 
direct alloreactive lytic killing by HLA-A2-mismatched PBMC as assessed by 51Cr-
release of th
 
e target population (Fig. 6.6).  
 
 
 
 
 
 
 
Fig. 6.6: Inhibitory effects of HLA-G in U87MG glioma cell transfectants on different subsets of
immune effector cells under primary alloreactive coculture conditions. U87MG-pEGFP, U87MG-HLA-
G1, or U87MG-HLA-G5 cells were used as targets in cocultures with freshly isolated HLA-A2-mismatched
PBMC at different effector:target (E:T) ratios (shown 100:1). Data are expressed as percentages of specific
lysis recorded in a 8-h 51Cr-release assay (*p<0.05, **p<0.01 compared with U87-pEGFP). 
 
Glioma cell death was also monitored by fluorescence microscopy. Modulation of glioma cell 
lysis after incubation of tumour targets with PBMC is demonstrated by the significantly 
higher survival rates of the HLA-G transfectants compared with the vector control 
transfectants at 48 h (Fig. 6.7).  
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Fig. 6.7: HLA-G overexpression protects glioma cells against immune-mediated lysis. U87MG-pEGFP
or U87MG-HLA-G1 were cocultured in 6-well culture plates with HLA-A2-mismatched PBMC for 48 h.
Visualization over time was performed by fluorescence microscopy. 
To further characterize the effector populations inhibited by HLA-G expressed on U87MG 
cells, primary alloreactivity assays were performed with purified lymphocyte subpopulations 
(CD56, CD4, CD8). U87MG parental cells showed resistance to NK cell lysis (Fig. 6.8).  
 
 
Therefore effects of ectopic HLA-G expression could not b
In contrast, MHC class I-negative K-562 cells were clearl
expression of HLA-G1. Unexpectedly, lytic assays with C
demonstrated that HLA-G1 directly inhibited lysis mediat
effector cell populations (Fig. 6.9).  
Fig. 6.8: U87MG glioma cells are
resistant to lysis by primary
alloreactive NK cells. CD56-positive
NK effector cells were added to
U87MG-pEGFP, U87MG-HLA-G1, or
U87MG-HLA-G5 target cells at the
indicated effector:target ratios. As a
positive control, the MHC class I-
negative K-562 and K-562-HLA-G1-
transfectants were used. e attributed to NK cell inhibition. 
y protected from NK lysis by the 
D8 and CD4 effector cell subsets 
ed by alloreactive CD4 and CD8 
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Fig. 6.9. HLA-G overexpression protects glioma cells against killing by alloreactive T cells. Freshly
isolated, HLA-A2-mismatched PBMC or purified CD4, CD8, or CD56 subsets were incubated with U87MG-
pEGFP or U87MG-HLA-G1 target cells at different E:T ratios (shown 80:1) for 8 h and specific lysis of the
target glioma cells was quantified by release of 51Cr (**p<0.01 compared with U87-pEGFP vector control
cells). Data are representative of at least 3 independent experiments with similar results. 
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HLA-G gene transfer inhibits alloproliferation and prevents effective priming of antigen-
specific cells 
To study the effects of HLA-G on the generation of primary and secondary immune 
responses, first the primary proliferative response of HLA-A2-mismatched responder PBMC 
against growth-arrested glioma cells (U87MG-pEGFP, U87MG-HLA-G1 or U87MG-HLA-
G5) was quantified by measuring [methyl-3H] thymidine incorporation. The proliferative 
response towards glioma cells was significantly suppressed by U87MG-HLA-G1 and 
U87MG-HLA-G5 cells (Fig. 6.10).  
 
 
 
 
 
 
 
 
Figure 6.10. HLA-G inhibits primary alloproliferative responses. A: PBMC were cultured for 5 days in
the absence or presence of growth-arrested stimulator cells (U87MG-pEGFP, U87MG-HLA-G1, U87MG-
HLA-G5). Primary alloproliferation of the HLA-A2-mismatched responder population was determined by
[3H]-thymidine incorporation added for the last 24 h of coculture. Data are expressed as mean cpm ± SD of
triplicate cultures (**p<0.01 compared with U87MG control cells). 
 
To assess whether induction of apoptosis in the effector cells (19) contributes to these 
inhibitory effects, the cellular viability within the effector cell population was assessed during 
coculture of freshly isolated lymphocyte subpopulations (CD8, CD4) with  U87MG-pEGFP, 
U87MG-HLA-G1 or U87MG-HLA-G5 transfectants. HLA-G1 did not induce apoptosis in the 
effector cell populations as detected by AnnexinV staining up to 72 h after coincubation of 
freshly isolated and not previously stimulated PBMC or lymphocyte subsets with target cells 
(Fig. 6.11). As a positive control for the induction of apoptosis, PHA-stimulated PBMC were 
treated with CD95L. 
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 Fig. 6.11. HLA-G expressed by human glioma cell lines does not induce apoptosis in immune effector
cell population. U87MG-pEGFP or U87MG-HLA-G1 cells were cocultured with HLA-A2-mismatched
PBMC, CD4 or CD8 T cells and the amount of apoptosis in the lymphocyte population was quantified by
AnnexinV-FITC at 48 h. As a positive control for apoptosis induction, PHA-stimulated PBMC treated with
CD95L are shown. ext the effect of HLA-G1 on the mounting of secondary immune responses was 
nvestigated. Antigen-specific cytotoxic lymphocytes were generated by coculturing U87MG-
EGFP or U87MG-HLA-G1 target cells with HLA-A2-mismatched PBMC for 5 days. After 
ransferring primed effector cells, specific killing of parental U87MG target cells was 
ssessed by 51Cr release at different E:T ratios. The expression of HLA-G1 in the priming 
hase abrogated antigen-specific lysis by cytotoxic T cells (Fig. 6.12A). The protective effect 
f HLA-G against specific killing by cytotoxic effector cells depended on the presence of 
LA-G in the priming phase. When HLA-G was present in the target population after 
ntigen-specific cells had been primed against U87MG-pEGFP control cells, subsequent lysis 
f U87MG-pEGFP cells was not significantly different from U87MG-HLA-G1 (Fig. 6.12B). 
imilar results were obtained for U87MG transfectants expressing soluble HLA-G (U87MG-
LA-G5; data not shown). 
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Fig. 6.12. HLA-G overexpression prevents the priming of alloreactive, antigen-specific T cell
responses. A. Antigen-specific cytotoxic T cells were generated by coculture of HLA-A2-mismatched
PBMC with U87MG-pEGFP or U87MG-HLA-G1 target cells for 5 days. Primed effector cells were
removed and incubated with 51Cr-labeled U87MG-pEGFP target glioma cells at the indicated E:T ratios.
Data are expressed as percentage of specific lysis recorded in an 8 h [51Cr]-release assay. B: Antigen-
specific cytotoxic T cells were generated by coculturing HLA-A2-mismatched PBMC with U87MG-
pEGFP (open bars) or U87MG-HLA-G1 (black bars) as described in A. After removing primed
lymphocytes from the cultures, effector cells were incubated with either U87MG-pEGFP or U87MG-
HLA-G1 as targets. Data are expressed as percentage of specific lysis recorded in an 8 h [51Cr]-release
assay. Data are representative of at least 3 independent experiments with similar results. 
 
Few HLA-G-positive cells are sufficient to inhibit alloreactive lysis of HLA-G-negative 
glioma cells 
To assess the possible immune modulatory effects of a minor population of glioma cells 
expressing HLA-G within a given tumour cell population, 51Cr-labeled U87MG-HLA-G1 
cells were mixed with 51Cr-labeled vector control U87MG-pEGFP cells, and lysis of targets 
was assessed after incubation with alloreactive, HLA-A2-mismatched PBMC. Significant 
inhibition of lysis was observed when 10% or more of the target cells expressed HLA-G (Fig. 
6.13A). To delineate whether the release of soluble HLA-G as a result of shedding into the 
supernatant might account for this effect, the levels of soluble HLA molecules in the 
supernatants were quantified by ELISA. However, the levels of sHLA-molecules (classical 
and non-classical MHC molecules absorbed by W6/32 mAb) in the supernatant of HLA-G1 
cells were unaltered upon coincubation of PBMC with U87MG-HLA-G1 (Fig. 6.13B). 
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Fig. 6.13: Single HLA-G-expressing tumor cells convey immune inhibitory effects. A: U87-HLA-G1
cells were mixed with U87MG-pEGFP cells and used as target cells. After coincubation with HLA-A2-
mismatched PBMC, the percentage of specific lysis was recorded in a 8-h [51Cr]-release assay.
Significant protection was observed, when 10% or more percent of the cells expressed HLA-G
(**p<0.01, *p<0.05 compared with U87MG-pEGFP control cells) B: The levels of soluble HLA
molecules were measured by ELISA in the supernatants of PBMC alone, U87MG-pEGFP, U87MG-
HLA-G1, U87MG-HLA-G5 or U87MG-HLA-G1 coincubated with PBMC for 48 h. Levels of sHLA
molecules were unaltered during coculture of PBMC and U87MG-HLA-G1 (**p<0.01 compared with
PBMC). Data are representative of at least 3 independent experiments with similar results. 
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Discussion 
In order to investigate the role of HLA-G in glioma immunobiology, the expression of HLA-
G in human glioma was characterized in vitro and in vivo and the functional properties of the 
2 major isoforms HLA-G1 and HLA-G5 in modulating primary and secondary immune 
responses were studied. HLA-G mRNA-transcripts were detected in 6 of 12 untreated glioma 
cell lines and in 10 of 12 cell lines after IFN-γ stimulation (Fig. 6.1). 
A weak constitutive surface expression of HLA-G protein was observed in 4 cell lines 
(U373MG, LN-319, T98G, A172), cell surface expression of HLA-G protein was detected in 
8 of 12 cell lines after IFN-γ stimulation (Fig. 6.2). These data confirm and extend a previous 
report (359) which provided the first evidence of HLA-G expression in two glioma cell lines 
(T98G, N59).  
 
The expression of HLA-G rendered glioma cells less susceptible to alloreactive cytolytic 
killing as demonstrated by blocking experiments using a HLA-G-specific neutralizing 
monoclonal antibody (87G) in U373MG and T98G, two cell lines which constitutively 
express HLA-G at the cell surface (Fig. 6.4). Exposure to neutralizing HLA-G antibodies in 
U87MG, a glioma cell line which does not express HLA-G mRNA or protein (Fig. 6.1, 6.2), 
had no such effect.  
 
To further corroborate these results and to delineate the contribution of the two major HLA-G 
isoforms HLA-G1 (HLA-G1) and HLA-G5 (HLA-G5) to immunoregulatory properties of 
glioma cells, gene transfer studies were performed in the MHC-class I positive, HLA-A2 
positive glioma cell line, U87MG. This cell line lacks baseline or inducible expression of 
HLA-G (Fig. 6.1, 6.2). Gene transfer of HLA-G1 and –G5 rendered these glioma cells 
resistant to primary and secondary antitumoral immune responses under three different assay 
conditions: i) HLA-G directly inhibited alloreactive lysis (Fig. 6.6), ii) HLA-G inhibited the 
primary proliferative response to U87MG stimulator cells (Fig. 6.7), and iii) HLA-G 
prevented efficient priming of cytotoxic effector cells and protected glioma cells from lytic 
killing by antigen-specific cytotoxic lymphocytes (Fig. 6.9). 
 
The first descriptions of HLA-G tissue distribution were suggestive of a limited expression on 
extravillous cytotrophoblast cells (340) suggesting an important role in foetal semi-allograft 
reaction (360). Therefore, HLA-G functional studies were mainly carried out using HLA class 
I negative cell lines such as LCL 721.221 or K-562 that were protected from NK cell-
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mediated cytolysis when transfected with HLA-G (351). HLA-G was shown to interact with 
several receptors on NK cells, namely KIR2DL4, ILT-2, ILT-4, and putatively others (349-
351). The hypothesis of HLA-G expression as a possible tumour immune escape mechanism 
has recently been demonstrated in melanoma cells, where HLA-G surface expression was 
shown to inhibit antitumoral NK cell lysis (344). These data demonstrate that the immune-
paralytic effects of HLA-G expressed on glioma cells are NK cell independent (Fig. 6.8). 
HLA-G1 conveys immunoprotection by direct interaction with CD8 and CD4 alloreactive T 
cells (Fig. 6.9). Furthermore, HLA-G expressed on tumour cells inhibits primary proliferation 
in the effector population and prevents efficient priming of antigen-specific cytotoxic T cells 
(Fig. 6.10 and 6.12). Since human glioma cell lines constitutively express MHC class I, and 
some cell lines also MHC class II on the cell surface (Fig. 2), this study provides further 
evidence for an important immunoregulatory role of HLA-G coexpressed in the presence of 
MHC class I and class II (361). The effects can be attributed to HLA-G rather than being 
indirectly mediated by upregulation of other inhibitory molecules like HLA-E since lysis 
inhibition conveyed by the HLA-G transfectants was reversed by adding a neutralizing HLA-
G antibody (87G) (data not shown). These observations therefore extend the hypothesis that 
HLA-G is capable of modulating antigen-specific (352, 362, 363) as well as non-antigen-
specific cytotoxic T cell responses (353). HLA-G1 and HLA-G5 display similar immune-
inhibitory effects in the experiments performed here. One possible explanation would be 
binding to common receptor(s) expressed on different lymphocyte subsets. 
 
HLA-G1 as well as HLA-G5 inhibited the primary alloproliferative response in the responder 
population but did not render effector cells apoptotic (Fig. 6.11). Previous studies have 
suggested that soluble HLA-G molecules induce apoptosis in CD8 T cells (353), extending 
observations of such an effect of soluble HLA molecules in general (364). However, PBMC 
in those studies had already been prestimulated before encountering the soluble HLA-G 
molecules. The results obtained here from coincubation of unstimulated responder cells with 
HLA-G favour the mechanism of an HLA-G induced cell cycle arrest as possible explanation 
for the effect on effector cells. Of note, proliferative allogeneic responses in a mixed 
lymphocyte reaction induce soluble HLA-G production by CD4 T cells (365), an observation 
that underscores that the immune regulatory capabilities of HLA-G are broader than 
previously assumed. 
In order to address the question what frequency of HLA-G expressing tumour cells might be 
relevant for a down-regulation of antitumoral immune responses, mixing experiments were 
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performed in vitro. The resulting data indicate that a low number of HLA-G-positive glioma 
cells in a population of glioblastoma cells may be sufficient for an effective suppression of an 
antitumoral immune response in vivo (Fig. 6.13A). A direct interaction of HLA-G with certain 
receptors on immune effector cells is assumed to be the predominant pathway of HLA-G 
action. Shedding of HLA-G into the cell suspension would be a possible explanation for some 
of these observations. However, no release of soluble HLA-G by the HLA-G1 transfectants 
was detected, making that possibility rather unlikely (Fig. 6.13B). This surprising observation 
could be interpreted as a ”negative bystander” effect: few HLA-G positive cells render 
neighbouring HLA-G-negative cells ”resistant” to immune-mediated killing or induce non-
reactivity in cytotoxic cells. However, the molecular explanation for this phenomenon 
remains to be clarified. Whereas high levels of HLA-G in the transfected glioma cells are 
possibly required to directly suppress T cell responses, low levels or HLA-G as expressed 
constitutively by some tumour cells might modulate immune responses through other 
mechanism(s). 
 
Expression of HLA-G in vivo was demonstrated in 4 out of 5 brain tumour specimens (Fig. 3), 
thus strongly corroborating the functional in vitro observations in glioma. Although to date 
ectopic expression of HLA-G has been demonstrated in some tumours (366-370), the overall 
relevance of this molecule as an alternative principle of tumour immune escape remains 
controversial (371-374), an issue which is further complicated by the limitations of available 
antibodies to detect HLA-G expression in vivo (375, 376). 
 
The results outlined here provide the first functional analysis of HLA-G in human gliomas in 
vitro and in vivo. In summary these data support an important role of this molecule in the 
immune escape mechanisms of human gliomas. HLA-G displays its negative 
immunomodulatory effects severalfold on primary and secondary immune reactions: i) it 
directly interacts with alloreactive CD4 and CD8 cytotoxic T cells, ii) it prevents efficient 
antigenic priming of antitumoral cytotoxic effector cells, and iii) efficiently inhibits 
alloreactive proliferation without inducing apoptosis. Since minor portions of HLA-G 
expressing cells within a population of HLA-G negative cells are sufficient to convey relevant 
immune regulatory effects, expression of this molecule may have major implications also in 
other sites of desirable and undesirable immune reactions. 
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VII. SD-208, a novel TGF-β receptor I kinase inhibitor, inhibits 
growth and invasiveness and enhances immunogenicity of 
murine and human glioma cells in vitro and in vivo 
 
A related manuscript has been accepted by Cabcer Research. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This project was a collaborative effort of Scios Inc., Fremont, CA and our laboratory. 
Scios scientists (Ramona Almirez, Ruban Mangadu, Yu-Wang Liu, Alison Murphy, 
Darren H. Wong and Linda S. Higgins) developed the drug and characterized it for 
receptor kinase specificity and bioavailability. In our laboratory, most experiments were 
carried out by Dr. Martin Uhl who is also the first author of a submitted manuscript 
based on this project. Dr. Markus Weiler performed the migration studies, Dipl.-
Biochem. Steffen Aulwurm helped with the animal experiments and functional 
immunological assays. My contribution involved experiments on TGF-β signal 
transduction in glioma and primary immune effector cells, including phosphorylation-
specific immunoblotting and reporter gene assays. 
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Introduction 
 
The cytokine TGF-β, by virtue of its immunosuppressive and promigratory properties, 
has become a major target for the experimental treatment of human malignant gliomas 
(155). Experimental anti-TGF-β strategies including antisense approaches (377), gene 
transfer of TGF-β antagonists such as decorin (378), inhibition of TGF-β-processing 
proteases of the furin family (292) or drugs such as tranilast (379) have already shown 
that the specific deficits observed in the cellular ex vivo immune responses of glioma 
patients (294) may be relieved by antagonizing TGF-β signalling. Unlike other 
immunosuppressive molecules expressed by gliomas, which include prostaglandins 
(380), IL-10 (381), CD70 (261) and HLA-G (382), TGF-β also assumes a critical role in 
migration and invasion of glioma cells (383). This study investigates a novel therapeutic 
principle of TGF-β antagonism in malignant glioma, defined by SD-208, a 
pharmacological agent which blocks TGF-βRI signalling. Given the poor results 
obtained in glioma patients with the standard treatment of surgery, radiotherapy and 
nitrosourea-based chemotherapy (6), an orally available inhibitor of TGF-β mediated 
immunosuppression, migration and invasion could significantly improve the clinical 
management of gliomas. 
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Materials and Methods 
 
Materials and cell lines. PHA was from Biochrom (Berlin, Germany). [Methyl-3H] thymidine 
was obtained from Amersham (Braunschweig, Germany). 51Cr was purchased from New 
England Nuclear (Boston, MA). Human recombinant TGF-β1, TGF-β2 and mouse IL-2 were 
obtained from Peprotech (London, UK). Neutralizing pan-anti-TGF-β antibody was 
purchased from R & D (Wiesbaden, Germany). The human malignant glioma cell line LN-
308 was kindly provided by N. de Tribolet (Lausanne, Switzerland). The murine glioma line 
SMA-560 was a kind gift of D.D. Bigner (Durham, NC). CCL64 mink lung epithelial cells 
were obtained from the American Type Culture Collection (Rockville, MD). 
 
Cell culture. The glioma cells and CCL64 cells were maintained in DMEM supplemented 
with 2 mM L-glutamine (Gibco Life Technologies, Paisley, UK), 10% FCS (Biochrom) and 
penicillin (100 IU/ml)/streptomycin (100 µg/ml) (Gibco). Growth and viability of the glioma 
cells were examined by crystal violet staining, LDH release (Roche, Mannheim, Germany) 
and trypan blue dye exclusion assays. For crystal violet staining, the cell culture medium was 
removed and surviving cells were stained with 0.5% crystal violet in 20% methanol for 10 
min. The plates were washed extensively under running tap water, air-dried and optical 
density values were read in an ELISA reader at 550 nm wave length. Human PBMC were 
isolated from healthy donors by density gradient centrifugation (Biocoll, Biochrom). 
Monocytes were depleted by adhesion and differential centrifugation to obtain PBL. To obtain 
purified T cells, PBMC were depleted of B cells and monocytes using LymphoKwik TTM 
reagent (One Lambda Inc., Canoga Park, CA). The purity of this population was > 97%, as 
verified by flow cytometry using anti-human CD3-PE antibody (Becton Dickinson, 
Heidelberg, Germany). Human polyclonal NK cell populations were obtained by culturing 
PBL on irradiated RPMI 8866 feeder cells for 10 days (384). Murine NK cells were prepared 
from splenocytes from VM/Dk mice by positive selection using DX5 monoclonal antibody-
coupled magnetic beads with the corresponding column system (Miltenyi Biotech, Bergisch 
Gladbach, Germany) and cultured with mouse IL-2 (5000 U/ml) for at least 10 days before 
use. The human polyclonal NK cell cultures, PBL, T cells and mouse NK cells were grown in 
RPMI 1640 supplemented with 10% FCS, 2 mM L-glutamine, 1 mM sodium pyruvate, 50 
µM β-mercaptoethanol and penicillin (100 IU/ml)/streptomycin (100 µg/ml). 
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Characterization of SD-208. SD-208 is a TGF-βRI kinase inhibitor developed by Scios Inc. 
(Fremont, CA). To assess the specificity of SD-208 for TGF-βRI, various kinase activities 
were assayed by measuring the incorporation of radiolabelled ATP into a peptide or protein 
substrate. The reactions were performed in 96 well plates and included the relevant kinase, 
substrate, ATP and appropriate co-factors. The reactions were incubated and then stopped by 
the addition of phosphoric acid. Substrate was captured onto a phosphocellulose filter which 
was washed free of unreacted ATP. The counts incorporated were determined by counting on 
a microplate scintillation counter (TopCount, Perkin Elmer Corporation, Boston, MA). The 
ability of SD-208 to inhibit the respective kinase was determined by comparing counts 
incorporated in the presence of compound to those incorporated in the absence of compound. 
 
TGF-β bioassay. The levels of bioactive TGF-β were determined using the CCL64 bioassay. 
Briefly, 104 CCL64 cells were adhered to 96 well plates for 24 h and then exposed to 
recombinant TGF-β1, TGF-β2 or glioma cell culture SN diluted in complete medium for 72 h. 
Growth was assessed by crystal violet staining at 72 h. Glioma cell SN were harvested from 
subconfluent cultures maintained for 48 h in serum-free medium and heat-treated (5 min, 
85°C) to activate latent TGF-β (292). 
 
TGF-β reporter assays. Intracellular TGF-β signalling was assessed by reporter assays using 
pGL2 3TP-Luc (385) or pGL3 SBE-2 Luc (386) reporter gene plasmids kindly provided by J. 
Massagué (New York, NY) and B. Vogelstein (Baltimore, MD). The pGL2 3TP-Luc 
construct contains a synthetic promoter composed of a TGF-β-responsive plasminogen 
activator inhibitor 1 promoter fragment inserted downstream of three phorbol ester-responsive 
elements. The pGL3 SBE-2-Luc reporter contains two copies of the Smad-binding element 
GTCTAGAC. LN-308 and SMA560 cells were transfected using FuGene (Roche). At 24 h 
after transfection the cells were pretreated in serum containing medium with SD-208 for 12 h 
(1 µM). TGF-β1 (5 ng/ml) was then added for another 16 h. The cells were lysed and 
transferred to a LumiNuncTM plate (Nunc, Roskilde, Denmark) and luminescence was 
measured in a LumimatPlus (EG&G Berthold, Pforzheim, Germany), using Luciferase assay 
substrate (Promega, Mannheim, Germany). For T cell assays, 5 x 106 freshly isolated PBL 
were co-transfected with 4.5 µg pGL2-3TP-Luc or pGL3-SBE-2 Luc reporter gene plasmid 
and 0.5 µg pRL-CMV (Promega), using the NucleofectorTM device and the cell type-specific 
human T cell nucleofectorTM kit (Amaxa, Cologne, Germany). IL-2 (50 U/ml) was added 4 h 
after nucleofection and the cells were pretreated with SD-208 for 1 h before TGF-β1 (5 ng/ml) 
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was added for another 16 h. The respective activities of firefly and renilla reniformis 
luciferase were determined sequentially using the firelite dual luminescence reporter gene 
assay (Perkin-Elmer, Rodgau-Jügesheim, Germany). Counts obtained from the measurement 
of firefly luciferase were normalized with respect to pRL-CMV. NK cell assays were 
performed accordingly, using the NK cell nucleofectorTM kit (Amaxa). 
 
Immunoblot analysis. p-Smad2 levels in glioma cells were analyzed by immunoblot using 20 
µg protein per lane on 12% SDS polyacrylamide gels. PBMC were analysed using 120 µg per 
lane and 10% gels. After transfer to a polyvinylidene difluoride membrane (Amersham), the 
blots were blocked in PBS containing 5% skim milk and 0.05% Tween 20, and incubated 
overnight at 4°C with p-Smad2 antibody (2 µg/ml) (Cell Signalling Technology Inc., Beverly, 
MA). Visualization of protein bands was accomplished using horseradish peroxidase-coupled 
secondary antibody (Sigma, Taufkirchen, Germany) and enhanced chemiluminescence 
(Amersham). Total Smad2/3 levels were assessed using a specific Smad2/3 antibody 
(1 µg/ml) (Becton Dickinson). 
 
Matrigel invasion assay (Boyden Chamber). Invasion of glioma cells was measured by the 
invasion of 10,000 cells through Matrigel-coated transwell inserts (Becton Dickinson). 
Briefly, transwell inserts with 8 µm pore size were coated with Matrigel and preincubated 
SMA-560 cells were applied to the upper wells and allowed to transmigrate through the 
membrane towards conditioned medium derived from NIH-3T3 fibroblasts which was added 
to the lower wells. Migrated cells on the lower side of the membrane were fixed, stained in 
toluidine blue solution (Sigma) and counted in five microscopic high power fields using a 
microgrid. 
 
Spheroid collagen invasion assay. Multicellular SMA-560 glioma cell spheroids were 
cultured in 25 cm2 culture flasks base-coated with 1% Noble Agar (Difco Laboratories, 
Detroit, MI). Briefly, 4 x 105 cells were suspended in 10 ml medium, seeded onto 1% agar 
plates and cultured until spheroids had formed. Spheroids of about 200 µm diameter were 
selected for the experiments. Preincubated spheroids were seeded into collagen I and 
fibronectin containing wells. Spheroid radius, which is determined by the invasion of single 
cells into the matrix (387), was analyzed by morphometry using the MCID digitalization 
system (IMAGING Research Inc., Ontario, Canada) after 24, 48 and 72 h. 
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Lysis assay. HLA-A2-mismatched PBL or T cells (107/25 cm2 flask) were cocultured with 106 
irradiated (30 Gy) LN-308 glioma cells for 5 days. Glioma cell targets were labeled using 51Cr 
(50 µCi, 90 min) and incubated (104/well) with effector PBL harvested from the cocultures at 
E:T ratios of 100:1 to 3:1. The maximum 51Cr release was determined by addition of NP40 
(1%) (Sigma). After 4 h the SN were transferred to a Luma-Plate TM-96 (Packard, Dreieich, 
Germany) and measured. The percentage of 51Cr release was calculated as follows: 100 x 
[experimental release – spontaneous release]/[maximum release – spontaneous release].  
 
Cytokine release. IFN-γ, TNF-α and IL-10 release by immune effector cells was assessed by 
Elispot assay in multiscreen-HA 96 well plates (Millipore, Eschborn, Germany) coated with 
corresponding anti-human capture antibodies (Becton Dickinson). Briefly, 5 x 104 glioma 
cells were cocultured for 24 h with 105, 2.5 x 105 or 5 x 105 HLA-A2-mismatched, 
prestimulated (5 days) PBL. The cells were removed using double-distilled water and 
captured cytokines were visualized using biotinylated antibodies and streptavidin-alkaline 
phosphatase (Becton Dickinson). Spots were counted on an Elispot reader system (AID, 
Straßberg, Germany). 
 
p-Smad2/3 ELISA. Male mice (BALB/c, Jackson Labs, BarHarbor, ME) were studied in 6 
groups of 8 animals each. For each drug group, a single volume of SD-208 was administered 
by oral gavage 1 h prior to dosing with TGF-β1 (R&D Systems, Minneapolis, MN) diluted in 
100 µl 0.1% BSA / 4 mM HCL/PBS by i.v. injection. The mice were sacrificed by cervical 
dislocation 1 h later. Tissues were removed and lysed in 20 mM Tris, pH 7.5, containing 1 
mM EDTA, 0.5% TX-100, 0.5% NP-40, 150 mM NaCl and 1x protease inhibitor cocktail 
(Roche) and 1x phosphatase inhibitor cocktail set II (Calbiochem, San Diego, CA). Tissue 
was homogenized using an Ultra-turrax T8 (Reyom Instruments, Brabcova, Czech Republic). 
Tissue homogenates were clarified by centrifugation and the supernatant fraction was 
collected. Protein concentrations were determined with a BCA protein assay (Pierce, 
Rockford, IL). The levels of p-Smad were determined by sandwich ELISA. Briefly, 96 well 
ELISA plates were coated with an anti-Smad2/3 monoclonal antibody (100 ng/well, Becton 
Dickinson) for 18 h at 4°C. Excess antibody was removed and the wells were treated with 
blocking buffer (0.3% BSA/PBS) for 2 h at room temperature. Tissue lysates (125-150 µg 
total protein) were added to each well and incubated overnight at 4°C. Wells were rinsed 
before adding a polyclonal anti-p-Smad 2/3 antiserum diluted in 2% BSA/0.5% Tween-
20/PBS. Following a 2 h incubation at room temperature, the wells were washed and 
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secondary antibody was applied (horseradish peroxidase-conjugated goat-anti-rabbit IgG, 
Southern Biotech, Birmingham, AL). After 1 h the wells were developed with TMB (Sigma). 
The plate was incubated 5-30 min before the reaction was stopped with 0.5 N H2SO4 and read 
at 450 nm in a SpectraMax 250 plate reader (Molecular Devices, Sunnyvale, CA). 
 
Survival studies in vivo. VM/Dk mice were purchased from the TSE Research Centre 
(Berkshire, UK). Mice of 6-12 weeks of age were used for the survival experiments. The 
experiments were performed according to the German animal protection law. Groups of 8 
mice were anesthesized before all intracranial procedures and placed in a stereotaxic fixation 
device (Stoelting, Wood Dale, IL). A burr hole was drilled in the skull 2 mm lateral to the 
bregma. The needle of a Hamilton syringe (Hamilton, Darmstadt, Germany) was introduced 
to a depth of 3 mm. Five x 103 SMA-560 cells (388) resuspended in a volume of 2 µl PBS 
were injected into the right striatum. Three days later the mice were allowed to drink SD-208 
at 1 mg/ml in deionized water. The mice were observed daily and, in the survival 
experiments, sacrificed when developing neurological symptoms. 
 
Statistical analysis. The experiments were usually performed at least three times with similar 
results. Significance was tested by Student’s t-test. P values are derived from two-tailed t-
tests. 
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Results 
 
SD-208 is a functional TGF-β1 and TGF-β2 antagonist in vitro. 
 
The initial characterization of SD-208 in cell-free assays led to its identification as a 
potent inhibitor of TGF-βRI. SD-208 exhibited an in vitro specificity for TGF-βRI 
kinase of >100-fold compared with TGF-βRII kinase and at least 20-fold over members 
of a panel of related protein kinases (Table I).  
 
Table 7.1. Specificity of SD-208 for TGF-βRI kinase activity1 
 
TGF-βRI  0.048
TGF-βRII > 50
Epidermal growth factor receptor 68%
mutant Drosophila p38-α 0.867
p38 kinase γ > 50
c-jun N-terminal kinase > 50
Extracellular signal-regulated kinase-2 > 50
Mitogen-activated protein kinase-activated protein-2 87%
Mitogen-activated protein kinase kinase 6 > 50
Protein kinases A and C > 50
Protein kinase D 70%
 
1Data are expressed as EC50 [µM] or percentage inhibition at 5 µM SD-208 in cell-free 
systems in vitro 
 
 
CCL64 mink lung epithelial cells were sensitive to the growth inhibitory effects of 
human TGF-β1 and TGF-β2 at EC50 concentrations of 0.5 ng/ml. The inhibitory effects 
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of recombinant TGF-β as well as those of TGF-β-containing glioma cell SN were 
abrogated by specific TGF-β antibodies (11) (data not shown). The CCL64 bioassay 
was used here to verify the TGF-β-antagonistic properties of SD-208. SD-208 rescued 
the inhibition of growth mediated by TGF-β1 or TGF-β2 (10 ng/ml) or diluted SMA-560 
(not shown) or LN-308 glioma cell SN in a concentration-dependent manner, with an 
EC50 concentration of 0.1 µM (Fig. 7.1). When these bioassays were performed in the 
absence of serum in the CCL64 medium, the EC50 for SD-208 was 0.03 µM (data not 
shown), corresponding to the data in Table I. 
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Fig. 7.1. Prevention of the growth inhibitory effects of recombinant and glioma-derived TGF-β1 and
TGF-β2 by SD-208. CCL64 cells were exposed to human recombinant TGF-β1 (filled triangles), TGF-β2
(filled squares) (10 ng/ml) or heat-activated glioma cell SN (1:2) (open rhomboids) in the absence or
presence of increasing concentrations of SD-208 for 72 h. Cell density was assessed by crystal violet assay
(mean and SD, n=3).D-208 abrogates autocrine TGF-β-dependent signal transduction in glioma cells. 
e next examined the biological effects of SD-208 on murine and human glioma cells in 
itro. The concentrations required to block the growth inhibitory effects of TGF-β in the 
CL64 bioassay had no effect on the proliferation of either cell line. SD-208 did not reduce 
roliferation assessed by [methyl-3H] thymidine incorporation or viability assessed by LDH 
elease or trypan blue dye exclusion assays at concentrations up to 1 µM for 72 h (data not 
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shown). The inhibition of signalling transduced by endogenous or exogenous TGF-β was 
ascertained by demonstrating that SD-208 interfered with Smad2 phosphorylation without 
altering total cellular Smad2/3 levels (Fig. 7.2 A). Similarly, two different reporter assays 
revealed a strong inhibition of TGF-β signalling when the glioma cells were treated with SD-
208 (Fig. 7.2 B). 
 
 
 
Fig. 7.2. Abrogation of TGF-β 
signaling in glioma cells by 
SDD-208. A. Lysates from 
untreated glioma cells or cells 
preexposed to SD-208 (1 µM) 
for 24 h or exposed to TGF-β2 
(5 ng/ml) for 1 h or both were 
assessed for the levels of p-
Smad2 or total Smad2/3. Note 
that the antibodies are specific 
for p-Smad2 and total Smad 2 
and 3, respectively. B. The 
cells were untreated (open bars) 
or treated with TGF-β1 (5 
ng/ml, filled bars) for 16 h in 
the absence or presence of SD-
208 at 0.1 or 1 µM and 
assessed for TGF-β reporter 
activity in serum-containing 
medium. 
 
 
 
 
SD-208 inhibits constitutive and TGF-β-evoked migration and invasion.  
We next examined the biological effects of SD-208 on SMA-560 cells in two independent 
migration and invasion paradigms in vitro. SD-208 reduced the invasion of glioma cells from 
a spheroid into a three dimensional collagen I gel and also the transmigration of glioma cells 
in a Boyden chamber assay. Moreover, the proinvasive effect of exogenous TGF-β was 
neutralized by SD-208 in either assay (Fig. 7.3 A,B). 
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Fig. 7.3. Inhibition of constitutive and TGF-β-induced invasion of glioma cells by SD-208. A. 
SMA-560 spheroids were untreated or treated with SD-208 (1 µM), TGF-β2 (5 ng/ml) or both for 24 
h prior to placement into the collagen I gel and during the experiment and spheroid diameter was 
determined every 24 h. Data are expressed as mean radius in percent of the spheroid radius at 0 h set 
to 100% (n=3, *p<0.05, t-test, effect of SD-208; +p<0.05, t-test, effect of TGF-β2). The concentration 
of DMSO required to dissolve SD-208 had no effect in this assay. B. Invasion was analyzed with 
matrigel-coated membranes in a Boyden chemotaxis chamber assay applying 10,000 SMA 560 cells, 
control-treated or treated with SD-208 (1 µM), TGF-β2 (5 ng/ml) or both for 24 h prior to and during 
the experiment, in the upper chamber. Invaded cells were counted at 24 h. Data are expressed as 
mean cell counts (n=3, *p<0.05, t-test, effect of SD-208, +p<0.05, t-test, effect of TGF-β2). 
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SD-208 enhances allogeneic immune responses to glioma cells in vitro.  
Consistent with the effects of SD-208 on TGF-β-mediated signalling in glioma cells (Fig. 7.2 
A,B), immunoblot analysis and reporter assays also revealed a strong resistance to TGF-β 
signalling in the presence of SD-208 in immune cells (Fig. 7.4 A,B,C).  
 
 
 
 
 
 
 
 
Fig. 7.4. SD-208 inhibits TGF-β signaling in immune effector cells. A. PBMC were treated with 
TGF-β1 (5 ng/ml) in the absence or presence of SD-208 (1 µM) for 60 min and then subjected to 
immunoblot analysis for Smad2 phosphorylation (upper panel). Total Smad2 expression was 
assessed as a loading control (lower panel). B and C. PBL (B) or NK cells (C) were untreated or 
pretreated with SD-208 (0.1, 1 µM) for 1 h and then untreated (open bars) or treated with TGF-β1 (5 
ng/ml) (filled bars) for 16 h and subjected to the firelite reporter assay. 
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The next series of experiments was designed to examine whether SD-208 restores  allogeneic 
immune cell responses to cultured human glioma cells. When HLA-A2-mismatched PBL or 
purified T cells were cocultured with irradiated glioma cells in the absence or presence of SD-
208, their lytic activity in a subsequent 4 h 51Cr release assay was significantly enhanced by a 
preexposure to SD-208 (Fig. 7.5). Similar effects were obtained using neutralizing TGF-β 
antibodies (10 µg/ml, added every two days) (data not shown). 
 
 
 
 
 
 
Fig. 7.5. Modulation of alloreactive lysis of glioma cells by SD-208. The lytic activity of PBL
(squares) or purified T cells (triangles) preincubated with irradiated LN-308 cells in the absence (open
symbols) or presence (filled symbols) of SD-208 (1 µM) was determined in 51Cr release assays using
LN-308 cells as targets (+p<0.05, t-test, effect of SD-208 on PBL; *p<0.05, t-test, effect of SD-208 on T
cells). 
 
 
The release of IFN-γ by HLA-mismatched PBL was strongly inhibited when the priming had 
taken place in the presence of glioma cells. SD-208 restored the IFN-γ release to levels 
comparable to PBL pre-cultured in the absence of LN-308 cells (Fig. 7.6A). Similar results 
were obtained for TNF-α (Fig. 7.6B). In contrast, IL-10 release was stimulated after 
coculturing with LN-308 cells, and SD-208 reduced the release of IL-10 by immune effector 
cells generated both from unstimulated and glioma cell-primed cultures (Fig. 7.6C).  
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Fig. 7.6. Modulation of allogeneic anti-glioma immune responses by SD-208. PBL were cultured
in the absence (left) or presence (right) of irradiated LN-308 cells for 5 days. The cultures contained
SD-208 (1 µM) (filled bars) or not (open bars). Subsequently these effector cells were cocultured for
24 h with fresh non-irradiated LN-308 cells in the absence of SD-208. The release of IFN-γ (A),
TNF-α (B) or IL-10 (C) was assessed by Elispot assay. Data are expressed as cytokine-producing
cells per 5 x 105 effector cells (n=3, *p<0.05, t-test, effect of SD-208). 
 
The lytic activity of polyclonal NK cells against LN-308 targets was inhibited by exogenous 
TGF-β, and TGF-β-mediated inhibition was relieved by SD-208 (Fig. 7.7A). Similarly, LN-
308 SN inhibited NK cell activity, and this inhibition was also blocked by SD-208 (Fig. 7.7B) 
or neutralizing TGF-β antibodies (data not shown). Note that while the absolute lytical 
activity was donor-specific, the effect of SD-208 was consistent through all experiments. 
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thaFig. 7.7. Modulation of NK cell-mediated  lysis of glioma cells by SD-208. Polyclonal NK cell 
cultures were exposed to TGF-β1 (5 ng/ml) (A) or diluted (1:4) glioma cell SN (B) without or 
with SD-208 (1 µM) for 48 h and subsequently used as effectors in 51Cr release assays using LN-
308 cells as targets. SD-208 alone or TGF-β antibody alone had no effect on NK cell activity in 
these assays (data not shown, E: +p<0.05, t-test, effect of TGF-β; *p<0.05, t-test, effect of SD-
208; F: +p<0.05, t-test, effect of glioma SN; *p<0.05, t-test, effect of SD-208). -208 prolongs the survival of SMA-560 intracranial experimental glioma-bearing 
geneic mice.  
 verify the bioavailability of orally administered SD-208, inhibition of TGF-β-dependent in 
o phosphorylation of Smad2/3 by SD-208 was ascertained in spleen and brain (Fig. 7.8 
B). Exogenous TGF-β was a more potent inducer of Smad2/3 phosphorylation in spleen 
n brain, but that SD-208 was an equally effective antagonist of TGF-β in both tissues. 
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Fig. 7.8. SD-208 blocks TGF-β signaling in the brain. The animals were untreated (open bars) or
treated with 150 ng TGF-β1 i.v. (filled bars) at 1 h after oral exposure to SD-208 at increasing doses.
The mice were sacrificed 1 h later and analyzed for Smad2/3 phosphorylation by ELISA in spleen
(A) or brain (B) (*p<0.01, Bonferroni´s test, effect of SD-208 on TGF-β). 
The therapeutic effects of SD-208 administered via the drinking water (1 mg/ml) were 
assessed in the syngeneic SMA-560 mouse glioma paradigm. The development of 
neurological symptoms was delayed by SD-208-treated mice and the mean survival was 
prolonged to 25.1±6.5 days (median 23) compared with 18.6±2.1 days (median 18) in vehicle-
treated animals (Fig. 7.9) (p=0.004, t-test). The survival rate at 30 days was 29% in SD-208-
treated animals, but 0% in control animals. Preliminary evidence also indicated that SD-208 
modulated the immune response of the glioma-bearing animals. Elispot assays for IFN-γ 
release by splenocytes harvested at day 7 after the initiation of SD-208 treatment revealed an 
increase over background in 3 of 5 SD-208-treated animals, but only in 1 of 5 control animals 
(data not shown). 
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 Fig. 7.9. SD-208 blocks inhibits the growth of syngeneic SMA-560 experimental gliomas in vivo. 
VM/Dk mice received an intracranial injection of 5 x 103 SMA-560 cells. Three days later SD-208 
treatment was initiated, and survival was monitored. 
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Discussion 
 
Antagonizing the biological effects of TGF-β has become a very attractive experimental 
strategy to combat various types of cancer including malignant gliomas. Current 
rationales for anti-TGF-β strategies include its putative role in migration and invasion 
(383), metastasis (389) and tumour-associated immunosuppression (155, 390). All of 
the TGF-β-based therapeutic approaches evaluated in experimental gliomas so far 
appear to have limitations with regard to their transfer into the clinic. Antisense 
oligonucleotides pose severe problems in terms of delivery to the desired site of action. 
The same applies to gene therapy strategies based e.g. on the transfer of the decorin 
gene (378). Inhibition of furin-like proteases aiming at limiting TGF-β bioactivity at the 
level of TGF-β processing (292) may not be achieved with acceptable specificity at 
present since a whole variety of molecules require processing by such enzymes (391). 
More specificity may result from the use of soluble TGF-β receptor fragments which act 
to scavenge bioactive TGF-β before it may reach the target cell population (389, 392). 
However, this approach may find its limits in the complex pathways of storage and 
activation of TGF-β. These considerations suggest that specific small molecules 
designed to protect cells from the actions of TGF-β at the level of receptor-dependent 
intracellular signal transduction are a particularly promising alternative for antagonizing 
TGF-β. 
Here the activity of one such candidate agent, SD-208, against murine and human 
glioma cells is characterized in vitro and in vivo. Human LN-308 cells were chosen 
because they are paradigmatic for their prominent TGF-β synthesis (292, 393). SMA-
560 cells transplanted in syngeneic VM/Dk mice represent the best model for the 
immunotherapy of rodent gliomas (388). The data outlined in this section show that SD-
208 is a potent TGF-βRI kinase inhibitor (Table I) which blocks the biological effects of 
TGF-β1 and TGF-β2 as well as glioma cell SN in the CCL64 mink lung epithelial assay 
(Fig. 7.1). Since SD-208 did not modulate glioma cell proliferation at concentrations up 
to 1 µM (data not shown), a negative growth regulatory effect of TGF-β on SMA-560 
cells was not confirmed (394). Smad2 phosphorylation is induced by TGF-β in a SD-
208-sensitive manner (Fig. 7.2A), indicating that TGF-β signalling is not abrogated 
constitutively in glioma cells, but may not play a role in the modulation of glioma cell 
proliferation. Moreover, as expected (383), the antagonism of autocrine and paracrine 
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signalling by TGF-β in SD-208-treated glioma cells, as confirmed by reporter assay 
(Fig. 7.2B) resulted in a potent inhibition of migration and invasion (Fig. 7.3) (383). 
We then focused on the desired immune modulatory effect of SD-208 which were 
expected to result in an enhanced immunogenicity of glioma cells as a consequence of 
reduced TGF-β bioactivity. As predicted, human PBL and purified T cells developed 
enhanced lytic activity against LN-308 glioma cell targets when prestimulated with 
glioma cells in the presence of SD-208 (Fig. 7.5). This was paralleled by an enhanced 
release of proinflammatory cytokines such as IFN-γ and TNF-α and a reduced release 
of the immunosuppressive cytokine IL-10 in SD-208-treated cells (Fig. 7.6). Similarly 
SD-208 restored the lytic activity of polyclonal NK cell cultures cocultured with TGF-β 
or LN-308 SN (Fig. 7.7). 
The strong reduction of Smad phosphorylation in the unlesioned mouse brain indicates 
that SD-208 may reach sufficient levels beyond the intact blood brain barrier to 
counteract the biological effects of tumour-derived TGF-β (Fig. 7.8). Accordingly, SD-
208 prolonged the median survival of SMA-560 glioma-bearing mice significantly (Fig. 
7.9). No dose-limiting toxicity was reached in these experiments, but higher doses could 
not be administered by the drinking water because of poor solubility of SD-208, 
suggesting that the therapeutic effect of SD-208 or related agents might even be 
improved in that glioma model. The therapeutic effect of SD-208 might be mediated by 
the inhibition of glioma cell migration and invasion (383) (Fig. 7.3) or the promotion of 
anti-glioma immune responses (155) (Fig. 7.5 – 7.7). 
The present data strongly suggest a role for SD-208 or related molecules in the 
treatment of gliomas. Such a systemic treatment with TGF-βRI kinase inhibitors might 
well be combined with local approaches to limit the bioavailability of TGF-β, e.g., 
TGF-β antisense oligonucleotides which are already evaluated clinically. 
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VIII. Transforming growth factor-β suppresses NKG2D-mediated anti-tumour immune 
responses and enhances tumour migration and invasiveness 
 
A related manuscript has been accepted by Cancer Research. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This project is based on previous work from my colleague Dr. Manuel Friese (131) who also 
carried out most of the experiments. Dr. Alexander Steinle generated and supplied MICA and 
MICB-specific antibodies, Dr. Markus Weiler helped in characterizing the effect of TGF-β 
suppression on migration and invasiveness of glioma cells and Dr. Günter Eisele analyzed the 
expression of matrix metalloproteinases and UL-16 binding proteins (ULBP) in these cells. 
Yasmin Breithardt and Brigitte Frank provided expert technical assistance. I designed and 
cloned the constructs for the siRNA-mediated knock-down of TGF-β1 and TGF-β2, generated 
LNT-229 TGF-βsi glioma cells, characterized together with Manuel Friese and Günter Eisele 
the resulting immunological effects and was involved in the overall conception of the project. 
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Introduction 
 
NKG2D is a C-type lectin-like homodimeric receptor, first identified as activatory receptor on 
natural killer (NK) cells where it mediates responses to stress-induced ligands (94). Further, 
NKG2D has been shown to exert additional roles in innate immunity by activating 
macrophages (395) and γδ T cells (396), and in adaptive immunity by providing costimulatory 
signals to CD8+ αβ T cells (131, 397). NKG2D interacts with ligands that are not 
constitutively, but inducibly expressed by cell stress. In humans these are MHC class I-chain 
related molecules A (MICA) and MICB (398-401) and UL16-binding proteins (ULBP) 1, 2, 
3, and 4 (95, 402). The human NKG2D ligands (NKG2DL) are well conserved within 
families (~55% identity among the ULBPs and ~84% between MICA and MICB alleles) and 
more distantly related between families in terms of sequence and structure (23-27% identical). 
The various NKG2DL have distinct patterns of expression, indicating that they cannot be 
considered simply redundant in function. Generally normal cells in adults show absent or low 
level NKG2DL expression, with the exception of intestinal epithelia, where NKG2DL may be 
induced as a consequence of stimulation by the neighbouring bacterial flora (399). In 
pathological conditions, however, NKG2DL expression is often upregulated, as described for 
epithelial tumours, gliomas and cells infected by HCMV or Mycobacterium tuberculosis (131, 
396, 397, 399, 403-405). The molecular mechanisms underlying this induction of NKG2DL 
are still unclear. Heat-shock transcription elements have been implicated in the promoters of 
the MIC genes (399), however, neither MIC nor ULBP promoter regions have been 
characterized to date.  
Engagement of NKG2D can initiate perforin-mediated cytolytic responses (406) by providing 
an activatory signal to NK cells and a co-stimulatory signal to antigen-specific T cells. 
NKG2D ligands (NKG2DL) are therefore induced self ligands and represent molecular 
markers which flag stressed, transformed, or infected cells for killing by NK and CD8+ T cells 
(89). Thus, NKG2D is a potent mediator of antiviral and antitumour immune surveillance 
(131, 407-409). 
Unfortunately, since gliomas grow progressively and eventually kill their host, the immune 
system clearly fails to mount an effective immune response against these tumours. Evasion 
from NKG2D-mediated tumour immunosurveillance has been attributed to proteolytical 
shedding of MIC molecules (410, 411). The binding of soluble MIC (sMIC) has been reported 
to induce the endocytosis and degradation of cell surface NKG2D, causing impairment of the 
responsiveness of tumour antigen-specific effector T cells (410). This systemic immune 
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deficiency is associated with circulating tumour-derived sMICA encompassing the three 
extracellular domains which is released by tumour cells at high levels into the sera of cancer 
patients (410-412). The release of MICA from tumour cells is blocked by the inhibition of 
MMP, resulting in the accumulation of MICA at the cell surface (411). MMP are proteolytic 
enzymes which shape the cellular microenvironment. Compared to normal tissue, their 
expression and activation is increased in almost all human cancers (413). Particularly MMP-2 
and -9 are highly expressed in human gliomas (414).  
This high expression of MMP-2 and -9 in glioma cells has been found to depend on TGF-β 
(415). Some aspects of the immune-modulatory properties of TGF-β have already been 
described in the previous chapter and are well-documented in the literature (155). TGF-β 
inhibits the maturation and antigen presentation by dendritic cells as well as the activation of 
T and NK cells (416). Accordingly, TGF-β production is associated with the growth and 
malignant progression of a large variety of tumours (292, 417, 418). A novel aspect of TGF-β 
as a central mediator of immune evasion by glioma cells is its influence on NKG2D-mediated 
antitumour responses. The data presented here demonstrate that TGF-β promotes immune 
escape and motility of human glioma cells by (i) down-regulating NKG2D expression in 
CD8+ T and NK cells, (ii) (selectively) down-regulating NKG2DL gene expression in glioma 
cells, and (iii) mediating loss of cell surface MICA expression and (iv) enhanced motility, 
both in a MMP-dependent manner, in glioma cells. 
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Materials and Methods 
 
Patient characteristics. PBMC were from patients with glioblastoma (5 males, 2 females, 
median age: 56 years, range: 48-71 years) who had not received radiotherapy, chemotherapy 
or glucocorticoids for 12 weeks. The glioma patients were compared with a group of 17 age- 
and sex-matched healthy donors (controls) without neurological or any other known disease. 
CSF was obtained from glioma patients or patients with other neurological diseases as part of 
the routine diagnostic work-up. The study was performed according to a protocol approved by 
the University of Tübingen Medical School Ethics Committee (#131/99). 
 
Monoclonal antibodies and flow cytometry. Neutralizing pan-anti-TGF-β1,2,3 mAb (1D11, 
IgG1) was from R&D Systems (Wiesbaden, Germany). The following mAbs were used for the 
assessment of cell surface expression or the blocking of NKG2D, NKG2DL, CD3 and CD56: 
M585 IgG1 anti-NKG2D (kindly provided by Amgen, Thousand Oaks, CA), MAB 139 IgG1 
anti-NKG2D (R&D Systems, Wiesbaden, Germany), BAMO1 IgG1 anti-MICA/B, BAMO3 
IgG1 anti-MICA/B, AMO1 IgG1 anti-MICA, BMO2 IgG1 anti-MICB, AUMO1 IgG1 anti-
ULBP1, BUMO1 IgG1 anti-ULBP2, CUMO1 IgM anti-ULBP3 (405), HIT3a IgG2a anti-CD3-
FITC (BD Pharmingen, Heidelberg, Germany), HIT8a IgG1 anti-CD8-PE (BD Pharmingen) 
and B159 IgG1 anti-CD56-PE (BD Pharmingen). Biotin-conjugated rabbit anti-mouse IgG 
(Dako, Hamburg, Germany), streptavidin-APC (BD Pharmingen) and PE-conjugated goat 
anti-mouse IgG (Sigma, Deisenhofen, Germany) were used for detection. Conjugated and 
unconjugated IgG1 and IgG2a isotype-matched mAbs were used as controls (BD Pharmingen). 
Staining for intracellular NKG2D was done after the cells had been fixed and permeabilized 
(Cytofix/Cytoperm Plus kit, BD Pharmingen). PBL, or glioma cells detached using Accutase 
(PAA, Wien, Austria), were preincubated in PBS with 2% BSA and incubated with the 
specific mAb or matched mouse Ig isotype (5 µg/ml) for 30 min on ice. Where specified, 
immune cells were acid-washed in 150 mM NaCl and 0.1% acetic acid to strip ligands from 
cell surface receptors (259). Specific binding was detected with the specific conjugate or by 
using a secondary conjugated antibody. Fluorescence was measured in a Becton Dickinson 
FACScalibur. Specific fluorescence indexes (SFI) were calculated by dividing mean 
fluorescence obtained with specific antibody by mean fluorescence obtained with control 
antibody. 
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Production of soluble murine NKG2D in insect cells. Recombinant soluble murine NKG2D 
lacking the amino-terminal cytoplasmic region and transmembrane domain was produced in 
Sf9 insect cells (Invitrogen, Karlsruhe, Germany) using the BAC-to-BAC system (Gibco Life 
Technologies, Paisley, UK). The expression construct included an amino-terminal 
FLAG/hexahistidine (401).  
 
Purification of PBL and isolation of NK and T cells. PBL were prepared by density gradient 
centrifugation (Biocoll, Biochrom KG, Berlin, Germany) and depletion of plastic-adherent 
monocytic cells. PBL were cultured on irradiated RPMI 8866 feeder cells (384) to obtain 
polyclonal NK cell populations. To further enrich NK cells, PBL were sorted by 
immunomagnetic depletion using Dynabeads (NK Cell Negative Isolation Kit, Dynal, Oslo, 
Norway). CD3-CD56+ cells were used for cytotoxicity assays. To obtain purified CD8+ T 
cells, fresh PBL were sorted by immunomagnetic CD8 MACS beads (Miltenyi Biotec, 
Bergisch Gladbach, Germany). 
 
MICA/B ELISA. Glioma cell SN generated in the absence of FCS were concentrated with the 
Centriplus centrifugal filter device YM-3 (3000 Da cut-off; Millipore, Eschborn, Germany). 
The mAb AMO1 and BAMO3 were used in a sandwich ELISA for sMICA, and the mAb 
BAMO1 and BMO2 for sMICB as described (412).  
 
Cell lines and transfectants. The human SV-FHAS astrocytic cell line was provided by D. 
Stanimirovic (Ottawa, Canada). The human malignant glioma cell lines were provided by Dr. 
N. de Tribolet (Lausanne, Switzerland). Unlike LN-229 cells grown in other laboratories, our 
LN-229 cell line still harbours wild-type p53 (224) and is therefore also referred to as LNT-
229 (T for Tübingen, since 03/2004). Primary glioblastoma cells were established from 
freshly resected tumours, cultured in monolayers and used between passages 4 and 9 (419). 
The cells were maintained in DMEM medium supplemented with 2 mM L-glutamine (Gibco 
Life Technologies, Paisley, UK), 10% FCS (Biochrom KG, Berlin, Germany) and penicillin 
(100 IU/ml)/streptomycin (100 µg/ml) (Gibco). NKL cells, kindly provided by M. J. 
Robertson (Indianapolis, IN) (420), and YAC-1 cells (ATCC, Rockville, MD) were grown in 
RPMI 1640 medium supplemented with 15% FCS, 2 mM L-glutamine, 1 mM sodium 
pyruvate and penicillin (100 IU/ml)/streptomycin (100 µg/ml). The MMP inhibitor o-
phenanthroline (oPA) was obtained from Sigma.  
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Adenoviral construct and transduction. The generation of adenoviruses encoding MICA has 
been described (131). 
 
TGF-β siRNA. The human TGF-β1-specific oligonucleotide sequences 
GATCCCCGACTATCGACATGGAGCTGttcaagagaCAGCTCCATGTCGATAGTCTTTTT
GGAAA and TCGATTTCCAAAAAGACTATCGACATGGAGCTGtctcttgaa 
CAGCTCCATGTCGATAGTCGGG and the TGF-β2-specific oligonucleotide sequences 
GATCCCCTGCCAACTTCTGTGCTGGAttcaagagaTCCAGCACAGAAGTTGGCATTTTT
GGAAA and TCGATTTCCAAAAATGCCAACTTCTGTGCTGGAtctcttgaa 
TCCAGCACAGAAGTTGGCAGGG were obtained from Metabion (Munich, Germany) and 
cloned into the pSUPER vector (421), generously provided by Dr. Reuven Agami 
(Amsterdam, NL). The TGF-β-specific parts of the sequence are depicted underlined. A 
puromycin resistance cassette was cloned into the pSUPER vector before cloning to obtain 
stable transfectants. LNT-229 cells were stably cotransfected using a five-fold excess of 
pSUPER-TGF-β1 over pSUPER-puro-TGF-β2, using FuGENE 6 (Roche, Mannheim, 
Germany). Control transfectants were generated by transfecting pSUPER-puro into LNT-229 
cells.  
 
Immunoblot. Cell culture SN generated in the absence of FCS were concentrated with the 
Centriplus centrifugal filter device YM-3 (3000 Da cut-off; Millipore, Eschborn, Germany). 
Cell lysates were prepared in 50 mM Tris-HCl (pH 8) containing 120 mM NaCl, 5 mM 
EDTA, 0.5% NP-40, 2 µg/ml aprotinin, 10 µg/ml leupeptin and 100 µg/ml PMSF. Aliquots of 
concentrated SN or cell lysates were electrophoresed on 8-12% SDS-PAGE gels under 
reducing conditions and transferred to nitrocellulose (Schleicher & Schuell, Dassel, 
Germany). The lysates and SN were assessed at 10 µg total protein per lane. Equal protein 
loading was ascertained by Ponceau S staining. After blocking nonspecific binding sites with 
5% (w/v) dried milk in PBS for 30 min, the filters were incubated with specific mAbs 
overnight at 4°C, washed and incubated with peroxidase-conjugated goat anti-rabbit or goat 
anti-mouse IgG (diluted 1:3000) (Santa Cruz Biotechnology, Santa Cruz, CA) for 3 h at 22°C. 
The mAbs BAMO1 anti-MICA/B, M585 anti-NKG2D, sc-146 goat anti-TGF-β1 (Santa Cruz 
Biotechnology, Santa Cruz, CA), sc-90 goat anti-TGF-β2 (Santa Cruz Biotechnology), Ab-3 
mouse anti-MMP-2 (Oncogene, San Diego, CA), Ab-7 mouse anti-MMP-9 (Oncogene) or 
113-5B7 mouse anti-MT1-MMP (Oncogene) were used at 1 µg/ml in PBS containing 0.05% 
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Tween 20 and 1.3% skim milk. Labelling was visualized using enhanced chemiluminescence 
(ECL, Amersham, Braunschweig, Germany).  
 
Zymography. The activities of MMP-2 and MMP-9 were analyzed using SDS-PAGE gels 
containing 0.1% gelatine (wt/vol) and 10% polyacrylamide (wt/vol) (Biorad, Munich, 
Germany). Coomassie brilliant blue staining and subsequent destaining with glacial acid 
results in decreased staining at the level of electrophoretic migration of MMP-2 and MMP-9. 
 
Real time PCR. Total RNA was prepared using RNAeasy (Quiagen, Hilden, Germany) and 
transcribed according to standard protocols. cDNA amplification was monitored using 
SYBRGreen chemistry on the ABI PRISM 7000 Sequence Detection System (Applied 
Biosystems, Weiterstadt, Germany). The conditions for all PCR reactions were: 40 cycles, 
95°C for 15 s and 60°C for 1 min, using the following specific primers (forward, reverse): 
18S: 5´-CGGCTACCACATCCAAGGAA-3´ (450-469), 5´-GCTGGAATTACCGCGGCT-3´ 
(636-619); MICA: 5´-CCTTGGCCATGAACGTCAGG-3´ (518-537), 5´-
CCTCTGAGGCCTCGCTGCG-3´ (694-676); MICB: 5´-ACCTTGGCTATGAACGTCACA-
3´ (483-503), 5´-CCCTCTGAGACCTCGCTGCA-3´ (661-642); ULBP1: 5´-
GTACTGGGAACAAATGCTGGAT-3´ (584-605), 5´-AACTCTCCTCATCTGCCAGCT-3´ 
(730-710); ULBP2: 5´-TTACTTCTCAATGGGAGACTGT-3´ (579-600), 5´-
TGTGCCTGAGGACATGGCGA-3´ (687-668); ULBP3: 5´-
CCTGATGCACAGGAAGAAGAG-3´ (594-614) 5´-TATGGCTTTGGGTTGAGCTAAG-3´ 
(672-651); ULBP4: 5´-CTGGCTCAGGGAATTCTTAGG-3´ (573-593), 5´-
CTAGAAGAAGACCAGTGGATATC-3´ (665-643). Data analysis was done using the ∆∆CT 
method for relative quantification. Briefly, threshold cycles (CT) for 18S rRNA (reference) 
and NKG2DL (sample) were determined in duplicates. The values obtained for untreated cells 
were arbitrarily defined as the standard value (100%) and determined the relative change (rI) 
in copy numbers according to the formula rI = 2 – [(CTSample - CTReference) – (CTStandard Sample - CTStandard 
Reference)].  
 
 
TGF-β bioassay. Levels of bioactive TGF-β were determined using a modification of the 
CCL64 bioassay (378). Briefly, 103 CCL64 cells were adhered to 96 well plates for 24 h. 
After removal of regular medium, the cells were exposed to glioma cell SN, serum or CSF 
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from glioma patients or normal controls diluted in serum-free medium for 72 h. Viable cell 
counts were obtained by crystal violet staining. 
 
TGF-β reporter assays. Intracellular TGF-β signalling was assessed by reporter assays using 
pGL2 3TP-Luc (385) or pGL3 SBE-2 Luc (386) reporter gene plasmids kindly provided by J. 
Massagué (New York, NY) and B. Vogelstein (Baltimore, MD). The pGL2 3TP-Luc 
construct contains a synthetic promoter composed of a TGF-β-responsive plasminogen 
activator inhibitor 1 promoter fragment inserted downstream of three phorbol ester-responsive 
elements. The pGL3 SBE-2-Luc reporter contains two copies of the Smad-binding element 
GTCTAGAC. For assessment of TGF-β1 transcription, a pGL3b-TGF-β1-Luc construct, 
containing the TGF-β1 5'-flanking sequence (from -453 to +11 bp) (422) was used (a generous 
gift from C. Weigert, Tübingen). Cells were co-transfected with a ten-fold excess of the 
specific reporter over a pRL-CMV plasmid (Promega, Madison, WI), using FuGENE (Roche, 
Mannheim, Germany). At 32 h after transfection, TGF-β1 (5 ng/ml) or SD-208 (1 µM, see 
previous section) was added or not for 16 h. The respective activities of firefly and renilla 
reniformis luciferase were determined sequentially in a LumimatPlus (EG&G Berthold, 
Pforzheim, Germany) luminometer, using the firelite dual luminescence reporter gene assay 
(Perkin-Elmer, Rodgau-Jügesheim, Germany). Background was subtracted from all values 
and the counts obtained from the measurement of firefly luciferase were normalized with 
respect to pRL-CMV. 
 
T cell co-stimulation assay. T cell proliferation was measured using freshly isolated peripheral 
blood CD8+ T cells after activation with plate-bound mAbs. mAb were plate-bound overnight 
in 96 well flat-bottomed MaxiSorp plates. T cells were stimulated with solid-phase anti-CD3 
(OKT3, G. Jung, Tübingen, Germany) with or without anti-CD28 (9.3, G. Jung, Tübingen, 
Germany), anti-NKG2D (M585) or control IgG (2 µg/ml). Cultures were pulsed with [methyl-
3H] thymidine (1 µCi, Amersham) on day 3 and collected 16 h later using a cell harvester 
(Tomtec, Hamden, CT). Incorporated radioactivity was determined in a Wallac 1450 
Microbeta Plus Liquid Scintillation Counter. 
 
Cytotoxicity assay. Cytotoxicity was assessed in 4 h 51Cr release assays in the absence or 
presence of various mAb or soluble mNKG2D. The concentrations for the masking 
experiments were 10 µg mAb/ml and 20 µg/ml for soluble mNKG2D. NK cells were 
pretreated with normal human IgG to prevent antibody-dependent cellular cytotoxicity. 
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Effector and 51Cr-loaded target cells were incubated at various effector:target (E:T) ratios for 
4 h. Spontaneous 51Cr release was determined by incubating the target cells with medium 
alone. Maximum release was determined by adding NP-40 (2%). The percentage of 51Cr 
release was calculated as follows: 100 x ([experimental release – spontaneous 
release]/[maximum release – spontaneous release]). 
 
Glioma spheroids. Multicellular glioma spheroids were obtained by seeding glioma cell 
transfectants (4x104 cells/ml) in 96 well plates that were base-coated with 1.0% Noble Agar 
(Difco Laboratories, Detroit, MI) prepared in DMEM and culturing for 4-5 days until 
spheroids had formed. The extracellular matrix gel was prepared by mixing collagen I 
solution (Vitrogen 100, Cohesion, Palo Alto, CA) and modified Eagle´s medium (MEM) at a 
8:1 ratio at 4°C, supplementing fibronectin to a final concentration of 10 µg/ml and adjusting 
the pH by addition of NaOH/NaHCO3. This solution (400 µl) was added into 24-well plates 
and spheroids of defined size were implanted into the gel in triplicate. After gelation at 37 °C, 
the gel was overlayed with 400 µl complete medium and cultured in a humidified atmosphere 
(37°C; 5% CO2). Photographs of each spheroid were taken after 0, 24, 48, 72 and 96 h. For 
quantification, the mean radial distance of 10 randomly selected glioma cells that had 
migrated from the tumour spheroid into the gel matrix was measured every 24 h, and 
expressed in relation to the mean radial distance at 0 h. 
 
Matrigel invasion assays. Invasion in vitro was measured in Boyden chamber assays 
according to the manufacturer’s recommendations (BD Biosciences, Heidelberg, Germany). 
Briefly, glioma cells were harvested in enzyme-free cell dissociation buffer (Gibco Life 
Technologies, Karlsruhe, Germany). 200 µl of cell suspension (2.5 x 105 cells/ml) per 
condition were added in triplicates to each Matrigel-coated transwell insert. 500 µl NIH 3T3-
conditioned medium was used as a chemoattractant in the lower wells. Following a 20 h 
incubation period, cells on the lower side of each membrane were fixed in methanol at 4°C, 
stained with toluidine blue and sealed on slides. Photographs of representative microscopical 
fields were taken at 200-fold magnification. Quantification of cell invasion was expressed as 
the mean count of stained cells in five random fields of each membrane. 
 
Mice and animal experiments. Athymic CD1 nude mice were purchased from Charles River 
Laboratories (Sulzfeld, Germany). Mice 6-12 weeks of age were used in all experiments. The 
experiments were performed according to NIH guidelines "Guide for the Care and Use of 
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Laboratory Animals" and to the German animal protection law. Groups of 4-6 mice were 
injected subcutaneously in the right flank with transfected LNT-229 cells in 0.1 ml of PBS, as 
indicated. Mice were examined regularly for tumour growth using a metric caliper and killed 
when tumours reached >12 mm diameter. Mice were anesthetized by an intraperitoneal 
injection of 7% chloral hydrate before all intracranial procedures. For intracranial 
implantation the mice were placed in a stereotactic fixation device (Stoelting, Wood Dale, IL) 
and a burr hole was drilled in the skull 2 mm lateral to the bregma. The needle of a Hamilton 
syringe (Hamilton, Darmstadt, Germany) was introduced to a depth of 3 mm. Five x 104 
LNT-229 glioma cells in a volume of 2 µl PBS were injected into the right striatum. The mice 
were observed daily and sacrificed when developing neurological symptoms. 
 
Mouse lymphocyte isolation. Murine NK cells were prepared from splenocytes of CD1-nude 
mice by positive selection using DX5 mAb-coupled magnetic beads with the corresponding 
column system (Miltenyi Biotech, Bergisch Gladbach, Germany) before use in cytotoxicity 
assays. 
 
Statistics. Where indicated, analysis of significance was performed using the two-tailed 
Student’s t-test with P<0.05 considered significant and P<0.01 considered highly significant 
(Excel, Microsoft, Seattle, WA). Evaluation of survival patterns in mice bearing intracerebral 
gliomas was performed by the Kaplan Meier method (423) and P values were evaluated by 
the Mantel log-rank test (424). 
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Results 
 
Reduced NKG2D expression on CD8+ T and NK cells from glioma patients.  
The constitutive presence of MIC at the surface of fresh primary human glioma cells (131) in 
the apparent absence of relevant tumour immunity suggests that MIC expressed on glioma 
cells or NKG2D expressed on immune cells might be functionally impaired in glioma 
patients. Therefore NKG2D expression was examined on CD8+ T (CD3+CD8+) and NK 
(CD3-CD56+) cells from peripheral blood of glioma patients (n=7) and controls (n=17). 
NKG2D expression levels were significantly lower in CD8+ T and NK cells of untreated, 
steroid-free glioma patients than of controls (mean CD8+: 11.8 vs. 21, P=0.004; mean NK: 12 
vs. 16.5, P=0.02) (Fig. 8.1). 
 
 
 
 
 
 
Fig. 8.1. Downregulation of NKG2D on lymphocyte subsets from glioma patients. Freshly isolated PBL
from glioma patients (n=7) or controls (n=17) were examined for NKG2D expression at the cell surface by
three-color flow cytometry with gating on CD3+CD8+ (CD8+ T cells) or CD3-CD56+ (NK cells). Data are
expressed as individual SFI values (∗P<0.05, ∗∗P<0.01, t-test). 
 197
Glioma cell lines release sMICA.  
 
Immunoblot analysis was used to assess whether fresh primary polyclonal glioma cell cultures 
and long-term glioma cell lines release MICA into the cell culture supernatant (SN). sMICA 
(∼57 kDa) was detected in the SN of 3 of 4 primary glioma cell cultures and in all 12 glioma 
cell lines, but not in the non-neoplastic astrocyte cell line, SV-FHAS. sMICB (∼48 kDa) 
probably represents the smaller band in TU132 and TU140 cells (Fig. 8.2, A, B and C). 
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Fig. 8.2. Glioma cells release sMICA/B. The presence of sMIC in concentrated SN of primary glioma cell
cultures (A) or glioma cell lines (B) and (C) was assessed by immunoblot using anti-MICA/B mAb
BAMO1. pparent discrepancies in sMICA levels between immunoblot and ELISA might be due to the 
ifferent antibodies used which might detect different allelic variants of MICA preferentially. 
 comparison of immunoblots of cell lysates and concentrated SN of 4 cell lines showed that 
he MICA protein in the SN was ∼10 kDa smaller than the MICA protein in the cell lysates, 
uggesting proteolytic cleavage (Fig. 8.3).  
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Fig. 8.3. Comparison of soluble and membrane-bound MICA/B. SN and cell lysates of
corresponding glioma cell lines were compared. 
sMIC levels were also quantified by ELISA (Table 1). 
 
Table 1. Release of sMICA and sMICB by human glioma cell lines in 48 h SN. 
Cell line sMICA  (ng MICA / mg protein) 
sMICB  
(ng MICB / mg protein) 
A172 1.2 NDa 
D247 2.0 0.2 
LN-18 2.0 0.4 
LN(T)-229 1.0 ND 
LN-308 0.7 ND 
LN-319 1.8 ND 
LN-428 12.6 0.2 
T98G 3.9 0.5 
U87MG 0.4 ND 
U138MG 1.0 ND 
U251MG 0.7 ND 
U373MG 1.3 ND 
   
SV-FHAS ND ND 
   
TU113 ND ND 
TU132 0.13 ND 
TU140 ND ND 
TU203 ND ND 
 
sMIC concentration was determined by ELISA and normalized to the protein content of 
concentrated glioma cell SN (aND=not detectable). 
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To investigate whether glioma-associated MIC is released into the cerebrospinal fluid (CSF) 
or serum, the levels of sMICA and sMICB were measured in sera and CSF from glioma 
patients (n=10) and control patients with lumbar disc prolapse, lumbar stenosis or normal 
pressure hydrocephalus (n=10) by ELISA and immunoblot. There were no detectable levels 
(≥ 0.1 ng/ml) of sMICA or sMICB in any of the investigated samples (data not shown), using 
serum samples from leukaemia patients as a positive control (412).  
 
Glioma cell supernatants down-regulate NKG2D expression in immune cells in a sMICA-
independent manner.  
To investigate whether sMICA in the SN of glioma cells down-regulates NKG2D expression 
levels (410), freshly isolated and untreated PBL or NKL cells were incubated with glioma cell 
SN and then subjected to flow cytometry. LN-308 SN markedly reduced NKG2D expression 
on fresh CD8+ T (CD3+CD8+) and NK cells (CD3-CD56+) (Fig. 8.4). 
 
 
 
 
 
 
 
Fu
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un
noFig. 8.4. Downregulation of NKG2D on lymphocytes exposed to glioma cell SN. Freshly isolated PBL
were untreated (filled profiles) or exposed to LN-308 glioma cell SN (Glioma SN) (dilution 1/4) (open
profiles) for 48 h and analyzed for NKG2D expression on CD8+ T (CD3+CD8+) or NK (CD3-CD56+) cells.
The SFI values for NKG2D expression are indicated.  rther, glioma SN reduced NKG2D expression in isolated CD8+ T and NKL cells in a 
ncentration-dependent manner (Fig. 8.5). A decreased binding of anti-NKG2D mAb due to 
sking of NKG2D by sMICA was excluded by demonstrating that the SFI values remained 
altered when potential ligands were stripped off cell surface receptors by an acid wash (data 
t shown). 
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Fig. 8.5. Downregulation of NKG2D on CD8+ T cells exposed to glioma cell SN. CD8+ T cells freshly 
isolated by MACS beads (grey bars) or NKL cells (black bars) were examined accordingly, using increasing 
SN concentrations.
 
 
 
Surprisingly, the down-regulation of NKG2D mediated by glioma cell SN was not blocked by 
anti-MICA mAb or soluble NKG2D (Fig. 8.6A). The biological activity of either reagent was 
ascertained by their inhibition of MICA-mediated immune cell activation (131). It was 
confirmed that, in contrast to sMICA, membrane MICA down-regulates NKG2D expression 
levels. This was accomplished using adenoviral MICA gene transfer which resulted in high 
level MICA expression at the cell surface of glioma cells (131). The coincubation of 
transduced glioma cells with NKL cells strongly down-modulated NKG2D expression in 
NKL cells. The effect of adenoviral MICA gene transfer on NKG2D expression was nullified 
by anti-MICA (Fig. 8.6B). Moreover, the SN of Ad-MICA-infected cells, which contains high 
sMICA levels (23 ng/ml by ELISA), did not down-regulate NKG2D expression to a greater 
extent than the SN of Ad-dE1-infected or uninfected cells (both < 0.1 ng/ml by ELISA), and 
anti-MICA had again no effect (Fig. 8.6C). 
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Fig. 8.6. Downregulation of NKG2D on NKL cells by glioma cell SN depends on membrane-bound, but not
on soluble MICA. A. NKL cells were incubated with LN-308 SN in the presence of control IgG or anti-MICA
(BAMO1) (10 µg/ml) or soluble murine NKG2D (20 µg/ml). B. NKL cells (3 x 105) were co-cultured with LN-308
glioma cells (1 x 105) infected with Ad-MICA or Ad-dE1 (300 MOI) in the presence of control IgG or anti-MICA
(BAMO1) (10 µg/ml). C. The SN of Ad-MICA- or Ad-dE1- (300 MOI) infected glioma cells were incubated with
NKL cells for 48 h in the presence of control IgG or anti-MICA (∗P<0.05, ∗∗P<0.01, t-test). Data are expressed as
individual SFI values. 
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Glioma-derived TGF-β1 and TGF-β2 down-regulate NKG2D at the transcriptional level.  
In the context of further efforts to elucidate the mechanism of glioma-induced loss of NKG2D 
expression on immune cells, it was noted that TGF-β1 and TGF-β2 down-regulate NKG2D 
expression in freshly isolated CD8+ T and NK cells as well as in NKL cells (Fig. 8.7, A, B 
and C) (194). In contrast, IL-10 had no such effect (data not shown). 
 
 
 
  
 
 
 
Fig. 8.7. Downregulation of NKG2D on lymphocyte subsets by TGF-β. Freshly isolated PBL were untreated
(filled profiles) or treated with TGF-β1 or TGF-β2 (10 ng/ml) for 48 h (open profiles) and subjected to flow
cytometry analyzing NKG2D expression on gated CD3+CD8+ T or CD3-CD56+ NK cells. The SFI values for
NKG2D expression are indicated.  
TGF-β-mediated down-regulation of NKG2D expression was concentration- and time-
dependent (Fig. 8.8, A, B and C).  
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rFig. 8.8. TGF-β-mediated downregulation of NKG2D is time- and dose-dependent. Freshly isolated CD8+
T cells (A) or NKL cells (B,C) were treated with TGF-β1 (grey bars) or TGF-β2 (black bars) at increasing
concentrations for 48 h (A,B) or (C) lengths of time (NKL) at 10 ng/ml. ince glioma cell SN, notably from LN-308 cells, contains large amounts of TGF-β1 and 
GF-β2 (292), the next step was to investigate whether TGF-β mediated the effects of glioma 
N on NKG2D expression. Anti-TGF-β mAb nullified the inhibitory effects of glioma cell 
N on NKG2D expression, indicating that TGF-β is the principle soluble factor which 
educes NKG2D levels at the surface of immune effector cells (Fig. 8.9). 
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Fig. 8.9. Anti-TGF-β antibody prevents downregulation of NKG2D by glioma cell SN. NKL cells were 
incubated with LN-308 SN in the presence of control IgG or anti-TGF-β mAb (10 µg/ml). 
The reduced signal for NKG2D at the cell surface was not due to receptor internalization or 
failure to translocate NKG2D to the cell membrane since TGF-β decreased the NKG2D levels 
in permeabilized cells (data not shown). Further, real time PCR analysis showed a reduction 
of NKG2D mRNA levels in NKL cells at 48 h after exposure to glioma cell SN, TGF-β1 or 
TGF-β2 (Fig. 8.10). 
 
 
 
 
 
Fig. 8.10. Transcriptional downregulation of NKG2D by TGF-β. NKG2D mRNA expression was
assessed in NKL cells exposed to LN-308 glioma SN (dilution 1/4) or TGF-β1 and TGF-β2 (10 ng/ml) for
48 h. 
Further evidence for a decisive role of TGF-β was gained from the co-incubation of NKL 
cells with sera or CSF samples from glioma patients. Sera and CSF, as mentioned previously, 
showed no detectable sMICA levels by ELISA or immunoblot, but both body fluids reduced 
NKG2D expression in NKL cells. The inhibition of NKG2D expression by paired serum (20 
ng/ml) and CSF (22 ng/ml) samples from a glioma patient was reversed by pan anti-TGF-β 
(Fig. 8.11). The restoration of NKG2D expression was incomplete in serum, suggesting the 
presence of other modulators of NKG2D expression in these samples (425). 
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Fig. 8.11. The effect of glioma patient serum or CSF on NKG2D expression can be blocked by anti-
TGF-β antibody. Diluted serum (1/4) or CSF (1/4) from a glioma patient was added to NKL cells for 48 h in
the presence of control IgG or anti-TGF-β (10 µg/ml) (∗P<0.05, ∗∗P<0.01, t-test). 
 
TGF-β-regulated MMP expression mediates MICA shedding.  
Since TGF-β modulates MMP expression in glioma cells (415), the next question to be 
addressed was whether MMP mediates MICA release by glioma cells and whether this 
activity of MMP depends on TGF-β. MMP-2 levels were increased by TGF-β and reduced by 
neutralizing TGF-β mAb whereas MMP-9 levels showed no consistent change in response to 
altered TGF-β availability. Zymography, an assay based on the digestion of gelatine by 
electrophoretically separated MMP-2 and MMP-9, showed that MMP-2 (72 kDa) activity was 
enhanced by TGF-β and reduced by anti-TGF-β treatment. The effect of exogenous TGF-β 
was blocked in the presence of the MMP inhibitor oPA (Fig. 8.12A). Exposure to oPA, 
previously shown to reduce MMP activity in glioma cells (415), reduced the release of MICA 
in a concentration-dependent manner. In parallel, the expression levels of MICA at the cell 
surface increased (Fig. 8.12B). oPA did not alter the levels of TGF-β release by glioma cells 
(data not shown). 
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Fig. 8.12. MMP, that cleave MICA, are induced by TGF-β. A. The release of MMP-2 or MMP-9 by T98G
cells that were untreated or treated for 48 h with control IgG or anti-TGF-β (10 µg/ml), or recombinant TGF-
β2 (10 ng/ml), was monitored by immunoblot. MMP-2 (72 kDa) and MMP-9 (92 kDa) activity in the SN of
T98G were assessed by zymography (lower panel). Cells were treated as previously or with oPA (20 µM) or
oPA (20 µM) plus TGF-β2 (10 ng/ml). The numbers indicate relative densitometry units. B. sMICA levels in
the SN of T98G cells exposed to increasing concentrations of oPA for 48 h were analyzed by immunoblot
using mAb BAMO1. MICA levels at the cell surface were determined by flow cytometry in parallel. 
 
However, neutralizing TGF-β mAb reduced sMICA release by 63% and exogenous TGF-β 
increased the levels of sMICA in the SN (Fig. 8.13A). Accordingly, anti-TGF-β mAb or oPA 
alone increased the expression of MICA at the cell surface (Fig. 8.13B). oPA antagonized the 
loss of MICA induced by exogenous TGF-β, but not to the full extent, indicating another 
mechanism of MICA suppression by TGF-β (Fig. 8.13B). 
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Fig. 8.13. The levels of soluble and membrane-bound MICA are inversely correlated. A. The release of
sMICA by T98G cells that were untreated or treated for 48 h with control IgG or anti-TGF-β (10 µg/ml), or
recombinant TGF-β2 (10 ng/ml), was monitored by immunoblot. B, MICA expression at the cell surface of
T98G cells cultured for 48 h in the presence of control IgG (10 µg/ml), anti-TGF-β (10 µg/ml), oPA (20 µM)
or TGF-β (10 ng/ml) or both was assessed by flow cytometry (∗P<0.05, ∗∗P<0.01, t-test). 
TGF-β and MMP activity inhibit NK cell-mediated glioma cell killing and T cell co-
stimulation.  
The relevance of the TGF-β-mediated reduction of NKG2D expression in NK cells and the 
TGF-β-mediated increase in MICA shedding by glioma cells were functionally investigated in 
51Cr release assays using immune effector cells pretreated with TGF-β or target glioma cells 
pretreated with oPA. MMP inhibition by oPA, which increases MICA expression at the 
surface of glioma cells, enhanced the NK cell-dependent killing of glioma cells. This was 
attenuated by coincubation with anti-MICA mAb. Other NKG2DL and activating molecules 
might also be regulated by MMP activity, explaining the incomplete blocking of lysis by anti-
MICA in oPA-treated glioma cells (Fig. 8.14A). Exogenous TGF-β treatment of the NK 
effector cells had no effect on the lysis of control-transfected LN-229 cells, but markedly 
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reduced the specific lysis of stable LN-229.MICA (131) transfectants, indicating a specific 
effect on NKG2D-mediated glioma cell killing (Fig. 8.14B).  
 
 
 
 
 
 
 
 
To
pu
NK
aloFig. 8.14. Immune-mediated lysis of glioma cells is MICA-dependent and sensitive to TGF-β. A. LN-
308 glioma cells untreated or treated with oPA (20 µM) or anti-MICA (BAMO1) (10 µg/ml) or both were
used as target cells in a standard 4 h 51Cr release assay using polyclonal NK cells as effectors. Data are
expressed as specific lysis at different E:T ratios. In B, NKL cells untreated or pretreated with TGF-β (10
ng/ml) were used in a standard 4 h 51Cr release assay, using LN-229.MICA stable transfectants or mock
transfectants (LN-229.neo) as target cells.  evaluate the significance of TGF-β for NKG2D-mediated CD8+ T cell co-stimulation, 
rified human CD8+ T cells were stimulated with anti-CD3 mAb in combination with 
G2D mAb or CD28 mAb in the presence or absence of TGF-β. While anti-CD3 mAb 
ne induced a moderate T cell response, significant increases in T cell proliferation were 
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observed by inclusion of NKG2D mAb. This effect, however, was less potent than that of 
anti-CD28 mAb. The co-stimulatory activity of anti-NKG2D was reduced by TGF-β 
treatment of CD8+ T cells whereas anti-CD28 stimulation was less affected by TGF-β, 
showing a prominent effect of TGF-β on NKG2D-mediated activation (Fig. 8.15). 
 
 
 
 
 
 
 
 
Fig. 8.15. NKG2D-mediated co-stimulation is sensitive to TGF-β. Purified CD8+ T cells were cultured with
precoated CD3 mAb (OKT3) at different concentrations and immobilized control IgG, NKG2D mAb or CD28
mAb (2 µg/ml) and in the absence or presence of TGF-β2 (10 ng/ml) for 96 h. Cultures were pulsed with
[methyl-3H]-thymidine for the last 16 h. Data are expressed as mean cpm ± SD. 
TGF-β knock-down in glioma cells: in vitro phenotype. 
Pursuing a possible therapeutic perspective, siRNA technology was used to knock-down 
TGF-β1 and TGF-β2 expression in LNT-229 glioma cells. TGF-β1 protein was stably reduced 
by 95% and TGF-β2 by 99% with a combined approach using TGF-β1 and -β2 siRNA target 
sequences (Fig. 8.16A). TGF-β1 siRNA only targeted TGF-β1 but not TGF-β2 and vice versa 
(data not shown). Accordingly, reporter gene assays using p3TP-Luc (Fig. 8.16B) or SBE2-
Luc (Fig. 8.16B) confirmed that intracellular TGF-β signalling was repressed in TGF-β1/2 
siRNA cells compared to mock transfectants (controls). This effect was reversed (or, in the 
case of SBE2-Luc, diminished) by addition of exogenous TGF-β1. The TGF-β receptor I 
kinase inhibitor SD-208 reduced reporter gene activity in the control transfectants, but not in 
TGF-β1/2 siRNA cells. Further, the transcription of TGF-β1 itself was not impaired in the 
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TGF-β1/2 siRNA cells, consistent with posttranscriptional mRNA degradation triggered by 
siRNA (Fig. 8.16D).  
 
 
 
 
 
 
  
Fig. 8.16. Downregulation of TGF-β1/2 in LNT-229 TGF-β1/2 siRNA cells. A. The release of TGF-β1 and
TGF-β2 in SN of pSUPER-puro-TGF-β1 and- TGF-β2 stably transfected LNT-229 cells (TGF-β1/2 siRNA)
or mock transfectants (control) was monitored by immunoblot. B-D. Intracellular TGF-β signalling was
assessed in untreated or TGF-β1 (5 ng/ml, 16 h) or SD-208 treated control cells (white columns) and TGF-
β1/2 siRNA cells (black columns). Luminescence counts for pGL2-3TP-Luc (B), pSBE2-Luc (C) and
pGL3b-TGF-β1-Luc (D) were divided by the counts obtained from co-transfected pRL-CMV. Their ratio is
given as relative luciferase activity (mean ± SD, t-test, ∗P<0.05 ∗∗P<0.01).
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The expression of MMP-2 and MMP-9 was suppressed in TGF-β1/2 siRNA cells (Fig. 8.17), 
resulting in a 64% reduction in MMP activity by zymography (Fig. 8.17). No such effect was 
observed for MT1-MMP (data not shown).  
 
 
 
 
 
Fig. 8.17. Downregulation of MMP expression in TGF-β1/2 siRNA cells. MMP-2 (72 kDa) and MMP-9 (92
kDa) expression in the SN of control cells and TGF-β1/2 siRNA were assessed immunoblot and specific
activity by zymography. 
SN of control transfectants down-regulated NKG2D expression in NKL cells whereas the SN 
of TGF-β1/2 siRNA cells left NKG2D levels unaltered (Fig. 8.18). 
  
 
 
 
 
 
 
Fig. 8.18. SN from LNT-229 TGF-β1/2 siRNA cells does not affect NKG2D expression on NKL cells. NKL
cells were incubated with glioma cell SN (Glioma SN 1/4) of control or TGF-β1/2 siRNA cells for 48 h and
analyzed for NKG2D expression by flow cytometry.
MICA levels were also investigated by immunoblotting using lysates from untreated and 
treated LN-229 control or TGF-β1/2 siRNA cells (Fig. 8.19). 
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Fig. 8.19. MICA protein expression is enhanced in lysates from TGF-β1/2 siRNA cells.  The expression of 
MICA in cell lysates of LNT-229 control or TGF-β1/2 siRNA cells was monitored by immunoblot. An actin 
control was included to verify equal amounts of loaded protein for the cell lysates. 
Furthermore, MICA and ULBP2 expression were markedly increased on the cell surface of 
TGF-β1/2 siRNA cells by flow cytometry, while MICB, ULBP1 and 3 showed no change in 
their surface expression levels (Fig. 8.20). A specific mAb against ULBP4 is currently not 
available, therefore this NKG2DL could not be investigated on protein level. 
Importantly, the effects could be diminished by addition exogenous TGF-β2 (10 ng/ml, 7d), 
confirming the specificity of the observation (see Fig. 8.20B and data not shown).  
 
 
 
 
 
Fig. 8.20. MICA and ULBP2 surface expression is increased in LNT-229 TGF-β1/2 siRNA cells. A.
MICA, MICB, ULBP1, 2 and 3 expression at the cell surface of control (closed profiles) and TGF-β1/2 siRNA
cells (open profiles). B MICA expression at the cell surface of control, TGF-β1/2 siRNA cells untreated or
treated with TGF-β2 (10 ng/ml) for 7 days were analyzed by flow cytometry. SFI values are indicated in the
upper right corner.  
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Real time PCR analysis showed a marked induction of MICA, ULBP2 and ULBP4 mRNA 
levels in TGF-β1/2 siRNA cells (Fig. 8.21A). This effect of the knock-down was again 
reversed by exogenous TGF-β2 (Fig. 8.21B). 
 
 
 
 
 
 
 
Fig. 8.21. LNT-229 TGF-β1/2 siRNA cells shown increased mRNA expression of MICA, ULBP2 and
ULBP4. A. MICA, MICB, ULBP1, 2, 3 and 4 mRNA expression were assessed in control or TGF-β1/2 siRNA
cells by real-time RT-PCR. B. TGF-β1/2 siRNA cells were treated with TGF-β2 (10 ng/ml) for 48 h and assessed
for MICA, ULBP2 and ULBP4 mRNA expression. Data are expressed as the relative gene expression compared
with control transfectants in A or untreated TGF-β1/2 siRNA cells in B. 
 
The changes in the expression of NKG2D, MICA and ULBP2 resulted in the expected 
increase in the lysis of TGF-β1/2 siRNA cells by NKL (data not shown) or polyclonal NK cells 
(Fig. 8.22). This enhancement of immune-mediated lysis through TGF-β1/2 “knockdown” 
could be diminished by blocking antibodies against MICA, ULBP2 or NKG2D or by a 
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soluble NKG2D receptor. The effects of masking MICA and ULBP2 were found to be 
additive and to equal the effect achieved by blocking the receptor. Importantly, addition of  
TGF-β during the 4 h effector phase of the lysis experiment had no significant effect (data not 
shown). 
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sFig. 8.22. LNT-229 TGF-β1/2 siRNA cells are more susceptible to lysis by NK cells. Control or TGF-β1/2
siRNA cells (104 cells/well) untreated or treated with anti-MICA (AUMO1), anti-ULBP2 (BUMO1 ) or anti-
NKG2D (MAB 139) (10 µg/ml) were used as target cells in a standard 4 h 51Cr release assay using polyclonal
NK cells as effectors. Data are expressed as specific lysis at different E:T ratios.he TGF-β siRNA cells did not only exhibit enhanced immunogenicity, but also an altered 
ntrinsic tumour cell phenotype. Proliferation experiments showed a significant reduction in 
3H] thymidine uptake as a measure of proliferation in the TGF-β1/2 siRNA cells in vitro (Fig. 
.23A). Furthermore, migratory and invasive properties were markedly impaired in TGF-β1/2 
iRNA transfectants (Fig. 8.23B). 
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Fig. 8.23. LNT-229 TGF-β1/2 siRNA cells proliferate and migrate more slowly than LNT-229 control
cells. A. The growth of control or TGF-β1/2 siRNA cells was assessed by [3H]-thymidine incorporation,
measured in 96 well plates (5000 cells/well) after 48 h (cpm ± SD). B. The migratory and invasive
characteristics of LN-229 control and TGF-β1/2 siRNA cells were examined in a glioma spheroid model
(upper panel) and in matrigel invasion assays (lower panel). 
TGF-β knock-down in glioma cells: in vivo phenotype. 
Subcutaneous and intracerebral glioma xenograft models were used to assess a modulation of 
the tumorigenicity in TGF-β1/2 knock-down cells. LNT-229 cells were injected 
subcutaneously in nude mice which possess NK cells, but lack T cells, and the tumour sizes 
were measured every two days. Mock transfectants grew rapidly to form compact tumours 
whereas TGF-β1/2 siRNA transfectants did show tumour growth between day 3 and 7 before 
the tumours were rejected (Fig. 8.24).  
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 Fig. 8.24. LNT-229 TGF-β1/2 siRNA cells do not grow in the periphery of nude mice. The growth of
subcutaneous LNT-229 mock transfectants (control) (open symbols) or TGF-β1/2 siRNA tumors (black
symbols) was monitored every 2 days (mean ± SD, t-test, ∗P<0.05, ∗∗P<0.01).hen LNT-229 cells were implanted stereotactically into the brains of nude mice, animals 
arrying mock transfectants developed neurological symptoms and had to be sacrificed at 
ays 34-41. In contrast, animals carrying TGF-β1/2 siRNA transfectants showed no 
eurological symptoms after 90 days (Fig. 8.25) (log-rank test, P<0.01). 
 
Fig. 8.25. LNT-229 TGF-β1/2 siRNA cells are not tumorigenic in nude mice. LNT-229 control (broken
line) or TGF-β1/2 siRNA cells (solid line) (5 x 104) were inoculated intracerebrally in CD1 nude mice.
Survival data for six animals per group are shown, evaluated by the Kaplan-Meier method (log-rank test,
P<0.01). 
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NK cells isolated from mice inoculated with the TGF-β1/2 siRNA-transfected glioma cells 
showed a substantially enhanced cytotoxic activity against YAC-1 target cells compared with 
NK cells from animals receiving mock transfectants (Fig. 8.26), suggesting altered NK cell 
reactivity as a contributing mechanism mediating the anti-tumorigenic effects of RNA 
interference against TGF-β. 
 
 
 
 Fig. 8.26. Inoculation with LNT-229 TGF-β1/2 siRNA cells enhances NK cell activity in nude mice. LNT-
229 control (broken line) or TGF-β1/2 siRNA cells (solid line) (5 x 104) were inoculated intracerebrally in CD1
nude mice. At day 5, splenocytes were recovered from the differently treated animals. NK cells were isolated
and used as effector cells in a 51Cr release assay using YAC-1 cells as targets.
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Discussion 
 
Among solid tumours, glioblastoma is paradigmatic for its immune inhibitory properties 
which involve the expression of cell surface molecules such as HLA-G and CD70 as well as 
the release of soluble molecules such as TGF-β (155, 261, 382). TGF-β has been considered 
central to the malignant progression of glial tumours and to the immune dysfunction in human 
glioblastoma patients (155). Here a novel pathway of immunosuppression mediated by TGF-β  
is delineated. This involves (i) the down-regulation of NKG2D expression in CD8+ T and NK 
cells, (ii) the selective down-regulation of NKG2DL MICA, ULBP2 and ULBP4 expression 
in glioma cells and (iii) the enhanced shedding of the cognate ligand, MICA, from the cell 
surface in a MMP-dependent manner. By promoting the reduction of NKG2D on immune 
cells paralleled by the reduction of cell surface MICA expression through enhanced shedding 
and decreased transcription, glioma cells may efficiently escape innate immune recognition 
by reducing an induced-self danger signal (89, 426). 
The present study builds upon our prior observation of NKG2DL expression by freshly 
isolated primary glioma cells and of an enhanced immunogenicity of MICA-transduced 
glioma cells (131) and the novel finding of reduced NKG2D expression in CD8+ T and NK 
cells of human glioblastoma patients in vivo (Fig. 8.1). Although primary glioma cells and 
long-term glioma cell lines released sMICA into the cell culture SN (Fig. 8.2, 8.3 and Table 
1), the sMICA levels in patient sera or CSF were below the detection limit of the ELISA used 
here. Glioma cell SN was shown to reduce the expression of NKG2D at the surface of CD8+ 
T and NK cells (Fig. 8.4 and 8.5). However, this effect was not mediated by sMICA released 
by glioma cells, e.g., via NKG2D binding and subsequent internalization. Importantly, 
membrane-bound MICA was shown to down-regulate NKG2D expression (Fig. 8.6). 
In experiments similar to those excluding a role for sMICA in down-regulating NKG2D 
expression, recombinant TGF-β mimicked the effects of glioma cell SN on NKG2D 
expression. Blocking experiments confirmed that TGF-β was the principle molecule within 
the glioma cell SN mediating the loss of NKG2D in immune cells. Real time PCR indicated 
that the reduction of NKG2D mediated by TGF-β involved the level of NKG2D gene 
transcription (Fig. 8.7).  
Importantly, the disruption of the MICA/NKG2D recognition system by TGF-β does not only 
involve the loss of NKG2D expression in effector cells, mediated in a paracrine fashion, but 
also an autocrine effect of TGF-β on the expression of the cognate ligand, MICA, on the 
glioma cells. This is because the shedding of MICA from the surface of glioma cells is 
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mediated by MMP which in turn are under the control of TGF-β. However, suppression of 
MICA surface levels by TGF-β was not completely antagonized, when MMP activity was 
inhibited (Fig. 8.13). This may be due to a TGF-β-mediated decrease of MICA mRNA levels 
(Fig. 8.21). Inhibition via siRNA technology leads to an increase in MICA, ULBP2 and 
ULBP4 transcription, and suppression in MMP activity, leading to an increase in surface 
MICA and ULBP2 levels (Fig. 8.17, 8.19 and 8.20). A specific mAb against ULBP4 is 
currently not available, therefore this NKG2DL could not be investigated on protein level. 
Interestingly, TGF-β does not impair MICB, ULBP1 and ULBP3 mRNA and cell surface 
expression (Fig. 8.20 and 8.21). Blocking experiments using polyclonal NK cells as effectors 
and LNT-229 control or TGF-β1/2 siRNA transfectants show that MICA and ULBP2 have 
additive functions in triggering NKG2D, indicating that an anti-tumour immune response 
depends on the expression level of each NKG2DL at the cell surface of transformed or 
infected cells. Importantly, the effect of blocking both MICA and ULBP2 equalled that of 
blocking the receptor (Fig. 8.22). Further, blocking of MICA also inhibited lysis by NKL cells 
(data not shown). These observations suggest a prominent role for the NKG2DL, MICA and 
ULBP2 in glioma immune surveillance, while the other ligands may exert their immune-
stimulatory functions under different conditions. 
SN of TGF-β1/2 siRNA transfectants does not confer down-regulation of NKG2D in immune 
effector cells, supporting the importance of TGF-β in down-regulating NKG2D (Fig. 8.18). 
Consequently, either reducing TGF-β bioavailability, or MMP expression or activity, or their 
combination are suitable means to enable the immune cell-mediated lysis of glioma cells. An 
inhibition of MMP activity by TGF-β antagonism does also interfere with other aspects of 
malignancy such as proliferation, migration and invasiveness (Fig. 8.23) (427). Altogether, 
the significance of these biological effects of TGF-β were corroborated by the observation of 
a loss of tumorigenicity in vivo and enhanced NK cell activation when TGF-β1 and TGF-β2 
gene expression were impaired using siRNA technology (Fig. 8.24-26). 
The general importance for TGF-β as a mediator of impaired antitumour immune surveillance 
is no more disputed. The analysis of T cells expressing a dominant negative TGF-β-RII 
transgene confirmed an inhibitory role of TGF-β in the generation of antitumour CD8+ T cell 
responses (428). Such mechanisms might involve effects of TGF-β on co-stimulatory signals 
using NKG2D as the target molecule (Fig. 8.15). Of note, the highly lethal nature of 
glioblastoma suggests that the levels of NKG2D expressed by immune cells or of activating 
NKG2DL expressed by glioma cells in the current clinical setting are too low to induce anti-
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tumour immunity. Previous studies had already indicated that the activation potential for 
immune cells depends on the level of NKG2DL expression on glioma cells (131). Further, the 
inhibitory receptor CD94/NKG2A is induced by TGF-β and may thus potentiate the NK and 
CD8+ T cell inhibition by glioma cells (429). TGF-β also reduces the expression of the NK 
cell activatory receptor, NKp30 (194). Collectively, these observations confirm that TGF-β is 
central to the malignant progression of glial tumours and a principle target for the treatment of 
gliomas (155). Anti-TGF-β therapies may therefore not only relieve the immune dysfunction 
in human glioblastoma patients, but also inhibit MMP-activity and restore MICA, ULBP2 and 
ULBP4 expression to the levels required for an effective anti-glioma immune response. 
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Summary 
 
Our improved understanding of cancer biology has helped to establish criteria that appear to be 
prerequisites for tumour formation by transformed cells (430). Cancer cells must (i) be able to 
grow autonomously, (ii) develop insensitivity to negative growth regulation, (iii) display 
unlimited replicative potential, (iv) develop the capacity for angiogenesis, (v) develop 
competence for invasive growth and metastasis and (vi) evade intrinsic apoptotic signals. A 
further emerging precondition for the malignant phenotype in vivo is the capacity of a 
malignant cell to evade the extrinsic tumour suppressor functions of the immune system (154). 
 
Glioma cells display all of these “hallmarks of cancer”. Their intrinsic resistance to apoptosis 
and their immunosuppressive properties (chapter 1) have been analyzed in our laboratory 
(155, 431) and were also the main topics explored in my Ph.D. work. 
 
p53 is a potent activator of the intrinsic apoptotic pathway. It represents an ideal target for 
anti-cancer drug design, since it is mutated in more than half of human tumours. Most of the 
remaining tumours, although carrying wild-type p53, have defects in the p53-mediated 
apoptotic pathway. Unlike most other tumour suppressor genes, mutant p53 is overexpressed 
in tumour cells. Therefore it can function as a tumour antigen (432-434). However, the 
approach that was investigated here (chapter 2) aimed at restoring a tumour-suppressor 
function in mutant p53 variants. CP-31398 is a prototype small molecule that stabilizes the 
active conformation of p53 and promotes p53 activity in cancer cell lines with mutant or wild-
type p53 (19). CP-31398 was found to induce p53-like activity in all of 11 glioma cell lines 
harbouring wild-type or mutant p53, but not in p53 null LN-308 cells. However, upon 
prolonged exposure to CP-31398, all glioma cell lines, irrespective of their p53 status, 
undergo caspase-independent cell death displaying some characteristics of apoptosis. 
Posttranscriptional repression of p53 by an intracellularly transcribed siRNA as well as 
analysis of p53 transgenes in p53-deleted glioma cells allowed to delineate two pathways of 
CP-31398-induced cell death: an early, p53-dependent pathway that requires new p53 protein 
synthesis and a late, p53-independent pathway characterized by calcium release and 
epiphenomenal free radical formation. These observations point out some of the liabilities of 
CP-31398 as a prototype p53-based therapeutic and define a rationale for the further 
refinement of small molecules which specifically target the p53 pathway, but lack the p53-
independent effects. At the current stage of development, CP-31398 has promising effects on 
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mutant and wild-type p53 in cancer cell lines, but its strong p53-independent side effects are 
likely to prevent its use in the clinic. 
 
Surprisingly, posttranscriptional repression of p53 by an intracellularly transcribed siRNA in 
a p53 mt cell line resulted in the induction of a low, but detectable p53-like reporter gene 
activity. This observation prompted us to investigate the specificity of Stratagene´s p53 
PathDetect reporter plasmid (chapter 3), a widely used luciferase-coupled reporter gene for 
the detection of the transcriptional activity of p53. Both p63 and p73 were found to activate 
the promoter sequence contained in the p53-luc vector. This shows that data obtained using 
this system (or any similar one) should be interpreted with caution because they may not 
actually reflect p53 activity, but rather provide an integrated signal derived from different 
members of the p53 family. However, this does not seriously challenge the reporter gene data 
obtained with CP-31398, since a net effect of CP-31398 on p53, p63 and p73 is a 
physiologically perfectly sensible measure of CP-31398-dependent p53-related activity. In 
fact, treatment of glioma cells with CP-31398 also increases the cellular level of p73, while 
p63 is absent from most glioma cell lines (data not shown). Further, the potency of CP-31398 
as an inducer of apoptosis may even be enhanced by a cooperative effect on further members 
of the p53 protein family (176). 
 
Whereas in glioma cells CP-31398 activates an intrinsic, caspase-independent cell death 
pathway, the extrinsic or death receptor mediated apoptotic pathway may also potentially be 
exploited for an anti-cancer therapy, since the distribution of death receptors found on tumour 
cells apparently differs from that found on non-transformed cells. Further, the signalling 
originating from these receptors may be different in tumour cells. This has been described for 
CD40 (246), one of several members of the TNFR family that lack a death domain and yet can 
induce apoptosis (183, 435, 436). Physiologically, CD40 transduces antiapoptotic signalling 
in B and T cells whereas CD40-mediated apoptosis appears to be restricted to transformed 
cells (183, 246). Therefore adverse effects like the massive hepatotoxicity of CD95/FasL 
(179) are unlikely to occur with CD40. Instead, ligation of CD40 can induce antitumour 
immunity in vivo in mice (148, 185, 276, 437). CD40 is expression was detected in all of 12 
human glioma cell lines (chapter 4), even though in most cell lines the expression seems to 
be mainly intracellular. In contrast to various non-glial carcinoma cell lines, CD40-expressing 
glioma cells resist cytotoxic effects of CD40L. Resistance to CD40L-induced cell death has 
been described as the result of CD40 downregulation during long-term culture (285). CD40 
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gene transfer into LN-18 glioma cells induces (or restores?) susceptibility to cell death by 
soluble CD40L. Similar to CD95L- or Apo2L/TRAIL-induced apoptosis, CD40-dependent 
cell death is potentiated by CHX and involves receptor clustering and caspase 8 and 3 
processing. Surprisingly, CD40-transfected LN-18 cells acquire resistance to CD95L, 
resulting from the down-regulation of CD95 expression via a posttranslational, proteasome 
inhibitor-sensitive mechanism. In contrast, subtoxic concentrations of CD40L strongly 
sensitize these cells for TNF-α-induced apoptosis via a mechanism involving intracellular 
crosstalk between CD40 and TNF-R1 (p55). This suggests complex patterns of modulation of 
death receptor-mediated glioma cell apoptosis by CD40/CD40L interactions. Further, 
bispecific CD40xCD95, but not CD20xCD95, antibodies kill glioma cells, disclosing the 
property of endogenous CD40 to facilitate death signalling. However, the data obtained on 
CD40 in glioma cells do not strongly support a therapeutical application of CD40L as an 
inducer of apoptosis. On the other hand, CD40L had no stimulatory or antiapoptotic effects on 
glioma cells and could therefore be used as an adjuvant in a potential anti-glioma 
immunotherapy. 
 
Another TNFR-related cell surface receptor implicated in T, B and NK cell activation (311, 
438, 439) as well as in apoptosis (49, 333) is CD27. The ligand for CD27, CD70 was 
identified as a radio-inducible gene in U87MG glioma cells (chapter 5). A screening of a 
panel of human glioma cell lines revealed that 11 of 12 cell lines expressed CD70 mRNA and 
protein. CD70 protein was also detected by immunocytochemistry in 5 of 12 glioblastomas 
and 3 of 4 anaplastic astrocytomas in vivo. CD27 expression was not detected in any glioma 
cell line, and there was no evidence for autocrine or backward signalling of the CD70 system 
in human glioma cells. Unexpectedly, CD70 expressed on glioma cells did not increase the 
immunogenicity of glioma cells in vitro. In contrast, CD70-positive glioma cells induced 
apoptosis in PBMC in a CD70-dependent manner. Neutralization of CD70 expressed on 
glioma cells prevented apoptosis and enhanced the release of TNF-α in cocultures of glioma 
cells and PBMC. The effects of CD70-expressing glioma cells on PBMC were mimicked by 
agonistic CD27 antibodies. Conversely, the shedding of CD27 by PBMC was identified as a 
possible escape mechanism from glioma cell-induced CD70-dependent apoptosis. Thus, 
induction of B cell and T cell apoptosis via interactions of CD70 expressed on glioma cells 
and CD27 expressed on B and T cells may be a novel way for the immune escape of 
malignant gliomas.  
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Our in vitro results are in contrast to in vivo experiments describing CD27-mediated tumour 
rejection (329, 440). Further, a study using CD27 knockouts (312) supports a role for CD27 in 
costimulation. However, chronic stimulation via CD70 as occurs in CD70 transgenic mice 
results in B cell depletion and lethal T cell immunodeficiency (313, 314). Further, the immune 
system of glioma patients does not reject CD70-expressing tumours in vivo. Instead, the high 
proportion of CD70-positive gliomas found in this and a related (325) study suggests that 
there may rather be a selection pressure operating in favour of CD70-expressing glioma cells. 
These apparently contradictory data suggest that CD27 may be functioning in vivo together 
with other receptors that determine the outcome of CD27 stimulation. Thus CD27 may signal 
either activation or apoptosis, depending on the context. Given the capability of glioma cells 
to paralyse anti-tumour immune reactions (294), it is well conceivable that the stimulatory 
pathways originating from CD27 are inhibited in glioma patients whereas the pathway leading 
to T cell apoptosis may be enforced.  
 
One newly discovered mechanism by which glioma cells apparently inhibit anti-tumour T cell 
responses is expression and secretion of HLA-G molecules (chapter 6). HLA-G is a 
nonclassical MHC molecule with highly limited tissue distribution that has been implicated in 
foetal semi-allograft tolerance during pregnancy (342, 345). To delineate the potential role of 
HLA-G in glioblastoma immunobiology, expression patterns and functional relevance of this 
MHC class Ib molecule were investigated in glioma cell lines and brain tissue. HLA-G 
protein was detected in 4 of 12 cell lines in the absence, and in 8 out of 12 cell lines in the 
presence of IFN-γ. Immunohistochemical analysis of human brain tumours revealed 
expression of HLA-G in 4 of 5 tissue samples. Functional studies showed that expression of 
membrane-bound HLA-G1 and soluble HLA-G5 inhibited alloreactive and antigen-specific 
immune responses. However, HLA-G dependent T cell apoptosis was not detected (353). 
Gene transfer of HLA-G1 or HLA-G5 into HLA-G-negative glioma cells rendered these cells 
highly resistant to direct alloreactive lysis, inhibited the alloproliferative response and 
prevented efficient priming of cytotoxic T cells. The inhibitory effects of HLA-G were 
directed against CD8+ and CD4+ T cells, but appeared to be NK cell-independent. 
Interestingly, few HLA-G-positive cells within a population of HLA-G-negative tumour cells 
exerted significant immune inhibitory effects. These data suggest that aberrant expression of 
HLA-G may contribute to immune escape in human glioblastoma. 
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A long-established determinant of glioblastoma-induced immunosuppression is the cytokine 
TGF-β (155, 192, 417). However, TGF-β does not only compromise anti-tumour immune 
responses and induce T cell apoptosis (441), but also stimulates angiogenesis and invasion 
(193, 330, 415, 442). Therefore, TGF-β has become a major target for the experimental 
treatment of human malignant gliomas (443). The effects of TGF-β on NKG2D-mediated 
anti-tumour immunity (131, 406, 444) were investigated (chapter 8). NKG2D is an activating 
immunoreceptor expressed by NK, CD8+ αβ and γδ T cells. Human NKG2DL comprise 
MHC class I-chain related molecules A (MICA) and MICB and UL16-binding proteins 
(ULBP) 1, 2, 3, and 4. These ligands are expressed by infected and transformed cells and 
transmit danger signals to immune cells, leading to the lysis of NKG2DL-expressing cells. An 
effect of TGF-β on the expression of the activating immunoreceptor NKG2D in CD8+ T and 
NK cells has been shown by us and others in vitro (194, 445). Accordingly, a downregulation 
of NKG2D is also observed in glioblastoma patients in vivo. Moreover, TGF-β inhibits the 
transcription of the NKG2D ligands MICA, ULBP2 and ULBP4 and reduces their protein 
level at the cell surface. In contrast, MICB, ULBP1 and ULBP3 are unaffected by TGF-β. 
Further, TGF-β promotes the release of matrix metalloproteinases (MMP) by glioma cells 
which in turn mediate the shedding of MICA from the surface of glioma cells. siRNA-
mediated “knock-down“ of TGF-β synthesis in LN-229 glioma cells suppresses MMP 
expression and strongly enhances the immunogenicity of glioma cells by enhancing MICA, 
ULBP2 and ULBP4 expression and by preventing NKG2D down-regulation on immune cells 
treated with glioma cell SN. Further, the TGF-β knock-down leads to a decreased migratory 
and invasive tumour phenotype. Altogether, the knock-down of TGF-β results in a glioma cell 
phenotype which is less motile, more sensitive to immune cell lysis, and non-tumorigenic in 
nude mice. These data define downregulation of NKG2D expression on immune effector cells 
and of NKG2DL expression on glioma cells as a further mechanism by which TGF-β may 
promote immune escape.  
 
This confirms the importance of TGF-β as a principle inhibitor of anti-glioma immune 
responses. Strategies to counteract the immunosuppressive activities of TGF-β may be crucial 
to improve the current cancer immunotherapeutic approaches. In this context, a novel TGF-
βRI kinase inhibitor, SD-208, was characterized for its effects on the growth and 
immunogenicity of murine SMA-560 and human LN-308 glioma cells in vitro and the growth 
of, and immune response to, intracranial SMA-560 gliomas in syngeneic VM/Dk mice in vivo 
(chapter 7). SD-208 blocks autocrine and paracrine TGF-β signalling in glioma cells as 
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detected by phosphorylation of Smad2 or TGF-β reporter assays and strongly inhibits 
constitutive and TGF-β-evoked migration and invasion. PBL or purified T cells, cocultured 
with TGF-β-releasing LN-308 glioma cells in the presence of SD-208, exhibit enhanced lytic 
activity against LN-308 targets. The release of IFN-γ and TNF-α by these immune effector 
cells is enhanced by SD-208 whereas the release of IL-10 is reduced. SD-208 restores the 
lytic activity of polyclonal NK cells against glioma cells in the presence of recombinant TGF-
β or TGF-β-containing glioma cell SN. The oral bioavailability of SD-208 was verified by 
demonstrating the inhibition of TGF-β-induced Smad phosphorylation in spleen and brain. 
Systemic SD-208 treatment initiated three days after the implantation of SMA-560 cells into 
the brains of syngeneic VM/Dk mice prolongs their median survival from 18.6 to 25.1 days. 
Importantly, SD-208 could be administered together with adjuvant chemotherapy or an 
immunotherapeutic vaccine. Such a combined treatment might further improve the effect 
achieved by SD-208 alone. Thus, TGF-βRI kinase inhibitors such as SD-208 are promising 
novel agents for the treatment of human malignant glioma and other conditions associated 
with pathological TGF-β activity.  
 
In my Ph.D. research I have thus explored several novel approaches aiming at the selective 
induction of apoptosis in glioma cells and at an improved understanding of the immune-
paralysing capacities of glioma cells. While the connections between these various aspects of 
glioma biology may not be apparent at first sight, there are good reasons for taking a combined 
look at apoptosis and tumour immunology: Tumour immunosurveillance is mediated by 
immune effector cells that selectively induce apoptosis in cancer cells. Activated T and NK 
attack their targets by expression death ligands (446, 447) and by secretion cytotoxic granules 
(88, 406) and thus seek to activate both the death receptor and the intracellular apoptotic 
pathway. An apoptosis-resistant target cell is therefore less susceptible to immune-mediated 
lysis. Sensitization of tumour cells for apoptotic stimuli could therefore enhance the efficacy of 
ongoing anti-tumour immune responses. Further, the tumour may strike back and induce 
apoptosis in tumour infiltrating lymphocytes by various mechanisms, including the expression 
of CD95/FasL, HLA-G, TGF-β (262, 353, 441, 448, 449) and, under specific circumstances, 
CD70 (see section 5). Prevention of tumour cell-induced apoptosis of immune effector cells 
could also support endogenous anti-tumour responses. Finally, therapeutic induction of 
apoptosis in tumour cells is thought to provide a source of antigens that can be taken up and 
presented by professional APC, resulting in an anti-tumour immune response (68-71, 450). 
This, of course, implies that the low rates of spontaneously occurring apoptosis in vivo (451) 
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are simply insufficient to trigger an anti-glioma immune response. Further, the mounting of a 
productive anti-tumour immune response may be prevented by immune-inhibitory signals sent 
out by the tumour itself. Therefore, an apoptosis-based reduction of large tumour masses may 
require the simultaneous relief of tumour-dependent immunosuppression in order to be 
followed by a productive immune response that can finally clear residual glioma cells 
dispersed in the brain.  
 
Whether the emerging concepts outlined in this Ph.D. thesis have the potential to improve 
current glioma treatments will, of course, have to be explored in further models. Thus, the 
present work finally confirms George Bernard Shaw’s notion: “Science... never solves a 
problem without creating ten more.” 
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Zusammenfassung 
 
Gliomzellen zeichnen sich durch Resistenz gegenüber apoptotischen Stimuli aus. Die 
Überwindung dieser intrinsischen Apoptose-Resistenz ist daher ein wichtiges Ziel der 
Gliomforschung. Therapeutische Induktion von Apoptose in Tumorzellen führt in vivo zur 
Bereitstellung von antigenem Tumorzellmaterial. Dieses kann von dendritischen Zellen 
aufgenommen und präsentiert werden, sodass eine anti-Tumor-Immunantwort ermöglicht wird. 
Allerdings verfügen Gliomzellen über eine Reihe immuninhibitorisch wirksamer 
Mechanismen, die eine Tumorabstoßung verhindern. Zudem stellt die Apoptose-Resistenz von 
Gliomzellen auch für einen immuntherapeutischen Ansatz ein Hindernis dar, da immun-
vermittelte anti-Tumor-Effekte ebenfalls auf der (durch NK und T Zellen vermittelten) 
Induktion von Apoptose in Krebszellen beruhen. Darüber hinaus können Immunzellen bei 
Kontakt mit Gliomzellen ebenfalls apoptotisch werden. Daher befasst sich diese Arbeit mit den 
zellbiologischen Prinzipien des programmierten Zelltods (Apoptose) in Gliomzellen sowie mit 
den wechselseitigen Beziehungen zwischen Immuneffektorzellen und Gliomzellen, ebenfalls 
unter besonderer Berücksichtigung der Apoptose. 
 
Ein interessantes Agens zur Induktion von Apoptose in Tumorzellen ist das experimentelle 
Pharmakon CP-31398, das von der Firma Pfizer in den USA mit dem Ziel der 
Wiederherstellung funktioneller Aktivität in mutanten p53-Proteinen entwickelt wurde. Zur 
Charakterisierung dieser Substanz wurde unter Zuhilfenahme verschiedene Gentransfer-
Techniken ein p53-abhängiger und ein p53-unabhängiger Zelltodweg charakterisiert, die 
beide durch CP-31398 aktiviert werden. Somit erwies sich CP-31398 als interessante, für den 
klinischen Gebrauch auf Grund unspezifischer Effekte jedoch nicht hinreichend weit 
entwickelte Substanz. Die erzielten Ergebnisse könnten aber für die Entwicklung verbesserter 
p53-modulierender anti-Tumor-Agenzien von Bedeutung sein. Im Rahmen dieser 
Untersuchungen stellte sich heraus, dass klassische Reporter-Assays für transkriptionelle p53-
Aktivität nicht ausschließlich die Aktivität von p53 reflektieren, sondern ein umfassendes 
Bild der Gesamt-Aktivität von p53, p63, p73 und möglicherweise weiterer, noch nicht 
bekannter Mitglieder dieser Proteinfamilie liefern. Aufgrund dieses Befundes müssen 
zahlreiche bisher mit derartigen Reporter-Assays publizierte Daten neu interpretiert werden. 
 
In Ergänzung zu CP-31398, das auf die Aktivierung des intrinsischen apoptotischen 
Mechanismus abzielt (und in Gliomzellen Caspasen-unabhängigen Zelltod induziert), wurde 
auch der extrinsische oder rezeptor-vermittelte Apoptosemechanismus untersucht. Die 
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bekannten Todesrezeptoren gehören zur Familie der Tumor-Nekrose-Faktor (TNF)-
Rezeptoren, die auch bei Immunreaktionen eine wichtige Rolle spielen. Da sich das 
Expressionsmuster dieser Rezeptoren auf Tumorzellen von demjenigen auf nicht-
transformierten Zellen unterscheidet, bieten Todesrezeptoren potentielle therapeutische 
Angriffspunkte. Systemische Aktivierung des CD95/Fas-Rezeptors führt aber in Mäusen zu 
Leberversagen und auch die gegenwärtig verfügbaren Präparationen von Apo2L/TRAIL sind 
klinisch nicht einsetzbar oder ineffektiv. CD40L vermag nach dem bisherigen Kenntnisstand 
nur in transformierten Zellen Apoptose zu induzieren, was auf eine veränderte 
Signaltransduktion in Tumorzellen hindeutet. Zudem ist CD40L bereits in 
immuntherapeutischen Studien klinisch erprobt. Daher wurde im Kontext dieser Arbeit 
erstmals die Expression und funktionelle Bedeutung von CD40 auf Gliomen untersucht. Dabei 
wurde CD40-Expression auf allen 12 untersuchten Gliomzelllinien sowie in vivo 
nachgewiesen. Dennoch wurden keine zytotoxischen Effekte von CD40L auf Gliomzelllinien 
beobachtet. Da bei Tumoren eine Herunterregulation der CD40-Expression im Verlauf von 
Langzeit-Kulturen beschrieben ist, wurde eine CD40-überexprimierende Gliomzelllinie 
generiert. In dieser induziert CD40L Caspasen-abhängigen Zelltod, der durch Hemmung der 
Proteinbiosynthese potenziert wird. Gleichzeitig kommt es zu einem verstärkten proteasomalen 
Abbau von CD95/Fas, wodurch die Zellen ihre Sensitivität gegenüber CD95/Fas-vermittelter 
Apoptose weitgehend verlieren. TNF-α-abhängige Apoptose wird hingegen durch subtoxische 
Konzentrationen von CD40L verstärkt, was durch eine neu entdeckte intrazelluläre 
Wechselwirkung zwischen CD40 und TNF-R1 (p55) erklärt werden kann. Schließlich wurde 
gezeigt, dass die endogene CD40-Expression von Gliomzellen dazu benützt werden kann, 
Apoptose mittels eines bispezifischen CD40xCD95 Antikörpers zu induzieren. Somit wurden 
in diesem Teil der Arbeit komplexe Wechselwirkungen zwischen CD40 und verschiedenen 
anderen TNF-Rezeptoren nachgewiesen. 
 
Ein weiteres Molekül der TNF-Rezeptor-Familie ist CD27, dessen Ligand CD70 im Rahmen 
einer Array-Analyse als radio-induzierbares Gen in U87MG-Gliomzellen identifiziert wurde. 
Dieser Befund war überraschend, weil CD70-Expression bisher lediglich auf T- und B-Zellen 
nachgewiesen worden war. Während CD70/CD27-Interaktionen dort immunstimulatorisch 
wirkt (T, B und NK Zell-Aktivierung), zeigten umfangreiche immunologische Versuche, dass 
die Expression von CD70 auf Gliomen CD27-vermittelte Apoptose in Immuneffektorzellen 
zu induzieren vermag und somit möglicherweise zur Immuninhibition bei 
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Gehirntumorpatienten beiträgt. Als potentieller Schutzmechanismus wurde die Abspaltung 
von löslichem CD27 von Immunzellen beobachtet. 
 
Ein bereits bekannter Mediator der Immuninhibition in der Plazenta und bei Tumoren ist 
HLA-G, dessen funktionelle Relevanz auf Gliomen erstmals untersucht wurde. Dabei gelang 
der Nachweis der Expression in vitro und in vivo sowie die Charakterisierung einer Reihe T 
Zell-vermittelter immunsuppressiver Effekte: So wird sowohl die durch allogene Gliomzellen 
induzierte Proliferation als auch die direkte allogene und die antigen-spezifische Lyse nach 
Stimulation mit bestrahlten Tumorzellen durch lösliches und membranständiges HLA-G 
inhibiert. Interessanterweise genügt auch in Abwesenheit von löslichem HLA-G ein relativ 
geringer Anteil HLA-G positiver Tumorzellen, um einen Schutz der benachbarten HLA-G 
negativen Gliomzellen zu vermitteln. 
 
Neben diesen hier erstmals bei Gliomen beschriebenen Mediatoren der tumor-induzierten 
Immunsuppression wurden auch noch Untersuchungen zu TGF-β durchgeführt, das bereits 
1987 von Adriano Fontana als „glioblastoma derived T cell suppressive factor“ identifiziert 
wurde. Insbesondere wurden die Effekte von TGF-β auf NKG2D und die zugehörigen 
Liganden untersucht. NKG2D ist ein aktivatorischer Rezeptor, der auf NK, CD8+ αβ und γδ T 
Zellen exprimiert wird. TGF-β supprimiert die NKG2D-Expression auf NK und CD8+ T 
Zellen. Klinisch korreliert dies mit einer verringerten NKG2D-Expression bei 
Gliompatienten. Die NKG2D Liganden MICA/B (MHC class I-chain related molecule A/B) 
und ULBP1-4 (UL16-binding proteins 1-4) werden selektiv von infizierten und von 
transformierten Zellen exprimiert und können die immunvermittelte Lyse dieser Zellen 
induzieren. Anhand von TGF-β1,2 siRNA-Zellen, in denen die Expression von TGF-β1 und 2 
durch plasmidbasierte RNA-Interferenz inhibiert ist, konnte gezeigt werden, dass TGF-β nicht 
nur die Expression des NKG2D-Rezeptors, sondern auch die mRNA und Protein-Expression 
der NKG2D-Liganden MICA, ULBP2 und ULBP4 inhibiert, während sich kein Effekt auf 
MICB, ULBP1 und ULBP3 zeigte. Zudem fördert TGF-β die Freisetzung der Matrix 
Metalloproteinasen MMP-2 und MMP-9 (nicht von MT1-MMP), die wiederum die 
Abspaltung von MICA von der Zelloberfläche vermitteln, sodass es auch noch einen 
posttranslationalen Effekt von TGF-β auf NKG2D-vermittelte anti-Tumor Immunreaktionen 
gibt. Zudem führt der „knock-down“ von TGF-β zum Verlust des migratorischen und 
invasiven Potentials der Tumorzellen, vermutlich ebenfalls aufgrund der Herunterregulation 
der Matrix Metalloproteinasen. Die geringere Motilität und die erhöhte Immunogenität der 
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„TGF-β knock-down Zellen“ führt zu einem Phänotyp, der in Nacktmäusen nicht mehr 
tumorigen ist. 
 
Diese Daten zeigen bisher unbekannte Wechselwirkungen zwischen TGF-β und dem NKG2D 
Signalweg und belegen somit die Bedeutung von TGF-β als einem zentralen Molekül der 
Immunsuppression bei Gliomen. Anti-TGF-β-Strategien könnten daher therapeutische 
Bedeutung erlangen. In diesem Zusammenhang wurde die Wirksamkeit von SD-208, einem 
neuen TGF-βRI Kinase Inhibitor, auf Wachstum und Immunogenität von murinen SMA-560 
und humanen LN-308 Gliomzellen untersucht. SD-208 blockiert die autokrine und die 
parakrine TGF-β Signaltransduktion in Gliom- und Immunzellen, wie über die 
Phosphorylierung von Smad2 und die Induktion TGF-β abhängiger Reportergene 
nachgewiesen wurde. Zudem wird die TGF-β-abhängige Migration und Invasion von 
Gliomzellen gehemmt. Die allogene Lyse von Gliomzellen durch restimulierte humane 
Lymphozyten wird durch SD-208 erhöht, zudem sezernieren mit Gliomzellen kokultivierte T 
Zellen in Gegenwart von SD-208 mehr IFN-γ und TNF-α und weniger IL-10. Zudem kann 
SD-208 die durch Zugabe von Gliomzellüberstand bewirkte Inhibition polyklonaler NK 
Zellen aufheben. Die orale Bioverfügbarkeit von SD-208 wurde durch einen phospho-Smad2-
ELISA aus Milz und Gehirn TGF-β behandelter Mäuse nachgewiesen. Systemische 
Behandlung von VM-Dk Mäusen mit SD-208 verlängert das mediane Überleben der Mäuse 
nach intrakranieller Inokulation mit syngegen SMA-560 Gliomzellen von 18.6 auf 25.1 Tage. 
Dieser therapeutische Effekt liesse sich durch geeignete Kombinationen mit adjuvanter 
Chemo- oder Immuntherapie möglicherweise noch verbessern. Somit stellen TGF-βRI Kinase 
Inhibitors wie SD-208 vielversprechende neue Therapeutika für die Behandlung von 
malignen Gliomen und anderen TGF-β-abhängigen Erkrankungen dar.  
 
Somit könnten einzelne der im Rahmen dieser Dissertation zusammengefassten Projekte 
Grundlagen für neue, molekular definierte Therapieansätze bei Gliomen liefern. Bis zu einer 
klinischen Anwendung der hier vorgestellten Konzepte müssen die immun-inhibitorischen 
Eigenschaften von Gliomzellen noch weiter erforscht und insbesondere klinisch einsetzbare 
Agenzien für eine kombinierte Apoptose-Immuntherapie entwickelt werden. 
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